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Cultured EA.hy 926 cells were used as a model system in which to characterise the 
occurrence and role of the enzyme xanthine oxidoreductase (XOR) in human 
endothelial cells. XOR can act as a source of hydrogen peroxide and superoxide, 
reactive oxygen species (ROS) that are increasingly seen as agents of signal 
transduction. EA.hy 926 cells were shown to express low levels of XOR enzymic 
activity that followed a characteristic pattern.
In view of the possible intermediary role of XOR-derived ROS in cytokine-stimulated 
expression of cell adhesion molecules on endothelial cells, effects of inflammatory 
cytokines on XOR activity in the endothelial cells were examined. However, no such 
effects were observed. The subcellular distribution of XOR on EA.hy 926 cells was 
investigated by confocal microscopy. As generally assumed, the enzyme was found in 
the cytoplasm, where, interestingly, it was particularly concentrated in the perinuclear 
region. XOR was also found to be located on the cell surface. Such an extracellular 
localisation in endothelial cells has important implications in the context of the 
inflammatory response. Intriguingly, the surface distribution of XOR was highly 
localised towards neighbouring cells, suggesting some role for the enzyme in cell-cell 
interactions.
The possibility that cell-derived extracellular agents (e.g. ROS) might influence XOR 
expression and cell behaviour was studied. Frequent changes of medium were found 
to prevent expression of XOR, as did catalase. Although these findings suggest the 
involvement of hydrogen peroxide, attempts to modify XOR expression or behaviour 
of the cells were unsuccessful using either hydrogen peroxide or SOD.
The mouse fibroblast cell line, L929, is also interesting in that, although it contains 
XOR mRNA, it only expresses enzyme activity after exposure to molybdenum, an 
essential cofactor of the enzyme. XOR protein was detected in these cells, both with 
and without exposure to molybdenum salts. The enzyme showed a similar distribution 
in all respects to that on EA.hy 926 cells. NADH oxidase activity, an intrinsic 






ARDS Acute respiratory distress syndrome
BAECs Bovine aorta endothelial cells
BBXO Biozyme bovine xanthine oxidase
BPMVE Bovine pulmonary microvascular endothelial cell
BRLE Buffalo rat liver epithelial cell
Ca2+ Calcium
CAM Cell adhesion molecule
DHR Dihydrorhodamine




EA.hy 926 Human endothelial cell line
EC Endothelial cell
EDTA Ethylenediaminetetraacetic acid
ELISA Enzyme linked immunosorbent assay
ER Endoplasmic reticulum
FAD Flavin adenine dinucleotide
FADH2 Reduced flavin adenine dinucleotide
FCS Foetal calf serum





HAECs Human aortic endothelial cells
HB4a Human mammary epithelial cell line
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H20 2 Hydrogen peroxide
HPLC High pressure liquid chromatography
H/R Hyp oxia/Reoxygenation
HRP Horseradich peroxidase
HUVEC Human umbilical vein endothelial cell
HXOR Human xanthine oxidoreductase




IU International Units of activity
kDa KiloDalton
L929 Mouse fibroblast cell line
LDL Low density lipoprotein
LMVC Lung microvascular cell
MEM Minimum essential medium
Mo Molybdenum
NA Numerical aperature
NAD+ Nicotinamide adenine dinucleotide
NAD(P)H Reduced nicotinamide adenine dinucleotide (phosphate)
ND Non detectable
NF-kB Nuclear factor-Kappa B
NGS Normal goat serum
NO Nitric oxide
0 2. Superoxide anion
OH Hydroxyl radical
PAEC Pulmonary artery endothelial cell








ROS Reactive oxygen species
SDS-PAGE Sodium dodecyl sulphate polycrylamide gel electrophoresis
SEM Standard error of mean
SOD Superoxide dismutase
TGN Trans Golgi network
Temed N,N,N,,N,-tetramethylethylenediamine
TNF Tumour necrosis factor
VC AM Vascular cell adhesion molecule
vWF von Willebrand factor
XDH Xanthine dehydrogenase-Type D
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1.1. General enzvmology of XOR
The molybdoenzyme, xanthine oxidoreductase (XOR), first purified from bovine milk, 
has been thoroughly studied (Bray, 1975, 1988; Massey and Harris, 1997). The 
enzyme has a wide specificity for reducing substrates and it is best known for its role 
in purine catabolism, catalysing the hydroxylation of hypoxanthine and xanthine to 
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Fie. 1.1: Catabolism o f  purine nucleotides to uric acid.




XOR is a complex homodimer with a molecular weight of approximately 300 kDa. 
Each subunit contains one molecule of flavin adenine dinucleotide [FAD], one atom 
of molybdenum [Mo], and two iron sulphur [Fe-S] groups (Massey et al, 1969; Hart 
et al, 1970; Rajagopalan and Johnson, 1992). Electrons are passed to the 
physiological electron acceptors via the FAD centre. In vitro, the enzyme can also 
pass electrons via the iron sulphur centres to artificial electron acceptors such as 
methylene blue, as shown in Fig. 1.2.
The molybdenum centre is the site where xanthine and all reducing substrates are 
oxidised, apart from reduced nicotinamide adenine dinucleotide (NADH), which is 






Fig. 1.2: Electron transport fo r  xanthine oxidase and sites o f  substrate interactions.
XOR can accept up to six electrons per subunit from the reducing substrate under 
normal conditions. These electrons can he transferred around the electron centres, 
with the iron sulphur centres probably acting as an electron sink to maintain the 
molybdenum in an oxidation state of six and the FAD as FADH2 (Olson et al, 1974).
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Equilibrium exists between the three redox centres. Each redox centre has its own 
affinity for electrons, independent of the number of electrons accepted from the 
reducing substrate and also independent of the redox state of the other centres. 
Transfer of electrons is fast between redox centres, 90 s'1 at 20°C (Hille and 
Anderson, 1991).
1.1.2. Inactive forms of the enzyme
As well as the active form, XOR purified from cows' milk also contains two inactive 
forms, desulpho and demolybdo. The desulpho form lacks an essential Mo=S 
grouping, containing Mo=0 instead, and the demolybdo form lacks the molybdenum 
atom (Bray, 1975). These forms are, accordingly, inactive to most reducing 
substrates, which act at the Mo site. They will, however, still oxidise NADH which 
acts at the FAD site. A third inactive form, 'deflavo1, lacking FAD, can be produced in 
the laboratory but does not occur in vivo. The inactive forms represent about 60% 
and 98% of XOR in bovine and human milk respectively (Abadeh et al, 1992).
1.1.3. Xanthine oxidase and xanthine dehydrogenase interconversions
The enzyme exists in mammalian systems as Type D (dehydrogenase, XDH) and Type 
O (oxidase, XO) forms. XDH differs from XO in its ability to utilise NAD+ as an 
electron acceptor during the oxidation of xanthine, whereas XO can only use 
molecular oxygen (Stirpe and Della Corte, 1969; Waud and Rajagopalan, 1976; Saito 
and Nishino, 1989). They are encoded by the same gene and can only readily be 
differentiated by their preference for electron accepting species (Xu et al, 1994 and 
1995; Saksela and Raivo, 1996).
The dehydrogenase form predominates in vivo, but can be converted to the oxidase 
form, either irreversibly by proteolysis or reversibly by sulphydryl oxidation (Amaya et 
al, 1990). XDH contains fourteen sulphydryls per subunit (Della Corte and Stirpe, 
1972). These sulphydryls can be oxidised to disulphides by treatment with thiol 




Another mechanism of conversion (Fig. 1.3) is by proteolytic cleavage of a 20kDa 
fragment, which is not actually lost from the complex. However, the nick in the 
peptide backbone is sufficient to destabilise the NAD+ binding at the FAD site 
(Nishino and Tamura, 1991). Reversible and irreversible modification of XDH to form 
XO (Fig. 1.3) result in conformational changes particularly surrounding the FAD unit. 
This leads to changes in flavin reactivity and loss of the NAD+-binding site, resulting 
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> Uncertain pathways Irreversible XO
Fis.1.3: Pathways o f interconversions between XDH and XO forms.
(adapted from  Parks and Granger, 1986).
1.1.4. Inhibition of XOR
There are two categories of inhibitors of XOR: those whose structures are analogues 
of purine substrates, and those that are not structurally related to the physiological 
substrates. The best known are structurally similar molecules including allopurinol 
(Fig. 1.4) and oxypurinol (Moorhouse et al, 1987). Other less similar molecules 
include amflutizole (Wems et al, 1991) and BOF-4272 (Okamoto and Nishino, 1995). 
All these inhibitors inactivate the enzyme by blocking the Mo centre of XOR and do 
not affect NADH oxidation, which involves only the FAD centre (Sanders et al,
1997). Structurally very dissimilar inhibitors include compounds like cyanide, arsenite, 
formaldehyde and methanol (Parks and Granger, 1986).
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Allopurinol acts as a substrate of XOR and undergoes oxidation to produce 
oxypurinol, which binds tightly to the reduced form of XOR. The oxypurinol-xanthine 
oxidase complex has a half-life of about 5h at 25°C (Spector et al, 1986).
>Na
0=!
Allopurinol Amflutizole BOF 4272
Fis. 1.4: The chemical structures o f  XOR inhibitors.
1.1.5. cDNA sequences
cDNA for XOR for several species has been cloned and sequenced. The cDNA 
encodes a protein of approximately 1350 amino acids, which can be cleaved at two 
sites, generating the three distinct regions which make up the enzyme: the FeS domain 
(20KDa), the FAD domain (40KDa) and the Mo domain (85KDa) (Hille and Nishino, 
1995). The full amino acid sequences have been determined from cDNA cloning of 
the enzymes from human liver (Ichida et al, 1993; Xu et al, 1994), rat liver (Amaya et 
al, 1990), mouse liver (Terao et al, 1992), bovine milk (Berglund et al, 1996), 
chicken liver (Sato et al, 1995) and from Drosophila melanogaster (Keith et al,
1987) and Drosophilapseudoobscura (Riley, 1989). The amino sequences are highly 
homologous (90% identity) among the rat, mouse, bovine and human enzymes. A 




Drosophila melanogaster XO (53%) 
Drosophila pseudoobscura XO (53%)
r— Mouse XO (89%)




Fig. 1.5: Percentage o f homology o f XO from different species compared to human 
XO.
1.1.6. Human XOR
Human milk shows only low activity to xanthine and was, for many years, believed to 
contain little or no XOR (Carr et al, 1975). In 1987, Zeise and Zikakis were 
instrumental in showing the presence of XOR in breast milk, particularly colostrum, 
and reported an impure preparation of the enzyme that was highly contaminated by 
glycoprotein. Subsequently, apart from a brief report (Graham et al, 1989) of an 
enzyme preparation used for antibody production, the first characterisation of human 
milk XOR was that by Abadeh et al (1992). These workers showed that purified 
human milk XOR was essentially similar to that from bovine milk apart from very low 
specific activity to xanthine, which was attributed to a high proportion of inactive 
forms. The human milk enzyme has since been subjected to considerable further 
investigation which has demonstrated the presence of only very low (approximately 
5%) levels of Mo, largely explaining its low conventional activity (Sanders et al,
1997; Godber et al, 1997). In contrast, the only other human XOR to have been 
purified, from post-mortem liver, has much higher activity to xanthine, equivalent to 
that o f bovine milk enzyme (Krenitsky et al, 1986).
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1.2. Origin and functions of reactive oxygen species (ROS)
ROS are constantly produced by metabolic reactions in the human body (Palmer and 
Paulson, 1997). Mitochondrial generation of O2’. represents the major intracellular 
source of oxygen radicals under physiological conditions. Other major sources of 
oxygen radicals are phagocytic cells such as neutrophils, monocytes and macrophages 
(Davies, 1995). Phagocyte-derived ROS are known to cause hepatic dysfunction with 
proteinases and may result in tissue damage (Spolarics, 1998). Superoxide production 
may also be brought about, when electrons leak from their carriers within the 
respiratory chain of mitochondria and pass directly onto oxygen (Fridovich, 1989; 
Imlay and Fridovich, 1991). Potentially major sources of ROS are thus mitochondrial 
leakage, phagocytic cells such as neutrophils, monocytes and macrophages, NADPH 
oxidase and XO.
XO, in passing electrons to molecular oxygen, generates the reactive oxygen species, 
superoxide anions and hydrogen peroxide (Bray, 1975). XDH can also react slowly 
with molecular oxygen to produce ROS. However, XO is generally considered to be 
the predominant form of XOR that is responsible for ROS production. Various stages 
in the reduction of molecular oxygen are shown in Fig. 1.6. ROS include singlet 
oxygen (O2), hydrogen peroxide (H2O2), the superoxide anion (O2 .) and the hydroxyl 
radical (OH ). The Fenton reaction corresponds to the oxidation of reduced iron 
(Fe2+) by H20 2to generate OH.
ROS are thought to be important in an increasing number of physiological and 
pathological processes. They have a positive role in the defence against 
microorganisms and a negative role in damaging cell components (Khan and Wilson,
1995). ROS have also been implicated as second messengers. One of the most cited 
examples is the regulation pathway of the transcription factor, NF-kB. The inactive 
complex, NF-kB-IkB, is present in the cytoplasm of the cells, and is induced to 
dissociate by phosphorylation. NF-kB is then free to enter the nucleus and to induce 
genes involved in inflammation (Baeuerle and Baltimore, 1988 a/b; Beg et al, 1992; 
Brown et al, 1993; Henkel et al, 1993; Sun et al, 1993). ROS, particularly H2O2, have
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been implicated in this process. In 1991, Schreck and coworkers reported the 
induction by H20 2 of the expression and replication of HIV-1 in a human T cell line, 
an effect mediated by NF-kB. Moreover, DNA binding of the AP-1 transcription 
factor has also been shown to be induced by H20 2 (Devary et al, 1991). Low amounts 
of non-toxic ROS were found to increase the transient concentration of Ca2+ in 
cultured human and rat endothelial cells, modulating receptor-mediated calcium 
signalling. However, high doses of ROS caused the concentration of Ca2+ to increase 
via extracellular sources, leading to the process of cell death (Volk et al, 1997). 
Pathogenic roles of ROS have been implicated in ischaemia-reperfusion injury 
(Granger et al, 1981; Sussman and Bulkley, 1990), in atherosclerosis (Ohara, 1993), 
and in inflammatory and autoimmune rheumatic disease (Miesel and Zuber, 1993).
superoxide 
dismutase (SOD)
glutathione peroxidase (GPX) 
catalase
► o 2- . _
superoxide









Fig. 1.6: The reduction o f  molecular oxygen to water and partial reductions
yielding to ROS.
(Adaptedfrom Vanden Hoek et al, 1997).
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1.3. Role of XOR in ischaemia/reperfusion (I/R)
ROS were proposed by Granger et al (1981) as central mediators of the cell injury 
that occurs in post-ischaemia reperfusion. The proposed mechanism involves the 
following sequence of events. During ischaemia, energy depletion initiates the 
catabolism of purines and the accumulation of hypoxanthine. Concurrently, loss of 
energy status leads to an influx of Ca2+ into the cytosol and the activation of 
proteases. These proteases convert the native dehydrogenase form of XOR to XO.
On reperfusion, O2 is readmitted to the tissues, now containing high concentrations of 









• Oxygen supply to tissues halted
• Depletion of adenine nucleotides and accumulation 
of breakdown product, hypoxanthine
• Increased intracellular calcium concentration
• Activation of proteases
• Conversion of XDH to XO
V
REPERFUSION
• Oxygen supply restored
• Conversion of hypoxanthine to uric acid by 
XO generates ROS
• Activation of NF-kB
• Expression of adhesion molecules on the 
surfaces of endothelial cells
• Neutrophil-endothelial adhesion and 
neutrophil transmigration
• Tissue injury and death
Fig. 1. 7: Biochemical changes which occur during and a.fter ischaemia.
(Adapted from Granger et al, 1981).
This hypothesis has been extensively examined by subsequent authors and in many 
cases XOR has been implicated in the initial burst of ROS in post-ischaemic 
reperfusion (Zweier et al, 1988; Michiels et al, 1992).
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However, several aspects of the original scheme have been questioned, particularly 
the extent and time scale of XDH to XO conversion (Kooij et al, 1994; Frederiks and 
Bosch, 1996). Fig. 1.8 represents a modified scheme involving endothelial XOR and 
also neutrophils during ischaemia-reperfiision. During ischaemia, XDH is converted to 
XO within the endothelial cells. When reperfusion occurs, XO catalyses superoxide 
generation from molecular oxygen and the resulting production of ROS induces cell 
injury. Neutrophils can be attracted to the area either by the cell injury or by the 
chemotactic properties of superoxide. They are then activated, so amplifying the 
system and inducing further injury to endothelial and parenchymal cells. The initial 
burst of ROS which stems from the vascular endothelium is hypothesised to trigger 
the adhesion and migration of leucocytes across the endothelium and into the 
surrounding tissue (Bulkley, 1994; Brass, 1995). A fundamental assumption in these 
hypotheses is that xanthine dehydrogenase (80% predominant) is converted to 
xanthine oxidase during ischaemia. However, it has been shown that the conversion 
from XDH to XO by proteolysis is both slow and involves only a limited proportion 
of the enzyme (Nishino and Tamura, 1991). Therefore, the situation is likely to be 
more complex than originally thought. Alleviation of ischaemia-reperfusion injury by 
allopurinol has often been quoted in support of Granger's hypothesis (Martz et al, 
1989; Palmer et al, 1990 ), although its relevance has been questioned both on the 
grounds o f the substrate activity of allopurinol (Massey et al, 1970) and its ability to 
scavenge ROS (Bulkley, 1994).
ENDOTHLI |AL CELL
EN 0 0  THE U A L  CELL 
TRIGGER
Fis. /. 8: Endothelial cell trigger hypothetical mechanism:
PMN: polymorphonuclear leucocyte (Ratych et al, 1987).
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1.4. Inflammation and cvtokines
Ischaemia and inflammation are closely linked. As shown in the scheme of Fig. 1.8, 
ROS produced after human endothelial cells have been subjected to 
hypoxia/reperfusion have been implicated in increasing neutrophil adherence (Palluy et 
al, 1992), a key stage in inflammation. Vascular endothelial cells play an important 
role in controlling the migration of leucocytes to sites of inflammation and regulating 
the development of immune and inflammatory events in the tissue (Springer, 1995; 
Suzuki et al, 1991; Varani and Ward, 1994). Migration of leucocytes toward the 
inflamed tissue is modulated by the release of a number of inflammatory mediators 
which include cytokines, bacterial endotoxins and degenerative products of the 
inflamed tissues. During the inflammation process, endothelial cells are induced to 
undergo major changes in gene regulation and surface expression of important cell 
adhesion molecules (CAMs) (Baumann and Gauldie, 1994), and ROS have been 
implicated in these processes (Varani and Ward, 1994). CAMs interact specifically 
with neutrophils and other circulating leucocytes to slow their rate, initiate trans- 
endothelial passage and extravasation, and allow subsequent migration into the tissue 
(Lasky, 1992). While patterns of expression of CAMs are well defined, mechanisms 
controlling their induction are poorly understood.
1.5. Natural antioxidant defences in cells
Excess levels of ROS are controlled by specific antioxidant mechanisms in healthy 
persons. However, a pathological condition known as oxidative stress can result from 
an increase in ROS production or a decrease in antioxidant defences (Grisham, 1994; 
Halliwell, 1994; Neubauer and James, 1994). Enzymes specialised in the elimination 
of ROS include catalase, superoxide dismutase (SOD), and the glutathione peroxidase 




This iron-containing enzyme catalyses the conversion of hydrogen peroxide to water 
and molecular oxygen. The reaction is effectively a dismutation, involving oxidation 
of one molecule of H2O2 and the reduction of the other (Fig. 1.9).
1.5.2. Supcrcxide dismutase
The superoxide dismutases are a family of metalloenzymes that also catalyse 
dismutation, in this case of superoxide (Fig. 1.9). All members of the SOD family 
utilise a transition metal at their active site. In eukaryotes, a cytosolic form of the 
enzyme, Cu/Zn-SOD, contains copper and zinc. A manganese containing form, Mn- 
SOD, is present in mitochondria and bacterial cells. Finally, an extracellular form of 
SOD is attached to the endothelium by heparin-binding and has been implicated in 
protection from endothelium-derived oxidative stress (Mathews and van Holde, 1990; 
Davies, 1995). Mitochondrial SOD is highly inducible by cytokines (Wong, 1995).
2H 20 2 > 2 H2O + O2
catalase
2 0 2\  + 2 t f > H2O2 + O2
spontaneous or SOD
2 GSH + H20 2 * GSSG + 2 H20
glutathione peroxidase
GSSG + NADH + Y t ■> 2 GSH + NADP+
glutathione reductase
Fie. 1.9: Reactions catalysed by catalase, SOD and glutathione peroxidase.




1.5.3. Glutathione peroxidase and glutathione reductase
Glutathione peroxidase reduces H2O2 to water, simultaneously oxidising glutathione. 
Two molecules of GSH are oxidised to form the disulphide compound GSSG during 
the reduction of H2O2. Glutathione reductase utilises NADPH to re-reduce one 
molecule of GSSG to two molecules of GSH, thus permitting the continuous action of 
glutathione peroxidase (Fig. 1.9).
1.6. Distribution of XOR
XOR has been detected in all species studied, from bacteria to man. In most human 
tissues, the levels of XOR activity have been reported to be low (Parks and Granger, 
1986). XOR has been purified from human milk and shown to have very low activity 
to xanthine. Preliminary purification of XOR from human heart indicates this enzyme 
to be similar (Abadeh et al, 1992). Liver and intestine, on the other hand, show 
relatively high xanthine oxidoreductase activity (Parks and Granger, 1986; Samesto et 
al; 1996), and the enzyme purified from liver showed high specific activity very 
similar to those of the bovine milk and rat liver enzymes (Krenitsky et al, 1986). It is 
possible but not proven that XOR in human tissues can be classified in two groups.
On the one hand, 'high level activity1 enzyme occurs in a limited number of tissues 
such as liver and intestine; and on the other hand, 'low level activity1 enzyme is present 
in breast milk, heart and probably most other tissues. Study of purified human milk 
XOR indicates that high concentrations of the inactive XOR are present in vivo, 
suggesting the possibility of post-translational regulation of activity in response to 
certain stimuli. 'Desulpho'-'sulpho' enzyme conversion of bovine milk XOR has been 
effected by incubation of the reduced enzyme with sulphide ion, resulting in the 
activation of the enzyme (Wahl and Rajagopalan, 1982), and although the mechanism 
is unknown, evidence of post-translational upregulation of XOR in the human 
epithelial cell line HB4a has been reported by my colleagues (Page et al, 1998). A 
number of cytokines have been shown to stimulate XOR activity in these cells without 
a corresponding increase in specific mRNA or XOR protein. Endothelial cells appear 
to belong to the 'low level activity1 group of human XOR enzymes.
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The first report mentioning the presence of XOR in endothelial cells was from Jarasch 
and coworkers in 1981. Since this date, numerous studies have involved endothelial 
cells and tissues from bovine, porcine, rat and human sources (Appendix I). XOR has 
been mainly detected in capillary endothelial cells (Bruder et al, 1983; Jarasch et al, 
1986; Samra et al, 1991 etc.). Detection techniques include histochemistry (Kooij et 
al, 1992; Frederiks et al, 1993a, 1993b; Hellsten-Westing, 1993; Moriwaki et al, 
1993), fluorimetric assays (Bhat et al, 1992; Dupont et al, 1992; Michiels et al, 1992; 
Panus et al, 1992; Hassoun et al, 1994; er-Martinez et al, 1994; Poss et al, 1996; 
Zulueta et al, 1997), spectrophotometric assay of uric acid formation (Ratych et al, 
1987; Palluy et al, 1992; Wiezoreck et al, 1994; Zweier et al, 1994), HPLC (Rodell et 
al, 1987; Phan et al, 1989; Terada et al, 1991, 1992, 1993; Wakabayashi e/a/, 1995), 
radioassays (Jarasch et al, 1986), chemiluminescence (Hellsten et al, 1997), and 
spectrofluorimetric measure of the release ofH202(Yang and Block, 1995).
1.7. The role of endothelial cells
Endothelial cells are one of the most widely distributed cell types. They form a 
continuous layer, lining the blood vessels of the entire vascular system Vascular 
endothelial cells interact with their environment at three different interfaces (Fig. 1.10):
* The basal surface is the endothelial attachment to the basement membrane of the 
underlying vessel intima. The membrane is composed of plasma proteins (such as 
heparin), collagens; laminin; glycoprotein and fibronectin.
* The lateral surfaces interact with adjacent endothelial cells to form a junction which 
regulates permeability and maintains the cell surface polarity.
* The apical or luminal surface interacts with the blood and its cellular elements. The 
apical surface contains adhesion molecules that can bind leucocytes or platelets 
(ICAM-1, ICAM-2 etc.) and it plays a vital role in maintenance of homeostasis and 
vascular events. It is coated with peripheral components such as plasma proteins 










lie. 1.10: Schematic representation o f vascular endothelium.
The endothelium has a variety of roles, the most obvious being the exchange of 
metabolites, nutrients or secretory products between the blood and interstitial fluids. 
The endothelial cells also regulate membrane transport, coagulation and fibrinolysis, 
synthesis and release of vasoactive hormones, etc. Vascular smooth muscle cells as 
well as endothelial cells are capable of producing reactive oxygen species from a 
variety of enzymic sources (Harrison, 1997a).
1.8. Communication between cells
1.8.1. Cell Signalling
Endothelial cells, like other cells, need to communicate with each other or with other 
cells in order to coordinate their movement, metabolic activity and growth. There are 
three general mechanisms for intercellular signalling in multicellular organisms. The 
first is direct contact between the cells, which can communicate via cytoplasmic 
bridges. Cytoplasmic bridges allow intercellular signal molecules to pass from one cell 
to the other, without the necessity of secretion into the extracellular fluid. In animal 
cells, these bridges are referred as gap junctions. Cells can also communicate via
26
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extracellular signal molecules, also called first messengers. First messagers are usually 
secreted by one cell to activate or cause a response in another cell. Finally, surface 
molecules on one cell can interact directly with receptor molecules on another cell 








Fig. 1.11: Possible mechanisms o f cell signalling (Hardie, 1991).
1.8.2. Secretion pathway
Most first messagers are released from cells via exocytosis, a phenomenon which 
includes the fusion of secretory vesicles with the plasma membrane. Proteins that 
enter the endoplasmic reticulum (ER) are converted to glycoproteins by the covalent 
attachment of oligosaccharide side chains. At a number of locations, the outer 
membrane of the nuclear envelope is continuous with the endoplasmic reticulum. The 
proteins are then transported from the ER to the Golgi apparatus by means of 
transport vesicles. The Golgi consists of a collection of flattened, membrane
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bounded sacs, which are like stacks of plates (Fig. 1.12). Each Golgi stack has two 
distinct faces; cis, the entry face and trans, the exit face. The Golgi apparatus modifies 
the proteins and dispatches them. Those destined to be secreted are transported to the 
plasma membrane in transport vesicles that fuse with the membrane (Hardie, 1991; 
Barritt, 1992 and Alberts et al, 1998).
Fis.1.12: The pathway o f secreted proteins (Hardie, 1991).
1.8.3. Secretion of XOR
The intracellular location of XOR is not clear. It is associated with the milk fat 
globule membrane in milk, but can also be detected as a soluble form (Briley and 
Eisenthal, 1974). In other tissues, it is usually reported to be cytosolic. Jarasch et al 
(1981), used both light and electron microscopic immunohistochemical procedures to 
show that XOR is located throughout the cytoplasm of bovine capillary endothelial 
cells. Work on rat hepatocytes concluded that the enzyme was exclusively cytosolic 
with no significant association with intracellular organelles (Ichikawa et al, 1992). 
Moriwaki and coworkers (1993) showed the presence of XOR in human liver cytosol. 
The presence of XOR on the outer cell surface has also been briefly reported in 
bovine aortic endothelial cells (Bulkley, 1991; Schiller et al, 1991) and more recently 
by Vickers et al (1998).
Secretorygranules








The aims of this work were to use cultured human endothelial cells, EA.hy 926, as a 
model system in which to study XOR. Initially, activation of XOR via cytokines was 
investigated in view of a possible intermediary role of XOR-derived ROS in cytokine- 
stimulated expression of CAMs on endothelial cells. In the course of these studies, 
interesting patterns of XOR expression were observed in the EA.hy 926 cells. These 
observations led to demonstration of the extracellular localisation of the enzyme and 




GENERAL MATERIALS AND METHODS.
All the chemicals used were ordered from Sigma (Poole, Dorset), BDH (Poole, 
Dorset), or Fisons (Loughborough, Leicestershire), unless otherwise stated.
2.1. Cell culture
2.1.1. Materials and instruments
Sterile foetal calf serum (FCS) was obtained from Globepharm (Esher, Surrey).
Sterile plastic flasks for cell culture (25, 75, and 150 cm2) as well as disposable sterile 
cryogenic vials (2ml) were ordered from Western Laboratories Services (Hampshire). 
Phosphate buffered saline (PBS) tablets and trypan blue (0.4% solution) were from 
ICN Pharmaceuticals (Oxon). Needles and syringes were provided by South Syringe 
Services (Bristol). Interferon-y (IFN-y) was from Calbiochem-Novabiochem 
(Nottingham). L929 cells, glutamine, minimal essential medium (MEM), and M199 
were obtained from ICN Flow (High Wycombe). Haemocytometers were purchased 
from Gallenkamp-Weber Scientific (Lancing, Surrey). Centrifuges used were MSE 
Micro Centaur, Beckman Instruments L5-50B (for 175,000g) and a Beckman 
Instruments TL 100 (for 500,000g). Cell culture was carried out in a Microflow 
culture hood and a MSE 150 Watt Ultrasonic Disintegrator Mk2 was used for 
sonication.
2.1.2. Cell lines
Essentially, the same procedures of maintenance and subculture of the cells were used 




EA.hy 926, a permanent endothelial cell line, was a gift from Dr A. George, 
Hammersmith Hospital (London). The cells were maintained in RPMI 1640 medium, 
with 10%(v/v) FCS, penicillin/streptomycin [5000 IU/ml for penicillin and 5mg/ml in 
0.9%(v/v) sodium chloride for streptomycin]. They show typical endothelial cell 
characteristics and were positive for von Willebrand factor (vWF) by 
immunofluorescence (Fig.3.1).
2.1.2.2. L929
L929 is a mouse fibroblast cell line established in1943 by W.R. Earle. It was one of 
the first cell lines to be established in continuous culture. The cell line was derived 
from the subcutaneous and adipose tissue of a 100 day old male C3H/An mouse. The 
cells were maintained in MEM with 10%(v/v) FCS, penicillin/streptomycin [5000 
IU/ml for penicillin and 5mg/ml in 0.9%(v/v) sodium chloride for streptomycin] and 
2mM glutamine. The pH of the medium was adjusted to pH 7.4 with NaOH.
2.1.2.3. Human umbilical vein endothelial cells (HUVECs)
HUVECs were obtained from human umbilical veins, kindly donated by the nursing 
staff of the Princess Anne Wing, Royal United Hospitals (Bath). Primary cultures 
were isolated using a method modified from Jaffe et al (1973). HUVECs were 
cultured in M199 with 2mM L-glutamine, supplemented with 20%(v/v) FCS, heparin 
(17 IU/ml), penicillin (100 IU/ml), streptomycin (lOOpg/ml) and endothelial cell 
growth factor (30pg/ml).
2.1.3. Cell culture maintenance and subculturing
Attached cells were initially washed twice with prewarmed PBS (5ml/wash). Trypsin 
[lml; 0.5mg/ml] diluted with EDTA/PBS (3ml) was added to detach the cells. The 
trypsinisation reaction was stopped by the addition of an equal volume of prewarmed 
medium (4ml for a 75 cm2 flask). The cells were removed by trituration using a 
syringe and a No 19 needle to avoid clumps of cells, and then counted in a 
haemocytometer, using a 1:1 dilution with 0.04%(w/v) trypan blue in order to check
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the viability of the cells. The cells were then seeded at the required density, in a 75 
cm2 plastic tissue culture flask, with prewarmed medium (30ml), and incubated at 
37°C, humidified with 5% 00^95% air(v/v). The medium was then changed every 
three to four days, until cells formed a confluent monolayer. All experiments were 
conducted on cells with less than thirty passages after thawing from liquid nitrogen. It 
should be noted that volumes quoted were for a 75 cm2 plastic tissue culture flask; for 
a 25 cm2 flask, the volumes were divided by two.
2.1.4. Preparation of cell supernatant for XOR assay
Cells were trypsinised using the above procedure, transferred into centrifuge tubes 
and centrifuged at room temperature for 5min at 1500 rpm(lOOg). The supernatant 
was discarded and the pellet was resuspended in Cell Buffer [1.2ml; 50mM phosphate 
buffer, pH 7.4, containing 0. ImM EDTA, 0. ImM phenylmethylsulphonyl fluoride 
(PMSF), pepstatin A (1 fig/ml), leupeptin (lpg/ml), antipain (1 fig/ml) and aprotein 
(1 fig/ml)]. Stocks of these inhibitors were dissolved in distilled water except for 
pepstatin A which was dissolved in methanol. The cells were sonicated by using a 
3 mm probe for 20sec (power setting six). A benchtop micro centrifuge tube cooler 
was used during sonication to keep the temperature constant at 5°C. The resulting cell 
homogenates were ultracentrifuged at 4°C, either for 25min at 35,000 rpm 
(175,000g), or for lOmin at 100,000 rpm (500,000g). These supernatants were then 
used for fluorimetric assay (Section 2.3.2), for Western blotting (Section 2.4.3), and 
when necessary, for XOR protein ELISA (Section 2.6).
2.1.5. Cryopreservation
The cells were trypsinised, as described above, and the trypsinisation was stopped by 
adding medium and 10% dimethylsulphoxide (DMSO). The cells were aliquoted in 
cryogenic tubes and stored for 24h at -70°C, before being immersed in liquid nitrogen. 
Aliquots were thawed by immersion in a 37°C waterbath and the cells were set in a 25 
cm2 flask with the appropriate medium. After 24h, the medium was changed to 
remove the toxic effects of DMSO. When the cells were confluent, they were 





Bio-Rad protein dye reagent concentrate was obtained from Bio Rad (Hemel, 
Hempstead, Hertfordshire). Plastic cuvettes (1ml) were from Griffiths and Nielson 
Plastics Ltd (Billingshurst, Sussex). The 595nm absorbance was read on a Multimode 
computing UV spectrophotometer, CE6600 from CECIL Instruments Limited 
(Cambridge).
2.2.2. Method
The protein estimation was carried out on cell supernatants, using the method 
developed by Bradford (1976). Bovine serum albumin (BSA) in assay buffer (lmg/ml) 
was used as a standard, in a range from 2 to lOpg in a volume of lOOpl. Each sample 
was appropriately diluted and a final volume of lOOpl was used. The Bio-Rad protein 
assay dye reagent (1ml; dilutionl:5) was added and the mixture was left for 15min to 
react. The absorbance at 595nm was read on the spectrophotometer.
2.3. Assays of XOR enzymic activity
2.3.1. Chemicals and instruments
The fluorimetric assay was carried out on a Perkin Elmer (Beaconsfield, Bucks) LS- 
5B luminescence spectrometer. The xanthine oxidoreductase inhibitors amflutizole 
(Wems et al, 1991) and (-) BOF 4272 (Okamoto and Nishino, 1995) were gifts from 
Professor D.R. Blake (Postgraduate Medicine, University of Bath). Human milk 
xanthine oxidoreductase was prepared by Dr Steve Sanders (School of Biology and 
Biochemistry, University of Bath). Absorbances were read on a Multimode computing 
UV spectrophotometer, CE6600 from CECIL Instruments Limited (Cambridge). 
Acrylic cuvettes (1ml) were from Griffiths and Nielson Plastics Ltd (Billingshurst, 
Sussex). The cells (Section 2.1.2) were grown on four chambered polystyrene glass 
sides obtained from Nunc Inc. (Naperville, IL, USA).
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2.3.2. Fluorimetric assay of pterin oxidation
The fluorimetric assay used was based on that described by Beckman et al (1989).
This method was modified for our cell lines (principally EA.hy 926 cells) to detect 
XOR enzymic activity in cell homogenates (Rouquette et al, 1997). The fluorimeter 
was used with an excitation wavelength of345nm, and the emission wavelength set at 
390nm with 5nmband width slits. The recording was at scale five or one, at a chart 
speed of 0.5cm/min. All the reagents were first brought to room temperature. A 
baseline was obtained with a mixture of cell supernatant (0.5ml) and buffer (50mM 
potassium phosphate, pH 7.4, containing 0. ImM EDTA; 0.48ml). When a stable 
baseline was obtained, ImM pterin (lOjil) and ImM methylene blue (10pl) were 
added, each to a final concentration of lOpM. The increase in fluorescence was 
recorded and this value was a measure of the total (xanthine oxidase and xanthine 
dehydrogenase) activity in the cell supernatant. The specificity of the activity was 
checked by adding 50pM of allopurinol (50pl), a specific competitive inhibitor of 
xanthine oxidoreductase. Finally, the reaction was calibrated by addition of a range of 
concentrations of lOpM isoxanthopterin (2 to 4pi, repeating addition five times), see 
Fig. 3.4.
From the isoxanthopterin standard curve, a linear regression best fitted line was 
plotted. Rates from the chart recorder, expressed in fluorescence units/min (F/min), 
were converted to pmoles isoxanthopterin/min by plotting this rate into the linear 
regression line. The value was converted to pmoles isoxanthopterin/min/ml by 
dividing the results obtained by the volume of the sample (in most of the case 0.5ml). 
Finally, the result was expressed in pmoles/min/mg protein.
2.3.3. Determination of xanthine and dehydrogenase activities of XOR
The oxidase content of XOR was determined by measuring the rate of oxidation of 
xanthine to uric acid spectrophotometrically at 295nm, using an absorption coefficient 
of 9.6mM'1cm'1 (Avis et al 1956). Assays were performed at 37°C, in a 1ml cuvette in 
50mM sodium/Biocine buffer, pH 8.3 (800pl) containing lOOpM xanthine (100pi). 
The sum of oxidase and dehydrogenase contents was determined as above but in the 
presence of 0.5mM NAD (lOOp.1).
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The effects of a number of inhibitors of XOR were investigated. In each case, a linear 
rate was established for 2-3min before addition of the inhibitor. These were prepared 
as follows. Allopurinol was dissolved in 0.2M NaOH to a concentration of lOmM. 
The solution was diluted 1:10 in PBS at a final concentration of 50(xM (20pl was 
added to the cuvette). The presence of NaOH did not affect the final pH of the assay. 
(-) BOF 4272 was dissolved in distilled water (600ml) at a final concentration of 
0.118pM (10(xl was added to the cuvette). Amflutizole (3mg) was dissolved in 1ml 
DMSO and made up to a final volume of 100ml with distilled water at a final 
concentration of 0.104pM (lOpl was added to the cuvette). The percentage of 
activity which remained after the addition of the inhibitor was calculated.
2.3.4. Determination of NADH oxidase activity on cell surfaces
NADH oxidation was measured spectrophotometrically at 340nm, using an extinction 
coefficient of 6.22mM1cm 1. Cells were seeded in the four chambered glass slides at 
2xl05 cells/ml for EA.hy 926 cells and 1.5xl05 cells/ml for L929 cells the day before 
the experiment (Section 2.2). On the day of the experiment, the medium was poured 
off and the cells were washed twice with prewarmed PBS. Fresh medium (0.9ml) was 
then added to each chamber. NADH (stock solution 5mM) was added to the 
chambers to a final concentration of 500jxM (100fil). Blanks correspond to medium 
only. Controls were carried out in bijoux containing cell free medium (0.9ml) and 
NADH (0.1ml). The chambers and bijoux were incubated at 37°C, humidified with 
5% CC>2/95% air (v/v) throughout the experiment. Aliquots (100pi) were taken at 
different time points and were diluted in the acrylic cuvette to 1ml with prewarmed 
PBS. The absorbances were read at 340nm. The disappearance of NADH in terms of 
decrease in absorbance at 340nm was generally followed for 6h, apart for the first 
experiment in which a 5h assay was used.
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2.4. SDS-PAGE and Western blotting
2.4.1. Chemicals and instruments
Acrylamide was obtained from Flowgen Instruments, Staffordshire. BBXO (Biozyme 
bovine xanthine oxidoreductase) was ordered from Biozyme (Blaenavon, Gwent). 
Electrode paper and the Multiphor II Electrophoresis System were provided by 
Pharmacia Biotech (Uppsala, Sweden). Nitrocellulose membranes were obtained from 
Gelman Sciences. Blocking buffer was ordered as SuperBlock from Pierce &
Warriner (Chester). Rabbit anti-human XOR antiserum and affinity purified rabbit 
polyclonal anti-HXOR antibody were supplied by Dr M. Benboubetra and Richard 
Bryant (School of Biology and Biochemistry, University of Bath).
2.4.2. SDS-PAGE
SDS-PAGE was based on the method of Laemmli (1970) and vertical slab gels were 
used. The separating gel consisted of 10%(w/v) acrylamide in 1.5M Tris-HCl, pH 8.8 
containing 0. l%(w/v) SDS. The gel was polymerised by the addition of N,N,N’,N’- 
tetramethylethylenediamine (Temed, 0.4pl/ml) and 0.1%(w/v) ammonium persulfate. 
The stacking gel consisted of 5%(w/v) acrylamide, 1.5M Tris-HCl (pH 6.8), and 
0. l%(w/v) SDS, polymerised by the addition of Temed (lpl/ml) and 0. l%(w/v) 
ammonium persulfate. The cells, prepared as described in Section 2.1.4, were 
resuspended in phosphate buffer (pH 7.4), to obtain a concentration of lxlO6 cells 
per 50pi buffer. After sonication and ultracentrifiigation (Section 2.1.4), sample buffer 
[62.5mM Tris-HCl (pH 6.8) containing l%(w/v) SDS, 50%(w/v) glycerol, 10%(v/v) 
2-mercaptoethanol, and 0.005%(w/v) bromophenol blue] was added in a ratio of 1:1. 
These samples (lOOpl/well), including the molecular markers (2pl/well), BBXOR 
(Biozyme xanthine oxidoreductase; lOpl/well), and human xanthine oxidoreductase 
(HXOR, lOpl/well) were boiled for 5min, microcentrifuged and finally loaded onto 
the gel, and were run at 200V, 80mA using a running buffer [0.192M glycine, 25mM 
Tris and 0. l%(w/v) SDS; pH 8.3] diluted 1:10 in water. Unless used for 
electrotransfer, the gels were stained with Coomassie Blue [45%(v/v) methanol, 
10%(v/v) acetic acid, and 0. l%(w/v) Coomassie Brilliant Blue], and destained with 




3MM electrode paper and nitrocellulose, corresponding to the size of the gel, were 
impregnated with transfer buffer [0.048M Tris, 0.039M glycine, 1.3M SDS, and 
5%(v/v) methanol]. The electrode paper, the nitrocellulose and the gel were 
assembled on the electrophoresis system, taking care to avoid creating any air 
bubbles. Electrotransfer was carried out at a constant current of 0.8 mA/cm2 [i.e., 
current = length (cm) x width (cm) x 0.8], for 1.5h. When the transfer was finished, 
the gel was stained to check for complete transfer. The nitrocellulose was placed in 
Ponceau S [0.2%(w/v) in 5%(v/v) trichloroacetic acid] to visualise the bands of 
proteins. After marking the bands, the membrane was washed with TBS [lOmM Tris, 
0.9%(w/v) NaCI, pH 7.4] and incubated overnight at 4°C in blocking buffer 
(SuperBlock) or 2%(w/v) BSA solution in TBS.
For immunoblotting, the membrane was first washed with TBS-Tween [TBS 
containing 0.05% Tween 20]. The primary antibody was then incubated with the 
nitrocellulose for 2h in a 1:1000 dilution of rabbit anti-human XOR antiserum or 
affinity purified rabbit polyclonal anti-HXOR antibody in TBS-Tween (5ml), 
containing l%(w/v) BSA. After three washes with TBS-Tween (lOml/wash), the anti­
rabbit biotin conjugated antibody [diluted 1:500 in TBS-Tween, containing l%(w/v) 
BSA; 5ml] was added and incubated for lh. The blot was washed three times with 
TBS-Tween (lOml/wash), and incubated with ExtrAvidin-peroxidase (diluted 1:4000; 
5ml) for lh. The membrane was then washed three times with TBS-Tween 
(lOml/wash), followed by one wash with TBS. Finally, the antigen was revealed using 
a peroxide substrate [10ml;16.6%(v/v) 4-chloro-l-naphthol (3mg/ml) solution in 
methanol, 83.3%(v/v) TBS, and 0.04%(v/v) H20 2, 30%(w/w) volume].
2.5. Immunoprecipitation
Protein A-Sepharose CL-4B (50 mg) was first washed with PBS (5ml/wash) before 
the primary antibody affinity purified rabbit anti-human XOR (lOOmg) was added and 
incubated overnight at 4°C. After three washes with fresh PBS (5ml/wash), the cell 
homogenate (Section 2.1.4; 1.2ml/75 cm2 flask) was added and the solution was left
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rotating overnight at 4°C. Three washes with PBS (5ml/wash) were then carried out 
and the antigen-protein complex was dissociated by adding a solution (0.5ml) of 
6M(w/v) urea, 10% (w/v) SDS and 0. l%(w/v) bromophenol blue in H20. The 
dissociation was carried out for 30min at 4°C, after which insoluble matter was 
allowed to settle at room temperature for lOmin. The supernatant was boiled for 5min 
and loaded onto a gel for detection of XOR protein (Section 2.4.2). Western blotting 
was then carried out (Section 2.4.3).
2.6. Sandwich ELISA for determination of XOR protein
2.6.1. Materials and instruments
Eight well racks were obtained from Nunc Inc (Naperville, IL, USA). A Multiskan 
MCC/340, Labsystem (Finland), was used to read absorbances at 492nm.
2.6.2. Method
ELISA was carried out on cell supernatants using a method developed in this 
laboratory (Price and Harrison, 1993). Polystyrene wells were coated with affinity 
purified rabbit polyclonal anti-HXOR antibody (4 pg/ml; lOOpl/well). After blocking 
with PBS-Tween [PBS containing 0.05%(w/v) Tween 20] containing l%(w/v) BSA 
or casein, for 1.5h at 37°C or overnight at 4°C, the wells were washed three to five 
times with PBS-Tween (lOOpl/well; 5min/wash). Purified human milk XOR 
(lOOpl/well) was then added to the wells using serial dilutions, ranging from 175ng/ml 
to 0.62ng/ml, in order to establish a standard curve. Cell supernatant (Section 2.1.4) 
was added either undiluted or diluted (1:2 and 1:5) at 100pl/well. The second 
antibody, biotinylated affinity purified rabbit polyclonal anti-HXOR (100pi), was 
added. After lh incubation and washing, streptavidin-HRP (lOOpl) was added for 
20min and the wells were washed. The reaction was revealed by using the peroxidase 
substrate [lOOpl/well; 1% tetramethylbenzidine in DMSO diluted 1:100 in 0.1M 




It was then stopped after 10-15 min with 1M H2S04 (50pl/well), and absorbances 
were read at 492nm in each well.
2.7. Immunohistochemical characterisation and confocal microscopy
2.7.1. Materials and instruments
Affinity purified rabbit anti-human von Willebrand factor (vWF) antibody was 
provided by Dako (Denmark). Anti-rabbit FITC conjugated antibody came from 
Jackson Immunoresearch Labs., Inc. (West Grove, PA, USA). Vectshield Mounting 
medium for fluorescence was obtained from Vector Labs (Peterborough). Affinity 
purified mouse anti-TNG38 antibody was a gift from Dr George Banting (Department 
of Biochemistry, University of Bristol) and Dr Barbara Reaves (School of Biology 
and Biochemistry, University of Bath). Affinity purified rabbit polyclonal anti-bovine 
milk XOR was obtained from Chemicon (Harrow) and affinity purified rabbit 
polyclonal anti-HXOR antibodies were prepared by Richard Bryant (School of 
Biology and Biochemistry, University of Bath). Four chambered polystyrene slides 
were obtained from Nunc Inc. (Naperville, IL, USA). Images were collected on a 
confocal laser-scanning microscope: LSM510 with either a x40 1.30 NA or a x63 
1.40 NA Apochromatic objective, Carl Zeiss (Welwyn Garden). Where mentioned, 
some images were also collected either using a laser emission confocal fluorescence 
cytometer (Bio-rad MRC 500) or a fluorescent microscope (Leica BMIRB). The 
488nm and 468nm lines of a laser were used for excitation of FITC and rhodamine 
respectively.
2.7.2. Characterisation of endothelial cells with von Willebrand factor
Trypsinised cells were added to the chambers at approximately 2xl05 cells/ml 
(lml/chamber). The cells were left to adhere to the slide for 24h at 37°C, after which 
time the slide was washed twice with prewarmed PBS (lml/chamber) and then fixed 
by treatment for 15min with 5%(v/v) acetic acid / 70 %(v/v) ethanol (lml/chamber) at 
-20°C. Another wash with PBS (lml/well) was carried out before blocking with 
3%(v/v)FCS/PBS (lml/chamber) for 30min and incubating at room temperature.
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After blocking, the cells were incubated with affinity purified rabbit anti-human vWF 
antibody (lml/chamber; dilution 1:200 in 3%(v/v) FCS/PBS), for 2h at 37°C. The 
slide was then washed twice in 3%(v/v) FCS/PBS (lml/chamber), and incubated with 
anti-rabbit FITC conjugated antibody (lml/chamber, dilution 1:100 in 3%(v/v) 
FCS/PBS) for lh at 37°C. Finally, the cells on the slide were washed three times with 
PBS (lml/chamber) and mounted under a coverslip. They were observed using a laser 
emission confocal fluorescence cytometer (Fig. 3.1). Control chambers lacked either 
primary or conjugated antibodies.
2.7.3. Localisation of XOR protein
Cells were grown to confluence in four chambered polystyrene glass slides at 
approximately 2xl05 cells/ml (lml/chamber). They were first washed twice with PBS 
(lml/chamber) and fixed with 4%(v/v) formaldehyde [PFA in PBS with 0.11% (v/v) 
10M NaOH and 0.06% (v/v) concentrated HC1; lml/well]. This fixation step was 
followed by three washes in PBS (lml/chamber). To permeabilise the cells, a 45min 
incubation was used with 0. l%(w/v) saponin in PBS (lml/chamber). Then the first 
antibody (affinity purified rabbit polyclonal anti-HXOR or mouse monoclonal anti- 
HXOR antibody) was applied to the cells for 2h [different dilutions were used in PBS 
containing 0. l%(w/v) saponin, l%(w/v) BSA and 3%(w/v) NGS; 0.5ml/well]. Before 
the second incubation, the cells were washed three times in PBS/0. l%(w/v) saponin 
(lml/chamber). The second antibody was then applied for lh: anti-rabbit FITC 
conjugated or anti-mouse FITC conjugated antibodies [dilution 1/100 in PBS 
containing 0.1%(w/v) saponin, 3%(w/v) NGS and l%(w/v) BSA; 0.5ml/well]. Cells 
were washed three times before being mounted using 10pi of Vectashield Mounting 
medium over which a coverslip was placed with care to avoid air bubbles. The 
coverslip s were sealed with fingernail vanish and these sealed slides were kept in the 
dark at 4°C.
For unpermeabilised cells, the same procedure was followed but no saponin was used. 
In these conditions, cells did not stain when incubated with Golgi marker TGN38 and 
using anti-mouse rhodamine secondary antibody (Chapter 6). After the fixation step, 
the first antibody was directly added to the cells.
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All the washes were done in PBS only. In all cases, cells were assessed for 
fluorescence intensity using a laser emission confocal fluorescence cytometer.
2.7.4. Confocal microscopy
The laser was set on 70%. Slides were observed with oil for x400 and x630. The 
pinhole (small aperture) was adjusted to around one unit. Amplitude gain was 
adjusted up to three, depending on the sample. Amplitude offset was set at -0.5. 
Images were first scanned once, then the intensity and the focus were adjusted. Final 
images were scanned on eight units and saved on the computer linked to the 
microscope. When necessary the reuse conditions were utilised, so the same 
conditions were applicable and allowed comparison to controls. When colocalisation 
studies were done, krypton/argon ion lasers were operated at the same time with 
excitation of fluorescein at 488nm and of rhodamine at 468nm.
2.8. Heparin-agarose treatment of medium to remove XOR
2.8.1. Materials
Sterile and disposable filters, 0.2pm were obtained from Gelman sciences (Ann Arbor, 
USA). For medium, see Materials 2.1.1.
2.8.2. Method
A column (3.5cm x 1.5cm) of heparin immobilised on cross-linked 4% beaded 
agarose (activation: cyanogen bromide) was first washed with 30ml serum free 
medium (RPMI medium, penicillin/streptavidin). Growth medium (100ml) containing 
10%(v/v) FCS was then passed through the column and collected in a sterile 
container. This medium was then filtered sterile using a 0.2pm filter, and a 10ml 
syringe. This medium was used for growing cells and was called "XOR free medium". 
The column was washed with 25mM sodium phosphate buffer, pH 7.4, until the A28o 
reached a baseline level. XOR protein which would have bound to the column was 
then eluted using 25mM sodium phosphate buffer containing 1 M NaCl.
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This protein containing fraction (A280) was assayed for XOR enzymic activity using 
the fluorimetric method as described in Section 2.3.2.
2.9. Anti-XOR antibodies
2.9.1. Materials
Cyanogen bromide-activated (CNBr) Sepharose B was purchased from Amersham 
Pharmacia Biotech Ltd. (Herts). Capped tubes were obtained from Bibby Sterilin 
(Stone, Staffordshire).
2.9.2. Purification of monoclonal anti-XOR antibody
Cyanogen bromide-activated Sepharose B was resuspended in 0.001M HC1 (200ml), 
swirled gently and then left to swell for 15min. The gel was washed on a sintered 
funnel with 0.001M HC1 (600ml), distilled water (600ml), and 0.1M sodium hydrogen 
carbonate buffer, pH 8.3 (600ml). Protein A (20 mg) was dialysed against several 
changes of coupling buffer, 0.1M sodium carbonate buffer, pH 8.3, containing 0.5M 
sodium chloride. The protein A was added to the gel at a ratio of lOmg protein per ml 
swollen gel (3g Sepharose 4B swelled to approximately 10ml). The ligand and the gel 
were tumbled end-over-end for 12h at 4°C, in a capped tube. After coupling, the gel 
was centrifuged at 300 g for lOmin; the supernatant containing any uncoupled ligand 
was retained for a protein estimation. The gel was washed twice with coupling buffer 
(5ml/wash), by mixing the gel with the buffer and centrifugation. The remaining active 
groups on the matrix were blocked with 1M ethanolamine, pH 8, for 2h. The gel was 
washed with three cycles (5ml/cycle) of alternating pH: 0.1 M sodium acetate 
(containing 0.5M sodium chloride), pH 4, and 0.1M. sodium acetate (containing 0.5M 
sodium chloride), pH 8. The column (6cm x 1.3cm) was made up using the gel and 
was washed with PBS containing 0.02%(w/v) sodium azide at 4°C. It was then 
equilibrated with PBS.
Frozen supernatant from monoclonal clones was thawed and subjected to a protein 
precipitation with 50%(w/v) ammonium sulphate for 30min. After 15min 
centrifugation (3000 rpm), the pellet was rinsed twice with PBS (5ml/wash),
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resuspended in a few ml of PBS and dialysed against PBS (51) overnight, at 4°C. The 
contents of the dialysis tube were centrifuged for lOmin at 3000 rpm, before being 
circulated through the column, overnight. After this binding period, PBS was used to 
wash off non-specific proteins until the A2go was negligible. Bound antibodies were 
eluted with 4M urea and dialysed overnight against several changes of PBS (21). The 
antibody solution (5 to 10ml) was concentrated by dialysis against polyethylene glycol 
(lOg, PEG 20,000) for lh at 4°C. The specificity of the antibody was checked by 
using SDS gel electrophoresis (Section 2.4.2) and protein assay (Section 2.2).
2.9.3. Affinity purified rabbit polyclonal anti-XOR antibodies
Unless otherwise mentioned, antibodies used were raised in rabbits and affinity 
purified on human XOR in our laboratory by Dr Mustapha Benboubetra and Richard 
Bryant (School of Biology and Biochemistry, University of Bath). The specificity of 
affinity purified rabbit polyclonal anti-HXOR antibodies was established by Western 
blotting of human cell extracts (Page et al, 1998 and Chapter 5).
2.10. Statistics
For each assay, the mean was calculated as well as the standard error of the mean of 
at least four determinations. The number of times separate experiment was carried out 
is expressed by 'n' in the figures.
The Mann Whitney U test was used because the sample sizes were too small to 
support the assumptions of parametric tests such as the Student's /-test. Samples were 
considered significantly different when P<0.05 (Siegel, 1956). However, for samples 
on the borderline, a /-test for comparing the mean of two small samples was also 
carried out. In this case, the difference was considered to be significant when P<0.01. 
Note that the /-test assumes that samples are drawn from a normally distributed 




CHARACTERISATION OF EA.hy 926 CELLS 
AND EXPRESSION OF XANTHINE 
OXIDOREDUCTASE.
3.1. Introduction
3.1.1. Presence of xanthine oxidoreductase in human cells and tissues 
The presence of XOR in endothelial cells was first reported by Jarasch et al in 1981. 
They demonstrated by using immunolocalisation that XOR was present in the 
capillary endothelial cells of many bovine tissues (liver, heart, intestine, lung). In 
1986, Jarasch and coworkers showed the presence of XOR in human endothelial cells. 
The radioimmunoassay results indicated that levels of the protein were much higher in 
endothelial cells than in other types of cells. A number of researchers have since 
sought XOR activity in human cells and the overall results are shown in the following 
table. It can be seen that the conclusions are highly variable. In some cases, no activity 
was found in the basal state (Michiels et al, 1992; Hassoun et al, 1994; Paler- 
Martinez et al, 1994 and Powell, 1995), while in others, activities vary with cell type, 
and method of assay (Jarasch et al, 1981, 1986; Palluy et al, 1992; Frederiks et al, 
1993a, 1993b; Moriwaki et al, 1993; Terada et al, 1993; Zweier et al, 1994, Hellsten 
et al, 1997 and Telfer et al, 1997).
Cells/ tissues 
studied
XOR activity * 
XOR amount +
Method of detection References
Bovine EC and 
tissues.
+ Capillary EC from 
liver, heart, lung and 
intestine.




in bovine and 
human tissues.
*, + Positive: capillary 
EC of many tissues.
Histochemistry.
Radioimmunoassay.
Jarasch et al, 
1986.
HUVECs. * XO activity after 
hypoxia. Undetectable in 
basal state.




HUVECs. * Hypoxia induces an 
increase in XO activity 
and decrease in XDH 
activity.
Urate assay. Palluy et al, 
1992.
Human and rat 
tissues.
* High activity: EC and 
KupfFer cells from rat & 
human liver. Low 
activity: liver 




Frederiks et al, 
1993a.
Rat tissues: liver 
and small 
intestine.
* Rat liver: very low XO 
activity, with higher 
activity in EC. High 
activity in epithelial 




Frederiks et al, 
1993b.
Human liver and 
tissues.
+ Localisation: EC from 
heart, kidney, brain, 







Moriwaki et al, 
1993.
HUVECs. * XO + XDH activity 
detectable. Add IFN-y, 
no change seen.
Uric acid formation 
by HPLC.






* No activity in porcine 
PAEC and HUVECs 
even after exposure to 
hypoxia.
Fluorimetric assay. Hassoun et al, 
1994.
Bovine aorta EC, 
human aorta EC, 
human coronary 
artery EC, human 
microvascular 
EC, porcine aorta 
EC, rat aorta EC, 
rat pulmonary 
artery EC.
* No activity found 
except in BAEC and 
Pulmonary artery EC.













Zweier et al, 
1994.
















Hellsten et al, 
1997.
Endothelial cells 
of blood vessels in 
placenta.
+ XO was present in 
cells. No difference in 
tissues obtained after or 





Telfer et al, 
1997
Table 3.1: Summary o f  the studies effected on the expression o f  XOR in mainly 
human endothelial cells and tissues.
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3.1.2. The choice of the EA.hy 926 cell line
It was largely the lack of reproducible results (Table 3.1) that led to the work 
reported in this thesis. The aim was to develop a model human endothelial cell system 
in which the presence and the role of XOR could be studied quantitatively. In order to 
investigate the role of XOR in signal transduction, it was convenient to focus on a 
specific cell type and for these purposes, the immortal human endothelial cell line 
EA.hy 926 was chosen. This permanent cell line was established in 1983 by Edgell et 
al. It was derived by fusing HUVECs with a human epithelial carcinoma cell line, 
A549. The resulting hybridoma has been shown to retain a number of properties of 
the parental endothelial cells including the production of von Willebrand factor, vWF, 
(Edgell et al, 1983). The EA.hy 926 cell line contains measurable XOR, in contrast to 
HUVECs, in which XOR can only be detected using immunofluorescence and 
microscopy (Chapter 6). As a cell line, EAhy 926 cells have the advantages of 
avoiding the problems posed by primary HUVECs which are difficult to harvest from 
umbilical cords, prone to infection, have a limited useful passage life and require 
special growth factors. Finally, there are unacceptable variations in HUVECs from 
donor to donor, requiring the pooling of several umbilical cords for each population 
of HUVECs.
3.2. Characterisation of EA.hv 926 cells
The cells were characterised as endothelial cells by using an anti-human vWF 
antibody. All the cells showed fluorescent staining (Section 2.7.2), as already 
described by Edgell et al in 1983 (Fig.3.1). vWF is an adhesive protein synthesised by 
endothelial cells. In endothelial cells, vWF undergoes several post-translational 
modifications. It is secreted constitutively or stored in intracellular secretory Weibel 
Palade bodies (Vischer et al, 1995). vWF is released from endothelial cells as very 
large multimers and circulates in the plasma (Vlot et al, 1998).
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This cell line also expresses prostacyclin (Suggs et al, 1986) and thrombomodulin 
(Debault et al, 1984), and releases of platelet-activating factor (Bussolino et al,
1986). In 1988, Emeis and Edgell reported the fibrinolytic characteristics of EA.hy 
926 cells, resembling those of primary cultured human endothelial cells. EA.hy 926 
cells are widely accepted as a model for endothelial cells in different areas of research. 
They have been compared to HUVECs to which they were shown to have similar 
adhesive responses when stimulated with TNF, but not with IL-4 or IFN (Thornhill et 
al, 1983). When endothelin converting enzyme was purified from EA.hy 926 cells, the 
enzyme kept the properties of the primary cell line (Ahn et al, 1995). The cell line was 
also used as a model for studying endothelial cell-induced modification of LDL (low 
density lipoprotein), in which respect there were no significant differences from 
HUVECs (Pechamselin et al, 1996). However, in 1997, Claise and coworkers showed 
that the antioxidant enzyme activities of superoxide dismutase (SOD), catalase and 
glutathione peroxidase were significantly lower (respectively 54%, 71% and 8% of 
levels in HUVECs) in EA.hy 926 cells compared with HUVECs. These lower 
antioxidant defences need not affect our model in which catalase and SOD are of most 
interest (Chapter 5).
EA.hy 926 cells show the characteristic appearance of endothelial cells; Fig.3.2 
illustrates the cells at day 4. The endothelial cells grow into a single cell confluent 
monolayer, developing a characteristic "cobblestone" morphology. Their doubling 
time is 17h ± lh, as shown in Fig.3.3. The cells were routinely passaged up to a 





Fie. 3.1: Characterisation o f the EA.hy 926 cells with anti-vWF antibody.
Cells were permeabilised and fixed by incubation fo r  15min with 5%(v/v) acetic 
acid /70%(v/v) ethanol at -20 °C. Blocking was carried out with 3%(v/v) FCS/PBS. 
After washing with PBS, anti-vWF antibody was incubated with the cells fo r  lh  
(dilution 1:200). Cells were washed with PBS and secondary antibody, FITC 
conjugated anti-rabbit, was incubated with the cells fo r  lh  (dilution 1:100), 
(Section 2.7.2). Laser emission confocal cytometerwas used, x400. 
Immunofiuorescent images o f cells treated as mentioned above (A, C) and 
differential interference contrast (DIC) images (B, D) are shown.
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Fig. 3.2: Morphology o f cultured EA.hy 926 cells.
Cells were set up at 2x10s cells/ml on day 0, and photographed on day 4. 
(Magnification x 100).
The cell growth pattern (Fig. 3.3) shows a lag phase of between zero and two days 
after which the growth was exponential between 2-5 days. Confluence was achieved 
on day 8. During stationary phase the number of cells fluctuated until day 14 and even 
sometimes decreased after day 10. This variation might be due to cell death from 
overcrowding followed by cell proliferation when space and nutrients are available. 
The viability of the culture was checked by using trypan blue exclusion (Section 
2.1.3). A culture was not used if the viability was below 97%.
3.3. XOR activity in EA.hy 926 cells
Having characterised the cells, the next step was to detect any XOR activity in this 
cell line. For this purpose, a sensitive fluorimetric assay based on Beckman et al 
(1989) was used. Total XOR activity (oxidase and dehydrogenase forms) was 
calculated in pmoles/min/mg. As the same time, the number of viable cells was 




Fig. 3 .4 shows the growth profile obtained when the cells were set up at 2xl05 
cells/ml. The cells grew to form a monolayer reaching confluence after 8 days. XOR 
activity lagged behind cell growth, first becoming detectable on day 5. After this initial 
lag phase, the enzyme activity rose steeply and reached a plateau around day 8-9, 
when the cells are confluent. This plateau is followed by another rise which reached 
maximal values from day 11. The maximum activity obtained was between 2.5-3 
pmoles/min/mg protein. The first experiments were carried out using 
ultracentrifugation at 500,000g for lOmin as in the methodology described by Powell 
(1995). However, this was considered to be excessive and the speed was reduced to 
175,000g for 25min. As shown in Fig.3 .4 B, a similar pattern of XOR expression was 
found. Therefore a centrifugation speed of 175,000g was used for subsequent 
experiments.
Fin. 3.3: Growth curve o f the EA.hy 926 cell line.
Every day the cells were counted by trypan blue exclusion. Cell number expressed by 
n x  JO5 was plotted. Four growth curves, done in duplicate, were plotted together, 
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Fig. 3.4: Expression o f XOR in EA.hy 926 cells with time o f culture and cell 
number.
Every 24h, cells were trypsinised, counted by trypan blue exclusion, then centrifuged 
(1500 rpm, 5min) and the pellet was resuspended in cell buffer (1.2ml). Ihe cells 
were sonicated by using a 3mm probe fo r  20sec and the resulting homogenates were 
ultracentrifugedfor: A) lOmin at 100,000 rpm (500,000g), B) 25min at 35,000 rpm 
(175, OOOg). Specific XOR activities o f  cell supernatants were measured on a 
fluorimeter, in the presence o f pterin and methylene blue (Section 2.3.2). Protein 
assay was also carried out on the cell supernatants (Section 2.2). The specific XOR 
activity was expressed in pmoles o f  isoxanthopterin/min/mg protein. Cells were 
seeded at 2x105 cells/ml on day 0. Every day 2 x 75 cm2 flasks were assayed fo r  total 
XOR activity; two samples were analysed per flask. Values are given as mean ±  
SEM; A n=8; B n=2.
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3.3.2. Effects of different cell densities on induction of XOR
In view of the possibility that induction of XOR activity depended on cell density, the 
expression of XOR activity in EA.hy 926 cells was monitored in cultures with 
different densities. At the lowest density, lxlO5 cells/ml, (Fig.3.5 A) a very similar 
pattern was found compared to Fig.3.4. The enzyme was absent for the first five days. 
Its activity then increased to a maximum at a time when the cells are confluent. The 
plateau is less obvious in this experiment compared to Fig.3.4. A second steep rise 
then occurs during the time that the cell number is constant and then the activity starts 
to decrease. It can be noticed that the cell number, for example, rapidly reached the 
same level as when the cells were set at 2xl05 cells/ml, while both the patterns of 
expression and levels of specific xanthine oxidoreductase activity were comparable. 
When the cells were set at an higher density, the cell growth pattern appeared to be 
disturbed. XOR activity was detected earlier (Fig.3.5 B) and on day 3, activity at a 
relative high level was apparent. The cells did not grow very happily when set at this 
level, perhaps because of competition for space and nutrients, as they had a tendency 
to grow on top of each other.
3.3.3. Analysis of XOR activity during the growth cycle
It is possible that XOR activity is present but below the level of detection for this 
assay. Indeed, this is possibly the case because immunofluorescent techniques 
(Chapter 6) shows that XOR protein is present on the surface of cells at all stages of 
the growth cycle looked at. However, though the immunofluorescence shows XOR 
protein is present, it does not indicate whether or not this protein has enzyme activity. 
An attempt was made to increase sensitivity of the above XOR assay by increasing the 
amount of cell protein in the assay. It was found that cells from three 75 cm2 flasks 
could be combined, processed and assayed (see above). If more cell protein was used 
it would have interfered with the measurements. As shown in Fig.3.6, no activity was 
detectable using the sensitive fluorimetric assay on day 2 with three times the number 
of cells. On day 3, a very low activity was found in some samples but not in all. Some 
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Fig. 3.5: Expression o f XOR at lower and higher density with time o f culture and 
cell number.
Every 24h, cells were trypsinised, counted by trypan blue exclusion, then centrifuged 
(1500 rpm, 5min) and the pellet was resuspended in cell buffer (1.2ml). The cells 
were sonicated by using a 3mm probe fo r  20sec and the resulting homogenates were 
ultracentrifuged fo r  25min at 175,000g. Specific XOR activities o f  cell supernatants 
were measured on a fluorimeter, in the presence o f  pterin and methylene blue 
(Section 2.3.2). Protein assay was also carried out on the cell supernatants (Section 
2.2). The specific XOR activity was expressed in pmoles o f isoxanthopterin/min/mg 
protein. Cells were set up on day 0 at: A) 1x105 cells/ml, B) 3x105 cells/ml.
Every day, 2 x 7 5  cm2 flasks were assayed fo r  total XOR activity; two samples were 
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Fin. 3.6: Expression o f XOR activity during the first part o f the time course, 
determined by using higher celt number.
Every 24h, cells were trypsinised, counted by trypan blue exclusion, then centrifuged 
(1500 rpm, 5min) and the pellets were put together in the case o f the three flasks and 
were resuspended in cell buffer (1.2ml). The cells were sonicated by using a 3mm 
probe fo r  20sec and the resulting homogenates were ultracentrifuged fo r  2 5m in at 
35,000 rpm (175,000g). Specific XOR activities o f  cell supernatants were measured 
on a fluorimeter, in the presence ofpterin and methylene blue (Section 2.3.2). 
Protein assay was also carried out on the cell supernatants (Section 2.2). The 
specific XOR activity was expressed in pmoles o f  isoxanthopterin/min/mg protein. 
Cells were seeded at 2x10s cells/ml on day 0, every day 2 x 7 5  cm2 flasks were 
assayedfor total XOR activity; two samples were analysed per flask. Values are 
given as mean +SEM; n 2.
3.3.4. Effects of trypsinisation of cells on XOR activity
A control was needed to ensure that the XOR expression was not related to the use of 
trypsin. To examine the possible effect of trypsin on the subsequent expression of 
XOR in replated cells, the latter were removed by scraping, using a 'rubber 
policeman'. However the cells grew grossly abnormally each time this approach was 
tried and eventually this method of cell removal from the tissue culture flask was 
abandoned. This experiment was unsuccessful in that it was not possible to find an 
acceptable alternative to trypsinisation for cell removal. EA.hy 926 cells are extremely 
sensitive to their growth conditions and so they are not amenable to detergent, cold 




After investigating different conditions of growth, it was concluded that the best 
method for measuring specific XOR activity in EA.hy 926 cells was the following, 
which was used for all measurements of XOR activity in the remaining chapters.
Cells were set up at 2xl05 on day 0 in a 75 cm2 flask. On the day required, the cells 
were trypsinised, counted by trypan blue exclusion, and centrifuged for 5 min at 1500 
rpm The pellet was resuspended in phosphate buffer (1.2ml). The cells were 
sonicated by using a 3mm probe for 20sec and the resulting homogenates were 
ultracentrifuged for 25min at 35,000 rpm (175,000g). Specific XOR activity of cell 
supernatants was measured on a fluorimeter in the presence of pterin and methylene 
blue. Protein assays were also carried out on the cell supernatants (Section 2.2). The 
specific XOR activity was expressed in pmoles of isoxanthopterin/min/mg protein.
A characteristic pattern of the expression of XOR in EA.hy 926 cells emerged from 
the different experiments. XOR activity was not detectable in the initial stages of the 
growth cycle, up to four days, even when the number of cells assayed was increased 
three fold. A rise in specific XOR activity was then observed leading to a plateau, 
when the cells reached confluence. After confluence, a sharp increase in enzyme 
activity could be observed while the cell number remained stable and eventually 
decreased. Panus et al (1992) reported the expression of XDH and XO activity in 
cultured BAECs (bovine aorta endothelial cells) and observed a characteristic pattern 
of total activity under normoxic culture (95% air, 5% CO2). A single peak of activity 
was found on day 9 after the cells reached confluence. However, a decrease in specific 
activity was then observed on postconfluent cells (on days 10, 15, 24 and 30). This 
result is different to that described above.
The second rise in specific XOR activity, occurring when the cells are confluent, is of 
particular interest. The relevance and mechanism of this increase was investigated in 




EFFECTS OF CYTOKINES ON XOR 
ACTIVITY IN EA.hy 926 CELLS.
4.1. Introduction
Cytokines, protein mediators secreted by mononuclear blood cells following 
stimulation by antigens or other means, can modulate the expression of adhesion 
molecules on the endothelial cell surface (Pober, 1988). The release of cytokines is 
preceded by a complex series of events, involving signal transduction, nuclear factor 
activation and transcription of the various cytokine genes. Interleukins 1 and 6 (H-1 
and 11-6), tumour necrosis factor-a (TNF-a), and interferon-y (IFN-y) have the most 
central roles in inflammation (Larrick and Kunkel, 1988). During inflammation 
processes, endothelial cells are induced to undergo major changes in gene regulation 
and surface expression of important cell adhesion molecules (CAMs). CAMs mediate 
the entry of the leucocyte into the inflamed tissue. Neutrophils mediate reactive 
oxygen metabolites upon activation (Varani and Ward, 1994).
The postulated role of XOR in inflammation suggests the possibility of regulation by 
cytokines. ROS are produced after human endothelial cells have been subjected to 
hypoxia/reperfusion and have been implicated in increasing neutrophil adherence 
(Palluy et al, 1992). Cellular levels of XOR activity have recently been shown to be 
increased by hypoxia in a variety of cells such as bovine pulmonary artery smooth 
muscle cells (PASMC), bovine pulmonary artery endothelial cells, rat epididymal pad 
endothelial cells and rat lung (Hassoun et al, 1994). Moreover, various cytokines, 
such as TNF-a; IFN-y, 11-1 and 11-6 were shown to have a similar effect on bovine 
renal epithelial cells and on Madin-Darby bovine kidney cells (MDBK) (Pfeffer et al, 
1994). XOR was also reported to be upregulated by cytokines in endothelial cells: for 
example, pulmonary endothelial cells from rats (rat lung microvascular cells and 
pulmonary artery endothelial cells) showed an increase in XOR activity and mRNA in 
response to IFN-y (Dupont et al, 1992).
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It was hoped that EA.hy 926 cells could be used as a model human endothelial cell 
system in order to investigate the possible roles of XOR in signal transduction leading 
to cytokine-induced expression of adhesion molecules.
4.2. Methods
Experiments were carried out with TNF-a, IFN-y and Il-l-p. These were incubated 
with the cells for 24h at 37°C at final concentrations of 0, 1, 10, 50, 100 and 150 
IU/ml. On day 0, cells were seeded at 2xl05 cells/ml. The medium was changed every 
three days. The control cultures contained medium alone which was changed at the 
same time as that for cells treated with cytokines. Stock solutions of TNF-a, IFN-y, 
and Il-l-p were kept at -70°C. The final concentrations were calculated for 30ml of 
medium from the concentrations of the stock solutions (TNF-a: 40 IU/pl; IFN-y: 500 
IU/fil and H-l-P: 100 IU/pl). Assays for XOR were done on day 5 and on day 11. The 
cytokines were added 24h before the assays. These different time points were chosen 
because day 5 is when XOR activity is first detectable by the fluorimetric assay (see 
Fig. 3.4). The addition of cytokines at that point might induce an early increase in the 
expression of XOR activity. On the other hand, day 11 corresponds to a situation 
where the cells are confluent and they show a high level of XOR specific activity. The 
cells were assayed for XOR activity as described in Sections 2.1.4, 2.3.2 and 2.2. 
ELISAs were carried out on cells treated with Tumour Necrosis Factor-a (Section 
2.6). Mann Whitney U tests were used to compare controls and treated cells.
4.3. Results
4.3.1. Effects of Tumour Necrosis Factor-a (TNF-a) on EA.hy 926 cells
This factor is named for its ability to shrink some tumours by reducing their blood 
supply (Darling and Morgan, 1994). TNF has widespread effects in inflammation, 
activating macrophages, granulocytes and cytotoxic cells and increasing leucocyte 
adhesion to endothelial cells (Playfair, 1996).
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No significant difference (P>0.05) was observed compared to controls when cells 
treated with TNF-a were assayed for XOR activity either on day 5 (Fig.4.1 A), or on 
day 11 (Fig.4.1 B). The level of XOR protein was quantified using an ELISA which 
was carried out on the same samples from day 11. The results did not show any 
increase in XOR protein (Table 4.1).
4.3.2. Effects of Interferon-y (IFN-y) on EA.hy 926 cells
Interferons (IFN) are a group of proteins generated in response to viral infection and 
also to bacterial lipopolysaccharide. They not only inhibit viral replication but also 
have a synergistic anti-tumour activity with TNF (Darling and Morgan, 1994), and are 
more species specific than most other cytokines. IFN-y is produced by lymphocytes 
and has a wide range of activities. Its major role is to inhibit viral replication in 
infected cells and to enhance activity of macrophages. Of interest in the present 
context is its ability to induce an increase in endothelial cell/lymphocyte adhesion 
(Roittefa/, 1989).
In these experiments the specific XOR activity in cells stimulated by a range of 
concentrations of IFN-y was assayed on day 11. No significant increase in activity was 
seen, as shown in Fig.4.2. When interferon (lOOIU/ml) was added to the cells and 
assayed on day 9, there was again no significant difference between the treated and 
control specific activities, as shown in Table 4.2.
4.3.3. Effects of Interleukin-l-P (IL-l-P) on EA.hy 926 cells
Il-l-p was formerly known as lymphocyte activating factor or endogenous pyrogen
(Roitt et al, 1989). It has two forms and shares many of its functions with TNF. It is 
produced by macrophages and induces lymphocyte activation, stimulates 
macrophages and, of particular relevance to the present study, increases adhesion 
between leucocytes and endothelial cells. H-l-P at various concentrations was found 
to have no significant effect on XOR activity when incubated with EA.hy 926 cells for 
24h and assayed on day 11 (Fig.4.3). The specific activities shown in Fig.4.3 are 
relatively high. It is possible that the XOR activity expressed is influenced by the 
number of passages the cells have undergone; in this case the cells had a relatively 
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Fig.4.1: Effects o f TNF-a on XOR activity in EA.hy 926 cells.
Cells were seeded at 2x105 cells/ml on day 0. TNF-a was added to the cells to fina l 
concentrations o f 1, 10, 50, 100 and 150 IU/ml. After 24h incubation, the cells were 
removed from the culture flask by trypsinisation and centrifuged. The cell pellets 
were resuspended in phosphate buffer, sonicated and ultracentrifuged. The resulting 
supernatants were assayed fluorimetrically fo r  XOR activity. Protein assays were 
carried out, and the specific activity was expressed in pmoles/min/mg o f protein 
(Sections 2.1.4, 2.2. and 2.5.2). A) Assays on day 5 B) Assays on day 11.















control 13 1.69 - -
1 >12.48 1.152 0.68 0.95
10 9.28 2.31 1.36 0.71
50 11.49 2.072 1.22 0.88
100 >12.51 1.67 0.988 >0.96
150 8.079 2.154 1.27 0.62
Table 4.1: Change in XOR activity and protein in TNF-a stimulated EA.hy 926 
cells.
ELISA was carried out on samples as the same time as fluorimetric assays on cell 
supernatants from day 11 (Section 2.6). n—1.
Control: Interferon-v:




Table 4.2: Effect o f  IFN-y (lOOIU/ml) on day 9.
IFN-y was added to the cells at a final concentration o f 100 IU/ml. After 24h 
incubation, the cells were removed from the flask by trypsinisation and centrifuged. 
The cell pellets were resuspended in phosphate buffer, sonicated and 
ultracentrifuged. The resulting supernatants were assayedfluorimetrically for XOR 
activity. Protein assays were carried out, and the specific activity was expressed in 
pmoles/min/mg o f protein (Sections 2.1.4., 2.2.2. and 2.3.2).
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control 1 IU 10 IU 50 IU 100IU 150IU
Units IFN per ml.
Fis.4.2: Effects o f IFN-y on XOR activity in EA.hy 926 cells.
Cells were seeded at 2x105 cells/ml on day 0. IFN-y was added to the cells at fina l 
concentrations o f  1, 10, 50, 100 and 150 IU/ml. On day 11, the cells were removed 
from the flask by trypsinisation and centrifuged. The cell pellets were resuspended 
in phosphate buffer, sonicated and idtracentrifuged. The resulting supernatants were 
assayedfluorimetrically fo r  XOR activity. Protein assays were carried out, and the 
specific activity was expressed in pmoles/min/mg o f protein (Sections 2.1.4, 2.2 and
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control 1 IU 10 IU 50 IU 100 IU 150 IU
Units 11-1 per ml.
Fie.4.3: Effects o f Il-l-fi on XOR activity in EA.hy 926 cells.
Cells were seeded at 2x105 cells/ml on day 0. Il-l was added to the cells at final 
concentrations o f  1, 10, 50, 100 and 150 IU/ml. On day 11, the cells were removed 
from  the flask by trypsinisation and centrifuged. The cell pellets were resuspended in 
phosphate buffer, sonicated and idtracentrifuged. The resulting supernatants were 
assayed fluorimetrically for XOR activity. Protein assays were carried out, and the 
specific activity was expressed in pmoles/min/mg o f protein (Sections 2.1.4, 2.2. and




As mentioned in the introduction to this chapter, XOR activity has been shown to be 
increased by a range of cytokines in bovine epithelial cells (Pfeffer et al, 1994) and by 
interferon-y in rat endothelial cells (Dupont et al, 1992). Moreover, the results from 
our own laboratory show cytokine stimulation of XOR in a human mammary 
epithelial cell line (HB4a) particularly in the case of interferon-y (Page et al, 1998). 
IL-ip, 11-6 and TNF-a all showed one to two fold enhancement of XOR activity in 
the HB4a cells, while EFN-y stimulated by eight to eleven fold.
Similar stimulation might have been expected in EA.hy 926 endothelial cells which 
would then have served as a model with which to explore links between XOR activity 
and expression of cell adhesion molecules. The endothelial lining of blood vessels 
plays the role of "gatekeeper" of the tissues and is a critical focus for the actions of 
many cytokines. However, neither TNF-a, IFN-y nor II-1 -(3 had any significant effect 
on the expression of XOR activity in EA.hy 926 cells, at any of the cytokine 
concentrations used in these experiments.
Although the cytokines did not stimulate XOR in these cells, they have been shown to 
induce CAMs. For example, Mattila et al (1992) showed that ICAM-1 (intercellular 
adhesion molecule) and VCAM-1 (vascular cell adhesion molecule), were both 
upregulated in EA.hy 926 cells stimulated by TNF-a. While these findings were not 
checked in the present work, the overall implication is that XOR is not involved in 




ROLES OF XOR IN EA.hy 926 CELLS.
5.1. Introduction
The interaction of XOR with an inhibitor is interesting as an aspect of the mechanism 
of enzyme reaction but also for its medical implications. As XOR is involved in urate 
production, the inhibition of the enzyme is useful for treatment of hyperuricemia and 
gout, as well as of post-ischaemic injury. Allopurinol is the best known inhibitor of 
XOR It has been used as an effective remedy for hyperuricemia and gout. The 
inhibition is time dependent and is due to oxypurinol, the oxidation product of 
allopurinol, which binds stoichiometrically and with high affinity to the reduced 
molybdenum site (Massey et al, 1970). In 1991, a potent new inhibitor was found 
which inhibits liver xanthine oxidase in vivo more effectively than does allopurinol 
(Sato et al, 1991). This inhibitor, BOF-4272, does not show a time dependent 
inhibition and the (-) isomer binds to the enzyme more tightly than the (+) isomer 
(Okamoto and Nishino, 1995). Amflutizole is also a potent inhibitor of xanthine 
oxidase, acting non-competitively (Wems et al, 1991). The effects of these inhibitors 
on the growth patterns of EA.hy 926 cells were investigated in attempts to provide 
clues concerning the role of the enzyme in a cellular system
Other approaches were used to study the possible role of XOR in intercellular 
communication. Attempts were made to perturb the growing cells, or their XOR, or 
both, using agents which would, for example, remove H20 2 or superoxide from the 
medium Alternatively, the XOR activating "message" molecule might be a metabolic 
product of the cell growth, and so conditioned medium was used to see if it would 
alter the expression of XOR within the growth cycle. Likewise, experiments were 
designed so that the medium was changed frequently in an attempt to prevent the 
build-up of signal molecules within the medium and thus to lessen any effect such 




5.2.1. Determination of the kinetics of inhibition of XOR
Inhibition of human XOR enzyme (prepared by Dr Sanders, School of Biology and 
Biochemistry, University of Bath) was first checked spectrophotometrically at 295nm 
(Section 2.3.3). The initial rate was recorded in a 1ml cuvette containing 50mM Na+- 
phosphate buffer (800pl), IOOjiM xanthine (lOOpl), 0.5mM NAD (lOOfxl) and human 
XOR (10|il, 0.3 p,g/assay). After 2-3 min of a stable rate, ImM allopurinol (20pl), 
11.8pM BOF (-) 4272 (lOpl) or 104pM amflutizole (10pl) was added to the cuvette 
(optimal conditions from Dr Sanders) and the percentage of inhibition calculated.
5.2.2. Effects of inhibitors on EA.hy 926 cells
On day 0, EA.hy 926 cells were seeded at 2xl05 cells/ml. Inhibitors were added 
directly to the medium at the required concentration from day 0, or later where 
mentioned. At appropriate times, cells were trypsinised, the cell supernatants were 
prepared as described in Sections 2.1.3 and 2.1.4, and assays of XOR activity were 
carried out following the procedure described in Section 2.3. Allopurinol was added 
to the medium to a final concentration of 50p,M, amflutizole to a final concentration 
of lpM and BOF (-) 4272 to a final concentration of lOOnM.
5.2.3. Assay of cell viability
50pM allopurinol was added to the cells from day 0 to day 8 or 11. The inhibition of 
XOR in the treated or non-treated cells was checked using fluorimetric assays 
(Section 2.3). The percentage viability of the non treated and treated cells was 
calculated using the trypan blue exclusion method (Section 2.1.3).
5.2.4. Studies with frequently changed or with conditioned medium
On day 0, EA.hy 926 cells were seeded at 2xl05 cells/ml. On the day of the 
experiment, cells were trypsinised and the supernatants were prepared for XOR 
fluorimetric assays as detailed in Sections 2.1.4 and 2.3. Cell numbers were counted 
by trypan blue extraction. For studies with fresh medium, the medium was changed 
four times a day. The medium of the controls was changed, as usual, every three days.
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For the conditioned medium experiment, used medium was stored at 4°C prior to 
addition to the cells. Day 'n' medium corresponds to a mixture of 50%(v/v) three day 
old medium from cells reaching day 'n' and 50%(v/v) fresh medium (Section 2.1.2.1).
5.2.5. Addition of catalase, H20 2 or SOD
Cells were incubated with medium containing either catalase from Aspergillus niger 
(lOOIU/ml), different dilutions of a 8.8M (30%w/w) stock solution ofH202, or SOD 
(120IU/ml).
5.2.6. Statistics
A Mann Whitney U test was carried out to compare controls to different samples of 
treated cells. The difference was considered to be significant when P<0.05. For 
samples on the borderline, a /-test for comparing the mean of two small samples was 
also carried out. In this case, the difference was considered to be significant when 
P<0.01. Note that the /-test assumes that samples are drawn from a normally 
distributed population (Fowler and Cohen, 1990).
5.3. Results
5.3.1. Determination of the kinetics of inhibition of XOR
The different inhibitors were first tested on pure human XOR before being incubated 
with EA.hy 926 cells (Results 5.3.2). Spectrophotometric assay at 295nm showed 
BOF (-) 4272 to be the most effective inhibitor (Table 5.1). Incubation of the 
inhibitors at 37°C prior to addition did reduce, but only slightly, their inhibitory 
capacities.
5.3.2. Effects of inhibitors on XOR activity in EA.hy 926 cells
The effects of inhibitors on XOR activity are shown in Fig. 5.1. It can be seen that 
allopurinol and BOF (-) 4272 induced significant reduction in enzymic activity by day 
12 (P<0.05). Amflutizole did not induce any change in XOR activity after being added
Chapter 5
65
Inhibitors: Stock solution Final
concentration in 
1ml cuvette.
% XOR activity 
remaining after 
addition of inhibitor.
Allopurinol, 4°C. ImM 20pM 13.6%
Allopurinol, 37°C. ImM 20pM 17.4%
Amflutizole, 4°C. 104p.M 0.104}.iM 6.9%
Amflutizole, 37°C. 104p.M 0.104|iM 13.6%
BOF (-) 4272, 4°C. 11.8pM 0.118p.M 6.4%
BOF (-) 4272, 37°C. 11.8(j,M 0.118pM 6.25%
Table 5.1: Per cent an e inhibition o f XOl? in the presence o f NAD and xanthine.
Assays were carried out in air saturated 50mM Na-phosphate buffer, pH  7.4. 
Production o f urate was followed spectrophotometrically at 295nm, using an 
extinction coefficient o f  9.6 m M lcm'1. A linear rate was establishedfor 2-3 min 
before addition o f  inhibitor solution, which never diluted the cuvette contents more 
than 2%. Stock solutions o f inhibitors were prepared as described in Section 2.3.3. 
Inhibitors were preincubated fo r  24h, either at 4X1 or at 37 qC. Percentage o f  
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day 0 day 7
Fig. 5.1: Effects o f inhibitors on XOR activity in EA.hy 926 cells.
Inhibitors were added to the medium at the final concentration required on day 0 
(and on day 7 fo r  one allopurinol sample): allopurinol 50pM, amflutizole IpM  and 
BOF (-) 4272 lOOnM. On day 12, cells were trypsinised, counted, and centrifuged. 
The cell supernatants were sonicated, idtracentrifuged and the XOR activity was 
measured (Section 2.3). * represents significant difference (P<0.05) using Mann 
Whitney U test. Values are quoted as mean ±  SEM; n 2.
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to the medium for twelve days. This could be due to the inactivation of the inhibitor 
or to failure of the inhibitor to gain access to the enzyme. Incubation of amflutizole at 
37°C for 24h produced a marked decrease in its inhibition of XOR (Table 5.1.); the 
longer incubation with the cells could have reduced its efficacy still further. As far as 
access to the enzyme is concerned, subsequent findings (Chapter 6) suggest that at 
least some of the enzyme would be accessible on the surface of the cell. However, it is 
not possible to quantify what proportion of the overall activity this represents.
5.3.3. Effects of inhibitors on cell viability
As shown in Fig.5.2 A, allopurinol added from day 0 induced a 90% decrease in 
specific XOR activity on day 8 and approximately 60% on day 11. These significant 
results confirm the findings of 5.3.2. However, when cells were counted and the 
percentages of viability were calculated, no significant difference was found between 
cells treated with allopurinol and the controls (Fig.5.2 B).
5.3.4. Effects of addition of fresh medium
By changing the medium, the possibility of XOR expression being dependent on signal 
molecules secreted by the cells was investigated. Fig 5.3 shows that, after 24h, 
changing the medium four times per day did not significantly affect the expression of 
XOR in EA.hy 926 cells. However, after 48h of treatment, a decrease in the specific 
activity of nearly 90% compared to the controls can be seen. These results bordered 
on significance (P=0.067) with a Man Whitney U test, but were significant with a t- 
test (P<0.01). It is also interesting to note that the cell numbers were the same in 
control cultures compared to treated cells (Fig.5.3 A).
Regarding the results described in Fig.5.4 A (after 72h treatment), it should be noted 
that the cells grew to appreciably greater densities in the situation where the medium 
was changed four times a day for 72h. At this time, the controls were at a density of 
2. lxlO6 ± 0.22 cells/ml while the test cells were at a density of 4.14xl06 ± 0.76 
cells/ml. This difference is presumably the result of extra nutrients being accessible to 
the cells in fresh medium However, the specific XOR activity was found to be 50% 
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I Cell number □% viability
Fin. 5.2: Effects o f allopurinol on XOR activity and percentage o f cell viability.
A final concentration o f  50pM  o f allopurinol was added to the cells from day 0 to 
the day the cells were harvested (day 8 or day 11). A : XOR activity was determined 
as described in Section 2.3. B: cell number and % viability by trypan blue exclusion 
(Section 2.1.3). * represents significant difference (P<0.05) using Mann Whitney U 




□ Cell number-control ■  Cell number-fresh medium
B)
24h 48h
Days 7 & 8
□  XOR activity-control b XOR activity-fresh medium
Fig. 5.3: Effects o f changing medium four times per day on celI number and 
specific XOR activity.
Cells were set at 2 x l(f cells/ml on day 0 and medium was changed every three days. 
From day 6, medium was changed four times a day fo r  24h or 48 h. On the following 
days (day 7 and 8), the cells were trypsinised and the cell supernatant was prepared 
fo r  fluorimetric assays (Section 2.1.4 and 2.3). The cell numbers were counted by 
trypan blue exclusion (Graph A) and the specific XOR activity was calculated 
(Graph B). x  represents significant difference (P<0.01) using t-test. Values are given 




























□ XO-Control 0 XO-Fresh medium
Fin. 5 . Time course o f XOR expression in cells in which medium has been 
changed four times a day.
Graph A represents cells whose medium has been changed four times a day fo r  72h, 
i.e. from day 5 to day 7. Graph B compares the activity in controls to cells whose 
medium has been changed four times per day on day 4 and 5, before being changed 
again every three days. Cells were prepared as described in Section 2.1.4 and 
fluorimetric assays were carried out according to Section 2.3. * represents 
significant difference (P<0.05) using Mann Whitney U test. Values are given as 
mean ± SEM; n=2.
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significant difference between the two groups. The time course carried out in which 
medium was changed four times per day for 48h (day 4 and 5) allows us to conclude 
that an agent implicated in the expression of XOR in EA.hy 926 cells must be present 
in the medium (Fig. 5.4 B). This agent seems to be present at the beginning of the time 
course. Effectively, when the cells were washed four times a day on days 4 and 5, 
significant effects on the expression of the specific XOR activity were still visible on 
day 8, i.e. 72h after the end of the change of medium The specific XOR activity of 
the cells treated between day 4 and 5 is approximately half that of the controls 
(Fig.5.4). The difference between all the controls and the treated cells was significant 
(P<0.05) using Mann Whitney U test (day 6, 7 and 8).
5.3.5. The use of conditioned medium to perturb XOR
In Chapter 3, the characteristic growth pattern of EA.hy 926 cells was described.
A feature of this pattern is that XOR activity rises to a plateau value, achieved when 
the cells reach confluence. It then shows a second sharp rise before the cells start to 
peel off and die (Fig.3.4). Medium from cells producing high levels of XOR at the end 
of the time course (day 10), was added to cells at the beginning of their time course, 
at a time where little XOR is normally observed (day 5). Control experiments 
involved addition of day 5 medium for 24h, 48h or 72h. As shown in Fig. 5.5, no 
differences were observed in cells treated with either day 5 or day 10 medium 
compared to untreated controls. The cells appeared normal, even after 72h of this 
treatment. It was found that if conditioned medium was added directly to the cells 
without dilution by fresh medium then the XOR specific activity was very low and the 
cells did not look at all happy. Either essential nutrients were missing, or accumulated 
metabolic products inhibited cell growth. It is for this reason that 50% conditioned 
medium was always mixed with 50% fresh medium
5.3.6. Addition of catalase on XOR expression
Catalase was added to the cells to examine the possibility that H20 2 could be one 
agent implicated in the expression of XOR in human endothelial cells. The effects on 
XOR specific activity in EA.hy 926 cells were sought. As can be seen in Fig.5.6, 
exogenous catalase did not have an effect on the expression of XOR at the end of the 





□ Control aD ay 5 medium nDay 10 medium
Fie. 5.5: Conditioned medium experiment: effects o f used medium on XOR 
expression.
Cells were seeded at 2x10 cells/ml on day’ 0. The medium o f  the controls was 
changed every three days. Day 'n' medium corresponded to cells where medium was 
replaced on day 5 by a mixture o f  50% o f  fresh medium and 50% o f three day old 
medium from cells reaching day n. The cells were incubated with these different 
mediums fo r  24h, 48h, and 72h. Fluorimetric assays were carried out on day 6 (24h), 
day 7 (48h) and on day 8 (72h) according to Section 2.3. Values are given as mean ± 
SEM; n=2.
Controls Cells treated with catalase
Day 9-24h. 1 85x106 ± 0.175 2.12xl06 ± 0.51
Day 10-48h. 2.75x106 ± 0.205 2.54xl06 ±0.235
Day 1 l-24h. 2 34xl06 ± 0.1 2.58xl06± 0.015
Day 12-48h. 2.37xl06 ± 0.11 2.42xl06 ± 0.13
Table 5.2: CelI numbers corresponding to the catalase experiments.
On the day o f  the assays (see Results, Fig. 5.6), cells were counted by trypan blue 
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□ control ■ catalase
Fin. 5.6: Effects o f the addition o f catalase on the expression o f XOR in EA.hy 926 
cells.
Cells were seeded at 2x105 cells/ml on day 0. Catalase was incubated in the medium 
(lOOIU/ml) fo r  24h or 48h. On the day quoted, cells were trypsinised, and prepared 
fo r  fluorimetric assay (Section 2.3). * (P<0.05) and x  (P<0.01) both represent a 
significant difference using respectively Matin Whitney U test and t-test. Values are 
given as mean ± SEM; n=2.
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significant decrease of the specific XOR activity in cells treated with catalase was 
observed. This drop in XOR specific activity on day 12 was significant (P<0.05) and 
on day 10 the significance was borderline (P=0.067). However, the latter gave 
significant result when a /-test was used (P<0.01). The cell numbers were not 
significantly different between the controls and the cells treated with catalase and the 
cells looked totally healthy in the presence of catalase (Table 5.2).
5.3.7. Effects of hydrogen peroxide on XOR expression
Hydrogen peroxide (H2O2) is a small, stable molecule that carries no charge and is a 
potential signalling molecule. H2O2 can cross membranes and travel to its target in the 
cells (Schreck and Bauerle, 1991; Khan and Wilson, 1995). It is produced at sites of 
inflammation by neutrophils and macrophages and can be detoxified in a single 
enzymic step, in contrast with superoxide which is predominantly degraded via H20 2 
(Schmidt et al, 1995). Endothelial cells have been shown to synthesise H2O2 at an 
intracellular site accessible to peroxisomal catalase and at a site near the cell surface 
inaccessible to catalase or gluthione peroxidase (Kinnula, 1992). Catalase was shown 
to induce a specific decrease of XOR expression in EA.hy 926 cells, and as H20 2 is 
detoxified to H20  and 02by catalase, the effects of adding H2O2 directly to the cells 
were examined. However, a delicate problem was to try to define the concentration of 
H2O2 necessary to induce an effect without damaging or killing the cells.
An 8.8 M (30%, w/w) H20 2 stock solution was used. This solution was diluted in 
PBS to obtain the desired concentration. Trials of different H2O2 concentrations were 
carried out. It was found that in 29mM H20 2 the cells were damaged and killed. 
However, cells grew normally and appeared to be morphologically normal if grown 
with H20 2 at 2.9mM or 5.8mM (maximum values, assuming no loss of H2O2). Cells 
were incubated with 2.9mM or 5.8mM H20 2 for 4h, 24h, and 48h (Fig.5.7 and 5.8), 
but no significant differences were observed in cells treated with H2O2 compared to 
controls. It was thought that the effects of H20 2 might have appeared earlier than 24h 
as H20 2 is not a very stable compound in medium because it can be hydrolysed in a 
variety of ways by the constituents of the medium (Fig. 5.7 A). As shown in Table











Day 11- 24h. Day 12-48h.
□ control b H202
Fig. 5. 7: Effects o f the addition o f H20 2 on the expression o f XOR in EA.hy 926 
cells.
Cells were seeded at 2x10s cells/ml on day 0. H20 2from a stock solution o f 8.8M was 
diluted and added to the cells to a fina l concentration o f  2.9mMfor 4h, 24h, or 48h 
on day 9 (Graph A) and on day 10 (Graph B). On the day quoted, cells were 
trypsinised, and preparedfor fluorimetric assay (Section 2.3). Values are given as 
mean ± SEM; n=2 fo r  A, n 3 fo r  B.
Chapter 5
75
□ Control b  H202
Day 9- 24h.Day 8- 24h.
Fig. 5.8: Effects o f the addition o f H2O2 on the expression ofXOR in EA.hy 926 
cells.
Cells were seeded at 2x105 cells/ml on day 0. H20 2 , from a stock solution o f  8.8M was 
diluted and added to the cells to a fina l concentration o f 2.9mM fo r  day 8 and 
5.8mMfor day 9. On the day quoted, cells were trypsinised, and prepared fo r  
fluorimetric assay ( Section 2.3). Values are given as mean ± SEM; n=2.
Controls. Cells treated with H20 2.
Day 8-24h. 3.61x106 + 0.235 3.65xl06 + 0.4
Day 9-4h. 3.21xl06 + 0.283 2.97xl06 + 0.427
Day 9-24h. 3.89xl06 + 0.32 3.36xl06 + 0.145
Day 1 l-24h. 1.63x106 ± 0.07 1.93xl06 ± 0.105
Day 12-48h. 1.73xl06 ± 0.14 2.155x106 ±0.155
Table 5.3: Cell numbers corresponding to the H2O2 experiments.
On the day o f  the assays (see results, Fig. 5.7 and Fig 5.8), cells were counted by 
trypan blue exclusion (Section 2.1.3). Values are given as mean ± SEM; n 2.
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5.3.8. Effects of superoxide dismutase (SOD) on XOR expression
To carry on the investigation after the catalase and hydrogen peroxide results, SOD 
was added to the cells. An increase in the XOR expression was expected, as SOD 
produces H20 2 while catalase removes it. Superoxide dismutase is a highly specific 
scavenger of the superoxide radical, preventing reperfusion-injury (Sussman and 
Bulkley, 1990).
SOD was added at the same point of cell growth as was catalase (Section 5.3.8), i.e. 
when the cells are showing a second increase in XOR activity having reached 
confluence. SOD was added directly to the medium for 24h and 48h. No significant 
differences in results were observed in XOR activity compared to controls (Fig.5.9). 
As shown in Table 5.4, the cell numbers were similar in controls and cells treated with 
SOD. No morphological differences were observed between treated cells and 
controls.
Controls Cells treated with SOD
Day 1 l-24h. 2.58xl06 ± 0.18 2.88xl06 ± 0.52
Day 12-48h. 1.95x10s ±0.34 2.26x10s ±0.19
Day 12-24h. 2.78x10s ± 0.27 2.87x10s ±0.21
Day 13-48h. 2.06x10s ±0.015 2.6x10s ± 0.07
Table 5.4: Cell numbers corresponding to the SOD experiments.
On the day o f the assays (see Results, Fig. 5.9), cells were counted by trypan blue 















Day 11- 24h. Day 12- 48h.
□ control El SOD
B)
□ control b SOD
Fig. 5.9: Effects o f the addition o f SOD on the expression o f XOR in EA.hy 926 
cells.
Cells were seeded at 2x10? cells/ml on day 0. SOD was incubated in the medium 
(120IU/ml) fo r  24h or 48h. On the day quoted, cells were trypsinised, and prepared 




The inhibitors allopurinol, amflutizole and BOF (-) 4272 were shown, as expected, to 
inhibit purified human XOR. Allopurinol and BOF (-) 4272 also inhibited XOR 
activity when added to EA.hy 926 cells, confirming the specificity of the pterin assay 
for this enzymic activity in these cells. On the other hand, amflutizole failed to inhibit 
XOR activity in EA.hy 926 cells. This could be because of its inability to gain access 
to the cytosolic enzyme or because of its own inactivation. However, preincubation at 
37°C for 24h failed to significantly diminish its inhibitory activity (Table 5.1). 
Amflutizole has been shown to inhibit cell based XOR activity in other systems. For 
example, it abolished free radical formation and release in the ischaemic reperfused rat 
brain. It was previously demonstrated that xanthine oxidase activity did contribute to 
free radical formation in this model (Phillis et al, 1994). Other workers found that 
amflutizole enhanced ischaemia-induced release of hypoxanthine and suppressed 
xanthine formation in the rat cerebral-cortex. Cells treated with allopurinol through 
the time course showed no difference in cell number or viability compared to controls, 
providing no evidence for an involvement of XOR activity in cell death (O'Regan et 
al, 1994).
The effects of conditioned medium, catalase, hydrogen peroxide and SOD on XOR 
activity were analysed in detail, in an attempt to determine the role of XOR in 
signalling. Positive results were found when the medium was changed frequently to 
prevent build-up of cell secreted products. A similar effect was also found when 
catalase was present continuously in the medium.
It is interesting to note that, in both cases, it took 48h to show a significant decrease. 
This might represent the time necessary for the cells to readjust the production of 
XOR after these different stimuli. On the other hand, the addition of conditioned 
medium, SOD or H2O2 did not induce any observable change in the expression of 
XOR Though conditioned medium experiments did not change the expression of 
XOR, it had to be diluted otherwise essential nutrients would be missing and the cells 




All together, these results show that XOR expression can be modified and reduced in 





DISTRIBUTION OF XOR IN HUMAN 
ENDOTHELIAL CELLS.
6.1. Introduction
XOR is widely distributed in all human tissue including liver, intestine, heart, brain 
and in microvascular endothelium (Parks and Granger, 1986; Stevens et al, 1991; Xu 
et al, 1994). The localisation of XOR has not been extensively explored because 
xanthine oxidoreductase activity is extremely low in most of the tissues examined.
The enzyme is generally thought to be present in the cytosol; however there have been 
only limited publications on the subject of its subcellular localisation. As mentioned in 
Chapter 3 (Table 1), Jarasch et al (1981) described the immunolocalisation of the 
enzyme in the cytoplasm of bovine capillary endothelial cells. XO was also found to 
be localised in rat hepatocytes by high resolution immunoelectron microscopy. It was 
also found that the enzyme was present in the cytosol but not other cell organelles 
(Ichikawa et al, 1992). In 1993, Moriwaki and coworkers purified xanthine oxidase 
from human liver cytosol. Using this enzyme, a purified antibody was raised which 
precipitated XO from human liver cytosol. The immunohistochemical localisation of 
XO in human tissues showed positive results in the cytoplasm of hepatocytes and 
endothelial lining cells.
In order to determine the detailed subcellular localisation of XOR in cultured 
endothelial cells, the use of confocal microscopy was combined with classical 
immunolocalisation (Ojcius et al, 1996). In preliminary experiments, specific 
polyclonal and monoclonal anti-HXOR antibodies were prepared and tested by 
Western blotting and immunoprecipitation. These antibodies were then used to 





6.2.1. Validation of specific anti-human XOR antibodies
Cells were seeded at 2xl05 cells/ml and were trypsinised between day 10 to day 13. 
The cell supernatants (referred to as cytoplasmic fractions) were then prepared as in 
Section 2.1.4 before being subjected to SDS-PAGE. Gels were either stained with 
Coomassie Blue or transferred to a nitrocellulose membrane for Western blotting, as 
described in Section 2.4. Supernatants fromEA.hy 926 cells were also used for 
immunoprecipitation. XOR protein was extracted from the supernatants by a protein 
A-antibody complex (Section 2.5). The binding of the antibody to the protein A was 
first checked by protein assay (Section 2.2). Removal of XOR protein from the cell 
supernatant by the protein A-antibody complex was verified by fluorimetric assays 
(Section 2.3.2) carried out before and after incubation with the complex. Monoclonal 
antibodies, when used, were purified from hybridoma supernatants as described in
2.9.2. Rabbit polyclonal anti-HXOR was affinity purified as detailed in 2.9.3, using 
methods detailed in Page et al (1998).
6.2.2. Distribution of XOR in human endothelial cells
Permeabilised and unpermeabilised cells were used to localise XOR as described in 
Section 2.7.3. EAhy 926 cells were seeded at 2xl05 cells/ml, while HUVECs were at 
lxlO5 cells/ml. Initial results (Fig.6.8 and 6.10) were obtained by using a laser 
emission confocal fluorescence cytometer (Bio-rad MRC 500). Subsequent 
experiments were carried out with a confocal laser scanning microscope (LSM 510, 
with either x40 1.30 NA or x63 1.40 NA apochromatic objective: Carl Zeiss). Surface 
staining was checked on a fluorescent microscope, Leica BM IRB. Affinity purified 
rabbit polyclonal anti-HXOR and mouse monoclonal anti-HXOR antibodies were 




6.3.1. SDS-PAGE and Western blotting
Supernatants from an EA.hy cell homogenate were subjected to SDS-PAGE and 
Western blotting using rabbit anti-HXOR antiserum or affinity purified rabbit 
polyclonal anti-HXOR antibodies.
66*0 *
1 2 3 4 5
Fin. 6.1: Gel o f EA.hy 926 supernatants.
Cells were seeded at 2x105 cells/ml on day 0 and were trypsinised on day 13 (Section
2.1.3). The supernatants were prepared for Western blotting as described in Sections 
2.1.4 and 2.4, run on a SDS-PAGE gel and stained with Coomassie Blue. Lane 1: 
molecular weight markers. Lane 2: human XOR prepared from human milk. Lanes 3, 
4 and 5: cell supernatant from EA.hy 926 cells.
The characteristic smeared pattern shown in Fig.6.1 was obtained when EA.hy 926 
cell supernatants were run on a SDS-PAGE. The XOR activity of the cell supernatant 
used for this experiment was measured fluorimetrically before the cells were prepared 
for SDS-PAGE. The specific activity 0.98 ± 0.092 pmoles/min/mg protein is normal 
for cells at this stage of the time course, as previously shown in Fig.3.4. It is difficult 
to identify an XOR band in this pool of numerous different proteins. However, a 150 
kDa band appears to be present on the gel, at the same level as human XOR band 




Fig.6.2: Different conditions for Western blotting.
Pure XOR was transferred to nitrocellulose membranes. Lane 1 corresponds to 
molecular weight markers, lane 2 to human XOR purified from  human milk. I) lOOpg 
o f biotinylated affinity purified rabbit polyclonal anti-HXOR antibody (Img/ml), 
ExtrAvidin peroxidase 1:4000 dilution. II) lOOpg o f  biotinylated affinity purified 
rabbit polyclonal anti-HXOR antibody (lmg/ml), ExtrAvidin peroxidase 1:2000 
dilution. Ill) Rabbit anti-HXOR antiserum 1.500 dilution, anti-rabbit peroxidase 
conjugated 1:1000. IV) Rabbit anti-HXOR antiserum 1:500 dilution, anti-rabbit 
peroxidase conjugated 1:500. V) 50pg o f biotinylated affinity purified rabbit 
polyclonal anti-HXOR antibody (lmg/ml), ExtrAvidin peroxidase 1:4000 dilution.
VI) 50pg o f biotinylated affinity purified rabbit polyclonal anti-HXOR antibody 
(lmg/ml), ExtrAvidin peroxidase 1:2000 dilution.
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Different conditions for Western blotting were tested with pure human XOR. Fig.6.2 
describes the results obtained with purified HXOR using different concentrations of 
antibodies for Western blotting. The best results (V) were obtained with a biotinylated 
affinity purified rabbit polyclonal anti-HXOR antibody (50pg) together with 
ExtrAvidin (1:4000).
The antiserum (III and IV) did not give as clear a 150 kDa band as the biotinylated 
antibody. Degradation products were picked up in some lanes. This is particularly true 
for the HXOR lanes of III (antiserum) and of II, V and VI (in which cases the 
biotinylated antibody was used). Degradation of the protein can only be caused by 
proteolytic enzymes present in the sample.
i <-150 kDa->
1 2  3 4 1 2 3 4 5
Fig. 6.3: Western blots.
For the two blots, rabbit anti-human XOR antiserum (1:1000) and anti-rabbit 
peroxidase conjugated antibody (1:1000) were used (Section 2.4). Lane 1: molecular 
weight markers; lane 2: bovine XOR; lane 3: EA.hy 926 cytosolic fraction; lane 4: 
Buffalo rat liver epithelial (BRLEs) cell supernatant; lane 5: HB4a cell supernatant.
Chapter 6
85
Western blots were then carried out on supernatants from different cell lines. These 
cell lines are known to express different amounts of XOR activity. BRLEs (rat 
Buffalo liver epithelial cells) are a clonal cell line described by Coon (1968) which is 
now thought to be immortalised. These cells show very much higher XOR activity 
than do EA.hy 926 cells, usually around 77.9 ± 6.60 pmoles/min/mg (Powell, 1995). 
This is presumably because liver and intestine show relatively high XOR activity 
(Parks and Granger, 1986; Samesto et al, 1996). Human mammary epithelial cells 
(HB4a) show a low XOR specific activity of 0.57 ± 0.09 pmoles/min/mg total protein 
on day 12 (Page et al, 1998). Western blots of BRLEs, HB4a cells and EA.hy 926 
cells showed line blots corresponding to a band at 150 kDa, as well as degradation 
lines. The BRLEs and EA.hy 926 cells gave clearer results than did HB4a cells, 
probably because of the higher levels of XOR protein in these cell lines compared to 
HB4a (Fig. 6.3).
The quality of the Western blots was generally poor when directly carried out on cell 
supernatants, even with cell lines expressing higher activity than EA.hy 926 (Fig.6.3, 
BRLEs).
6.3.2. Immunoprecipitation
To concentrate the XOR protein present in the cytoplasmic fractions of the cells, it 
was decided to immuno-purify XOR from cells prior to Western blotting. The 
principle of the method is described in the following figure (Fig.6.4).
The immunoprecipitation technique is based on the affinity of the Fc region of 
antibodies for protein A, a polypeptide isolated from Staphylococcus aureus. The 
complex formed leaves free the binding domain of the antibody for its antigen, in this 
case XOR Therefore, XOR can be concentrated from cell supernatant. The samples 




Addition of affinity purified rabbit polyclonal anti-HXOR:
Wash excess of antibodies.
Addition of cell supernatant containing XOR: □  XOR protein.
Wash non binding protein. 
Dissociation of the complex.
□ □ 
' /  \  /
Fig. 6.4: Principle o f immunoprecipitation.
Affinity purified rabbit polyclonal anti-human XOR antibodies were coupled to 
Protein A-Sepharose beads by the Fc region. The cells' cytosolic fractions were then 
added to the Protein A-Antibody complex which removed 100% o f  the XOR activity 
in supernatants o f  EA.hy 926 homogenates. The complex was then dissociated by 
incubation with SDS and mercaptoethanol, run on a SDS-PAGE gel and Western 
blotting was carried out.
Two samples of cell supernatants were used to carry out immunoprecipitations 
(Fig.6.5 and 6.6). The binding of the affinity purified rabbit polyclonal anti-HXOR 
antibody to protein A was checked after 24h incubation. Protein assays on washes 
show that only a few proteins were present and that most of the antibodies bound to 
protein A (Table 6.1).
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0.06mg/ml. 3.9xl0'3 mg/ml 0
Table 6.1: Protein assays on the washes after incubation o f  the antibodies with 
protein A.
The XOR activity of the cell supernatant was checked by fluorimetric assay before 
addition to the protein A-antibody complex. This activity was compared to the one 
obtained from the supernatant after 24h incubation. It was found that the affinity 
purified rabbit polyclonal anti-HXOR antibodies bound to protein A, and removed 
100% of the activity present in the cytoplasmic fractions, following 
immunoprecipitation.
Samples obtained from the immunoprecipitate were run on a gel along with HXOR 
and molecular weight markers. Some gels were directly stained with Coomassie blue 
and others were transferred on a nitrocellulose membrane for Western blotting 
(Section 2.4).
SDS-PAGE of immunoprecipitates (Fig.6.5) shows degradation bands less than 150 
kDa in the sample lane (lane 1 and 4), as well as a band corresponding to the heavy 
chains of rabbit IgG (52 kDa).
Considering the absence of band at 150 KDa, no Western blotting was done on this 
sample after the immnunoprecipitation. Following the same method, another sample 
from a cell supernatant was prepared by immunoprecipitation (Fig.6.6).
Chapter 6
88
1 2 3 4 5 6
Fig. 6.5: SDS-PAGE get after an immunoprecipitation.
Immunoprecipitation was carried out as described in Section 2.5. Samples obtained 
(lanes 1 and 4) were run on an SDS-PAGE gel (Section 2.4), which was stained with 
Coomassie Blue. Lanes 2 and 5 correspond to human XOR (2 pg) prepared from 
human milk. Lanes 3 and 6 are the molecular weight markers.
On the Coomassie gel (Fig.6.6) a band could be observed in the cell supernatant (lane 
3) corresponding to 150 kDa. Fig.6.7 illustrates Western blotting on the samples 
shown in Fig.6.6. Two different Western blots were carried out: one with affinity 
purified rabbit polyclonal anti-HXOR antibody (Fig.6.7 A) and the other one with 
mouse monoclonal anti-HXOR antibody (Fig.6.7 B). The mouse antibody was chosen 
because it should not react with the IgG present on the gel. These IgG's are the 
affinity purified rabbit polyclonal anti-HXOR antibodies which have been dissociated 
from protein A (Fig.6.4). This system will give a Western blot, which will not 









Fig. 6.6: SDS-PAGE gel after an Immunoprecipitation.
Immunoprecipitation was carried out as described in Section 2.5 and the samples 
were run on a SDS-PAGE gel ( Section 2.4). Lane I corresponds to molecular weight 
markers. Lane 2 shows human XOR (2pg) prepared from human milk. Lane 3 
contains the cytoplasmic samples obtained from  EA.hy 926 cells.
9 10 116 7 8A 1 2 3 4 5 B
Fig. 6.7: Western blots after Immunoprecipitation.
The gel from the samples shown in Fig. 6.6 was transferred to nitrocellulose 
membranes and visualised using: A) biotinylated affinity purified rabbit anti-HXOR 
antibody (lOOpg) fo r  2h, then ExtrAvidin (1/4000) fo r  lh. B) mouse monoclonal 
anti-HXOR (200pi) fo r  2h, then an anti-mouse peroxidase conjugated antibody 
(1/1000) fo r  lh. Western blots were revealed by a solution o f 4 chloro-1-naphthol 
containing H20 2 (Section 2.4.3). Lanes 1, 2, 3, 9, 10 and 11: cytoplasmic samples 
from EA.hy cells; lanes 4, 7 and 8: human XOR (2pg) prepared from human milk 




In Fig.6.7 A, a clear band at 150 kDa as well as the IgG band are visible on the 
nitrocellulose (lanes 1, 2, 3). However, some of the markers also reacted with the 
biotinylated antibody (lane 5).
The mouse monoclonal antibody reacted only with HXOR. Some degradation 
products of XOR are visible at the same time as the 150 kDa band (lanes 9, 10 and 
i i ) .
6.3.3. Localisation of XOR in human endothelial cells
Two human endothelial cell types, EA.hy 926 cells and primary endothelial cells 
(HUVECs) were studied to determine the subcellular localisation of XOR. Affinity 
purified rabbit polyclonal anti-HXOR antibodies were mainly used, along with mouse 
monoclonal anti-HXOR, as the detection system With a confocal microscope, the 
sample analysed is scanned horizontally point after point, line after line, thus defining 
a field. Each field is analysed by displacing the sample vertically with respect to the 
objective. The fluorescence emission is detected by a photomultiplier tube, and once 
converted into an electric current, the signal produces an image on the screen.
6.3.3.1. Localisation of XOR inside human endothelial cells 
Cells permeabilised by a gentle detergent, saponin, were incubated with antibodies for 
the subcellular localisation of XOR.
Initial images clearly show the presence of the XOR enzyme in the cytoplasm of 
EA.hy 926 cells with a concentration around the perinuclear region (Fig. 6.8). Better 
quality images [fluorescent images and differential interference contrast (DIC)] were 
obtained with a confocal laser-scanning microscope (Section 2.7.1 and 2.7.4). The 
structure of the cells appears more clearly allowing a precise characterisation of the 
distribution of XOR protein. Fig.6.9 shows the immunolocalisation of XOR in 
permeabilised EA.hy 926 cells, confirming that the protein is diffusely distributed 
throughout the cytoplasm, although fluorescence was more intense in the perinuclear 
region. The outer membrane of nuclear envelope is known to be continuous with the 
membrane of the endoplasmic reticulum (Loewy et al, 1991).
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Fie. 6.8: Distribution o f XOR in permeabilised EA.hy926 cells.
Affinity purified rabbit polyclonal anti-HXOR (0.026mg/ml) and anti-rabbit FITC 
conjugated (1:100) antibodies were used to localise XOR inside the cells. 
Immunofluorescent (A, C, E) and differential interference contrast (DIC) (B, D, F) 




"Permeabilised EA.hy 926 cells":
Fig. 6.9: Distribution o f  XOR in permeabilised EA.hy 926 cells.
Cells were prepared as described in Section 2.7. Immunofluorescent (A, C, E) and 
DIC (B, D, F) images are shown. Antibodies used: affinity purified rabbit polyclonal 
anti-HXOR antibody (stock: 0. lmg/ml, 1:2 dilution was used) and anti-rabbit FITC 
conjugated antibody (1:100). Magnification x630 (A-D), x400 (E-F); 20pm bar.
■■
A t • '
Permeabilised EA.hy 926 cells
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The perinuclear membrane consists of two unit membranes enclosing a perinuclear 
space. In many protein secreting cells, the outer membrane is identical to rough 
endoplasmic reticulum, with attached ribosomes and a perinuclear space swollen with 
protein secretions (Cross and Mercer, 1993). The localisation of an enzyme capable of 
producing ROS in the cytoplasm of cells, and more precisely in the perinuclear region 
of the cells, has interesting implications for the function of the enzyme and will be 
examined in the discussion.
6.3.3.2. Localisation of XOR on the outer surface of human 
endothelial cells
Fig. 6.10 shows the presence of XOR on the surface of cells using a confocal 
fluorescence cytometer (Section 2.7.1). For this purpose, mouse monoclonal anti- 
HXOR antibodies were used. The antibodies are seen to be concentrated at the 
junction of the cells. Immunolocalisation of XOR in unpermeabilised cells with a 
confocal laser-scanning microscope (Fig.6.11) also showed the presence of the 
enzyme on the outer surface. Moreover, XOR appeared to be concentrated on parts 
of the surface that apposed or were extending towards neighbouring cells (arrows on 
Fig.6.11).
A fluorescent microscope was also used to verify the distribution of XOR enzyme on 
the surface of EA.hy 926 cells (Fig.6.12). Similar results to those with the confocal 
microscope were obtained. Monoclonal and affinity purified antibodies gave similar 
results, the latter being more punctate.
6.3.3.3. Control experiments
It is clear that the subcellular localisation of XOR is very well defined. Much of the 
enzyme is in the perinuclear space and significant amounts of the protein can be seen 
to be extracellular. In the latter case, strict controls must be set up because the 'cross 
reacting material' may not be exogenous cellular XOR It is quite likely that the serum 
in the medium contains soluble XOR which itself might become non-specifically 
bound to the outside surface of the cells. This is a crucial problem and several steps 
were taken to show that the medium could not have contained any XOR for cell 
binding. The first approach was to assay total calf serum for XOR activity by 
fluorescent assay (Section 2.3.2). No detectable XOR was seen.
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Fie. 6.10: Distribution o f XOR in unpermeabilised EA.hy 926 cells.
Mouse monoclonal anti-bovine XOR (50jul) and anti-mouse FITC conjugated 
(1:100) antibodies were used to localise XOR on the outer surface o f the cells. 
Immunofluorescent (A, C) and DIC (B, D) images are shown. Magnification x600; 
laser emission confocal fluorescence cytometer.
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"Unpermeabilised EA.hy 926 cells":
Fie.6.11: Distribution o f  XOR in unpermeabilised EA.hy 926 cells.
Cells were prepared as described in Section 2.7. Immunofluorescent (A, D, G) and 
DIC (B, E, H) images are overlaid (C, F, I) to emphasise the polarised distribution. 
Arrows (C) show examples where fluorescence is concentrated on surfaces that 
appose those o f neighbouring cells. Antibodies used: affinity purified rabbit 
polyclonal anti-HXOR antibody (stock: 0. lmg/ml, 1:2 dilution was usedfor D-F. 
Stock 0.22lmg/ml, 1:10 dilution was usedfor A-C and G-I) and anti-rabbit FITC 
conjugated antibody (1:100). Magnification x400 (A-C, G-I), x630 (D-F); 20pm bar.
Unpermeabilised EA.hy 926 cells
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"Unpermeabilised EA.hy 926 cells-Fluorescent microscope":
Fig. 6.12: Distribution o f  XOR in unpermeabilised EA.hy 926 cells, using a 
fluorescent microscope.
Cells were prepared as mentioned in Section 2.7. Immunofluorescent (A, C, E, G) 
and DIC (B, D, F, H) images are shown. Antibodies used: mouse monoclonal anti- 
HXOR antibody (4.3mg/ml IgG from clone 8) used to a final concentration o f 
0.15mg/ml for A-D or affinity purified rabbit polyclonal anti-HXOR (stock: 
0.55mg/ml, 1:13 dilution was used) for E-H and anti-rabbit FITC conjugated 
antibody (1:100). Magnification x 400.
Unpermeabilised EA.hy 926 cells-Fluorescent microscope.
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In a second control experiment, any XOR present but undetectable in the serum used 
to make the medium was removed using affinity chromatography (Section 2.8), and 
this XOR-depleted serum was then used to perform the fluorescent localisation of 
XOR (Section 2.7.3). XOR has high affinity for heparin (Adachi et al, 1993; Sanders 
et al, 1997), and heparin-agarose columns were used to remove any XOR present in 
the medium (Section 2.8). Different batches of serum (six in total) were run through 
the heparin columns; the columns were washed with 25mM sodium phosphate buffer 
and then eluted with 1M NaCl and the eluants were tested for XOR activity by 
fluorescence assay. In fact, no activity was detectable in these different eluants. The 
use of serum which was known to be free of XOR was considered to be an 
unambiguous proof that the extracellular bound XOR was in fact truly extracellular 
and not derived from the medium Cells were grown in medium which had been 
passed down heparin-agarose. The cells were set as usual in glass wells and were 
subjected to immunolabelling at the same time as cells grown in normal medium XOR 
was seen to be localised in both cases on the surface of the cells (Fig.6.13, A-D) and 
there was no observable difference between the two groups of cells. When assayed on 
the fluorimeter, no significant difference was apparent in the total XOR expressed in 
the two groups of cells.
In a further control experiment, cells were set and treated as usual, except that FITC 
conjugated secondary antibody was omitted and replaced by PBS. No fluorescence 
was observed. Secondly, the primary antibody was omitted and only the secondary 
antibody FITC was added to the cells. Again, no fluorescence was observed (Fig.6.13, 
E-H). These control experiments verify the specificity of the antibodies used for the 
distribution of XOR. It allows to check first that there is no background of 
fluorescence and secondly that the secondary antibody only binds to the primary one.
It can be noted that commercially supplied antibody, rabbit anti-bovine milk XOR 
(Chemicon International), gave similar results with permeabilised and unpermeabilised 




Fig.6.13: Control experiments testing antibodies and heparin-Agarose treatment o f  
medium.
EA.hy 926 cells were grown in medium that had (C, D) or had not (A, B) been 
preabsorbed on a heparin-Agarose column (Section 2.8). For the antibody controls, 
cells were treated as usual except that antibodies were replaced by PBS: secondary 
antibody (E, F), primary antibody (G, H). Immunofluorescent (A, C, E, G) and DIC 
(B, D, F, H) pictures were obtained as described in Section 2.7. Antibodies: 
affinity purified rabbit polyclonal anti-HXOR antibody (Stock: 0.221 mg/ml, 1:10 
dilution was usedfor A-D. Stock: 0.54mg/ml, 1:10 dilution was usedfor E-H) and 






Fig. 6.14: Control experiments showing that cell surface XOR is not derived from  
growth medium.
Heparin beads were incubatedfor 24h with PBS (A-B), with PBS containing bovine 
XOR (lOjug/ml) (C-D), with NGS (E-F) and with growth medium (G-H). 
Immunofluorescent (A, C, E, G) and DIC (B, D, F) images were obtained as 
described in Section 2.7. Antibody: affinity purified rabbit polyclonal anti-HXOR 
antibody (stock: 0.5mg/ml, 1:20 dilution was used) and anti-rabbit FITC conjugated 





In a final control experiment, heparin beads (300pl) were first washed with PBS 
before being incubated overnight with either PBS, bovine XOR (10(ag/ml), NGS 
(normal goat serum) or growth medium The beads were then labelled with affinity 
purified rabbit polyclonal anti-HXOR antibody (Section 2.7). Clear fluorescence was 
observed on beads incubated with bovine XOR (Fig.6.14, C-D). No fluorescence was 
found in the case of PBS, NGS or pure growth medium NGS was tested as it was 
added to the antibody at the same time as BSA, as a blocking agent (Fig.6.14, A-B 
and E-H)
6.3.3.4. Subcellular localisation of trans Golgi marker, TGN38 
Anti-TGN38, a mouse anti-trans Golgi antibody, was used as a further control to 
show that cells were permeabilised and also to specify the localisation of XOR inside 
the cells. TGN38 was originally identified as a marker for the trans-Golgi network in 
the mouse (TGN) (Luzio et al, 1990), and the antibody was shown to cross-react 
with human antigen (Ponnambalam et al, 1996). TGN38 used here as an intracellular 
marker protein was not stained by anti-TGN38 antibody in unpermeabilised cells 
(Fig.6.15, C-D). However, cytoplasmic staining was seen in permeabilised cells 
(Fig.6.15, A-B). This result confirms preliminary experiments in which the status of 
permeabilised and unpermeabilised cells was verified by staining with trypan blue. 
Permeabilised and unpermeabilised cells were stained with trypan blue (500pJ/well) 
for 5min, then three washes with PBS (lml/wash) were carried out. The staining of 
the cells was checked under a Nikon microscope, magnification x400. It was found 
that permeabilised cells took up 100% of the trypan blue compared with 
unpermeabilised cells, which took up only 5%.
Colocalisation of XOR and TGN38 (XOR with FITC conjugated antibody and anti- 
TGN38 with rhodamine linked antibody), was then examined. Permeabilised cells 
were first fixed and immunolocalisation of XOR was carried out with affinity purified 
rabbit polyclonal and anti-rabbit FITC conjugated antibodies. Then colocalisation was 
carried out with mouse anti-TGN38 and anti-mouse rhodamine conjugated antibodies 
(Section 2.7). In permeabilised cells, TGN38 and XOR were colocalised in most of 





Fis.6.15: Distribution o f  TGN38 in permeabilised (A, B, E, F) and 
unpermeabilised cells (C-D).
Cells were prepared as described in Section 2.7. Immunofluorescence (A, C, E) and 
DIC (B, D, F) images are shown. Antibodies: mouse anti-TGN38 antibody (1:100) 
for A, C, E, together with affinity purified rabbit polyclonal anti-HXOR (Stock:
0.5mg/ml, 1:20 dilution was used) for E and anti-rabbit FITC conjugated antibody 
(1:100) for A, C, E  as well as anti-mouse rhodamine conjugated antibody (1:100) for 





6.3.3.5. Localisation of free radicals using dihydrorhodamine 123 
Dihydrorhodamine 123 (DHR123) is oxidised to rhodamine 123 (R123), a fluorescent 
product, and is used as a specific fluorescent probe for visualising mitochondria in 
living cells (Sobreira et al, 1996). DHR123 can be oxidised by hydrogen peroxide in 
the presence of a cellular enzyme with peroxidase activity (Rothe and Valet, 1990; 
Henderson and Chappell, 1993), and is considered to be a good sensor for ROS 
(Vowells et al, 1995; Yvonne et al, 1995; Lopez-Ongil et al, 1998).
DHR123 was directly added to the medium and incubated with the cells for 45min at 
37°C. Cells were previously treated with a final concentration of 50pM allopurinol for 
24h. After 45 min, cells were washed three times with prewarmed PBS, fixed and 
mounted as described in Section 2.7. The presence of ROS was compared in cells 
treated with allopurinol, which had been shown to reduce XOR activity in EA.hy 926 
cells (Chapter 5), and in non-treated cells. As shown on Fig.6.16, cells treated with 
allopurinol for 24h have less staining than control cells. Moreover, the pattern of the 
staining is more punctate and concentrated to a few points which may correspond to 
the mitochondria. In the controls, ROS seem to be dispersed though the cytoplasm of 
the cells.
6.3.3.6 HUVECs
The experiments described with EA.hy 926 cells were repeated with HUVECs. 
HUVECs, isolated from human umbilical veins, were grown in 25cm2 flasks. When 
confluent, the cells were split and seeded in four well chambers. The same conditions 
as those described for EA.hy 926 cells were used (Section 2.7). Again, it was found 
that the enzyme was present in the cytoplasm of the primary cells, and around the 
perinuclear region of permeabilised cells. XOR was also present on the surface of the 
cells (Fig.6.17). The specific distribution of XOR in the perinuclear region and on the 
outer surface of the cells is accordingly as specific as in EA.hy 926 cells. No direct 
comparison on the fluorescence intensity was carried out; however, it is clear that the 





Fis. 6.16: Distribution o f  free radicals in EA.hy 926 cells.
Immunofluorescent (A, C, E, G) and DIC (B, D, F, H) images are shown. On day 0, 
cells were seeded at 3x105 cells/ml. On day 1, allopurinol was added to E-H to a 
final concentration o f 50pMper well. On day 2, DHR123 was added to all the 
samples to a final concentration o f 24pM, for 45min at 37°C. The cells were then 
washed and fixed with 4% formaldehyde. Finally, the cells were washed with PBS 





Fis. 6.17: Distribution o f  XOR in permeabilised (A-B) and unpermeabilised (C-G) 
HUVECs.
Cells were prepared as described in Section 2.7. Immunofluorescent (A, C, E) and 
DIC (B, D, F) images are shown. Images E and F are overlaid (G) to emphasise the 
polarised distribution. Antibodies used: affinity purified rabbit polyclonal anti- 
HXOR (stock: 0.221 mg/ml, 1:10 dilution was usedfor C-G. Stock: 0.175mg/ml, 1:10 
dilution was used for A-B, F-H) and anti-rabbit FITC conjugated antibody (1:100). 





A 150 kDa band corresponding to XOR protein was clearly seen following SDS- 
PAGE and Western blotting of an immunoprecipitate from the cytoplasmic 
supernatant of EA.hy 926 cells. Western blots on crude samples were positive but not 
as clear as for those obtained by immunoprecipitation. This can be due to the loss of 
protein during the transfer and the fact that the experiments were carried out on the 
cell supernatant, i.e. on a very low quantity of proteins. The specificity of the 
antibodies was additionally tested with HXOR purified from human milk. These 
antibodies were then used for the specific localisation of XOR inside and outside 
different human cell lines as described in the following paragraphs.
The anti-HXOR antibodies, verified as above, were used to clarify the distribution of 
XOR in EA.hy 926 cells as well as in HUVECs. XOR enzyme was found in the 
cytoplasm of the cells as expected, but particularly concentrated in the perinuclear 
region. This may well reflect its proposed function. As previously mentioned, ROS 
were shown to activate some transcription factors, such as nuclear factor NF-xfi 
(Schreck et al, 1991; Meyer et al, 1993; Sen and Packer, 1996). XOR is a major 
source of ROS, and the presence of XOR might be linked to the presence of inactive 
complex I-xfi and NF-xfi in the cytoplasm (see General Introduction).
Another finding was that the presence of ROS inside the cells can be reduced and 
modified by the treatment of the cells with allopurinol for 24h. The presence of XOR 
on the outer surface of endothelial cells has not been previously published, apart from 
brief abstracts reporting the extracellular localisation of XOR in bovine aortic 
endothelial cells (Bulkley, 1991; Schiller et al, 1991). This finding presence raised 
questions about the function of the enzyme. The main question is whether the enzyme 
is active and this idea will be developed in Chapter 8. To verify that these results were 
not an artefact, different controls were carried out. It was first shown that similar 
results were obtained using a fluorescent microscope as well as commercial antibody. 
It was then checked that the cells were really not permeabilised by the method used. 
For this an internal marker (TGN38) was used and the results were compared 
between permeabilised and unpermeabilised cells.
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The last control consisted of showing that XOR present on the outer surface of 
unpermeabilised cells could not be due to the presence of XOR in the medium and 
particularly in the serum Cells were grown in medium in which XOR was removed 
using an heparin column. These cells still showed presence of XOR on their surface. 
Different compounds used in the methods were also tested for the possible presence 
of XOR, but the results were negative.
It can be noted that a similar distribution of XOR in the cytoplasm and on the outer 
surface of cells was found in mammary epithelial cells, HB4a (Rouquette et al, 1998) 




THE L929 CELL LINE.
7.1. Introduction
L929, a mouse fibroblast cell line, was one of the first cell lines to be established in 
continuous culture (Earle et al, 1943). In the present context, L929 cells are unique 
because of their capacity to show XOR enzymic activity only in presence of 
molybdenum (IV) salts. In 1994, Falciani and coworkers demonstrated that L929 cells 
show no detectable XOR activity either under normal conditions or following 
stimulation with cytokines. However, when a molybdenum salt was added to the cells, 
significant levels of XOR activity were detected under all conditions. This induction 
was thought to be post-translational as it was insensitive to cycloheximide, indicating 
that inactive enzyme protein was present in cells prior to addition of molybdenum
In this Chapter, the L929 cell line was used as another approach to study the 
regulation of XOR expression. The results of Falciani et al (1994) were checked 
before investigating whether similar effects could be observed with EA.hy 926 cells. 
The distribution of XOR was studied in permeabilised and unpermeabilised L929 cells 
both before and after exposure to molybdenum, in order to compare results with those 




L929 cells were cultured as described in Section 2.1.2.2. On day 0, the cells were 
seeded at 2xl05 cells/ml. For studies of molybdenum addition, sodium molybdate was 
added to the medium of L929 cells or EA.hy 926 cells to a final concentration of 
0.5mM, from day 0 and every time the medium was changed. Cell supernatants were 
prepared as described in Section 2.1.4, and fluorimetric assays were carried out as in 
Section 2.3. The fluorimetric assay was slightly modified from that of Section 2.3 in 
that XOR activity was measured in the absence and presence of methylene blue, in 
order to determine XO and XO + XDH activities respectively. The distribution of 
XOR was analysed in permeabilised and unpermeabilised cells following the 
procedures described in Section 2.7.
7.3. Results
7.3.1. Effects of molybdate on expression of XOR enzymic activities
In the absence of molybdate, L929 cells expressed no detectable XOR activity. When 
molybdate salt was added to the medium, XOR activity began to be detectable after 
only 24h. Activity continued to increase with days in culture as shown in Fig. 7.1 A. 
The controls (no addition of molybdate) showed no detectable XOR specific activity 
(Fig. 7.1 A). XO activity represented 60% to 80% of the total XOR activity (XO + 
XDH). Molybdate added to the EA.hy 926 cell line did not induce any significant 
increase in XOR activity (Fig. 7.1, B) compared to the controls.
7.3.2. Distribution of XOR in L929 treated or not with molybdate salt
The distribution of XOR was investigated by means of confocal microscopy and 
immunolocalisation using affinity-purified anti-HXOR antibody. Quantitative 
comparisons between cells treated with added molybdate and non-treated cells were 
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Control Mo (XO) - a-  Mo (XO+XDH)
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Control 24h Mo 24h Control 48h
Fig. 7.1: Effects o f molybdate on L929 and EA.hy 926 cells.
A fina l concentration o f 0.5mM molybdate (Mo) was added to the cells. A) L929 cell 
line, XO and XO+XDH activities are shown. B) EA.hy 926 cell line, XO+XDH 
activity only. Values are quoted as mean ±SEM; n=2.
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7.3.2.1. Permeabilised L929 cells
As in EA.hy 926 cells, XOR was found to be present in the cytoplasm of L929 cells 
with increased fluorescence around the perinuclear region. The cells treated with 
molybdate initially appeared brighter than controls, and so the confocal microscope 
conditions were set up to the cells treated with molybdate (Pictures A-D), and images 
were collected from the controls under similar conditions (Pictures E-F). When the 
two groups were compared, no significant difference was apparent. However, 
fluorescence was clearly stronger in L929 cells (Fig. 7.2) than in EAhy 926 cells 
(Fig. 6.9), although quantitative comparisons were not possible.
7.3.2.2. Unpermeabilised L929 cells
Again, results for L929 cells were similar to those found for EA.hy 926 cells or 
HUVECs. XOR protein was seen to be present on the outer surface of the cells, 
whether or not they were grown in medium containing 0.5mM molybdate. 
Photographs of cells treated with molybdate and controls were collected under similar 
conditions on the confocal microscope, and no significant difference was found 
between the two groups. However, the pictures do suggest that the presence of XOR 
enzyme on the surface of the cells is more striking in the case of the L929 cell line 
(Fig.7.3) than in the case of EA.hy 926 cells (Fig.6.11), although no quantitative 
comparisons were possible. The presence of XOR is very polarised on the surface of 
L929 cells. For most of the cells, XOR is only present on one side of them The 
arrows on Fig.7.3, indicate the junctions of cells where XOR is usually present. 
Overlaid fluorescence and DIC pictures (S, F, I, L) emphasise the relationship 




Fig. 7.2: Distribution o f  XOR in permeabilised L929 cells.
Cells were prepared as mentioned in Section 2.7. Immunofluorescent (A, C, E, G) 
and differential interference contrast (DIC) (B, D, F, H) images are shown. Cells 
were grown either in medium containing molybdate (A-D) or in normal medium (E- 
F), see Section 2.1.2.2. Antibodies used: affinity purified anti-HXOR antibody (stock 
0.54mg/ml, 1:10 dilution was used) and anti-rabbit FITC conjugated antibody 
(1:100). Magnification x400; 20pm bar.
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Fig.7.3: Distribution o f  XOR in unpermeabilised L929 cells.
Cells were prepared as mentioned in Section 2.7. Immunofluorescent (A, D, G, J) 
and DIC (B, E, H, K) images are overlaid (C, F, I, L) to emphasise the polarised 
distribution. Cells were grown either in medium containing molybdate (A-F) or in 
normal medium (G-L), see Section 2.1.2.2. Antibodies used: affinity purified anti- 
HXOR antibody (stock 0.54mg/ml, 1:10 dilution was used) and anti-rabbit FITC 











According to Falciani et al (1994), activation of XOR by molybdenum (IV) salts was 
specific to the L929 cell line, and in my work, this was not observed in EA.hy 926 
cells. Studying L929 cells provides another model for the expression of XOR in cell 
culture. The fact that, after many years of culture, XOR is still expressed in these cells 
in an inactive form, lacking Mo and/or its cofactor, suggests that the XOR protein 
may play a more complicated role in the cell than is apparent.
EA.hy 926 and L929 cells must have access to a similar amount of molybdenum 
initially present in the medium, in normal conditions. However, the L929 cells are 
incapable of utilising directly this source of molybdenum salt. Exogenous 
molybdenum salt must be added to the medium in a relatively high quantity, for XOR 
to be fiilly active. This raises the question of which pathway the exogenous 
molybdenum uses to activate XOR
Molybdoenzymes have been particularly well studied in E.coli, in which the 
production of the enzyme relies upon the efficient uptake of molybdate via the 
molybdate specific transporter encoded by the modABCD operon (Grunden et al,
1996). Rajagopalan and Johnson (1992) showed that some E.coli mutants, referred as 
'mod' and 'mog were unable to synthesise the molybdenum cofactor essential for these 
molybdoenzymes. However, both mutants have been reported to respond to elevated 
levels of molybdate in the culture medium (Rajagopalan and Johnson, 1992; 
Shanmugam et al, 1992). Joshi and colleagues (1996) proposed that molybdopterin 
might be synthesised normally but might be subjected to degradation if further 
assembly into molybdenum cofactor and incorporation into molybdoenzymes was 
interrupted, leaving low levels of residual pterin in the cells. On the other hand, the 
mutant cells respond to elevated levels of the metal in culture because molybdate 
uptake can be accomplished by mass action through transport by cellular phosphate or 
sulphate uptake systems.
This system was described in E.coli and more studies need to be carried out on the 
subject on the mammalian enzyme.
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It is also conceivable that post-translational activation of XOR could be by way of 
molybdenum incorporation into basically depleted cells (Godber et al, 1997). 
However, as mentioned before, EA.hy 926 cells and HB4a cells are capable of using 
molybdenum salt present in their respective media to express an active XOR enzyme. 
L929 cells need an excess of molybdate in their medium for XOR to be active. The 
system of incorporation of molybdenum salt into the cells might not be efficient in 
L929. No increase in XOR activity was observed in EA.hy 926 cells incubated with 
0.5mM molybdate. The result of this experiment does not preclude the existence of 




DETERMINATION OF NADH OXIDASE ACTIVITY 
ON THE OUTER SURFACES OF CELLS.
8.1. Introduction
XOR commonly exists in vivo as the xanthine dehydrogenase (XDH) form which 
utilises NAD+ as an electron acceptor during the oxidation of xanthine. Xanthine 
oxidase (XO), on the other hand, utilises molecular oxygen as its electron acceptor, 
giving rise to ROS (Hille and Massey, 1991; Nishino and Hille, 1995). A little 
recognised activity of XOR is its ability to act as an NADH oxidase. The NADH 
oxidase activities of the dehydrogenase and the oxidase forms of the human XOR 
were studied by Sanders et al (1997). It was found that the human milk enzyme was 
capable of oxidising NADH to form superoxide anions, particularly in the case of the 
dehydrogenase form. NADH differs from other reducing substrates in acting at the 
FAD, rather than the Mo site. No specific inhibitor for the FAD centre of XOR has 
been reported, while diphenyleneiodonium chloride (DPI) will certainly inhibit this 
activity. Several flavoproteins are similarly inhibited, including NADPH oxidase of 
phagocytes (Cross and Jones, 1986; O'Donnell et al, 1993), nitric oxide synthase 
(Stuehr et al, 1991) and NADPH-cytochrome P-450 reductase (Doussiere and 
Vignais, 1992). Allopurinol inhibits only the molybdenum centre of XOR and does 
not interact with the FAD centre of the enzyme (Fig. 8.1). In view of the presence of 
XOR on the outer surface of human endothelial cells (Chapter 6), the enzyme may 
well play an important role in signalling, particularly as the enzyme was found to be 
concentrated on those surfaces of cells apposed to those of neighbouring cells.
Attempts to demonstrate XOR enzymic activity on the surfaces of EA.hy 926 and 
L929 cells are complicated by the membrane permeability of xanthine, hypoxanthine 
and most reducing substrates of the enzyme.
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NADH, on the other hand, is membrane impermeable and it was decided to 
investigate whether NADH oxidase activity of XOR was likely to participate in such 
signalling activities. As a preliminary exercise, experiments were designed to attempt 
to measure the XOR-catalysed oxidation of NADH to NAD by following the loss of 
absorbance at 340nm. However, this spectrophotometric measurement may not be 
sensitive to the very low levels of XOR present on the outer surface of the cells.
Inhibitable by Allopurinol
XO XO




Fig. 8.1: Schematic diagram o f the inhibition by DIP and allopurinol.
(Adapted from Zhang et al, 1998).
8.2. Methods
8.2.1. Assays
Cells were seeded at 2xl05 cells/ml for EA.hy 926 cells and at 1.5xl05 cells/ml for 
L929 cells. 'High' cell densities (mentioned later) correspond to double these densities. 
For the cells treated with allopurinol, a ImM solution was used to produce a final 
concentration of 50pM in the medium (50pl). Diphenyleneiodonium chloride (DPI) 
was added to a final concentration of lOpM (stock solution, 1 mg/ml in PBS). For 
inhibition studies, allopurinol and DPI were added directly to the medium of the cells 
a few hours after seeding and incubated for a total of 20h. NADH (stock solution 
5mM) was added to all samples to a final concentration of 500pM (lOOpl) and
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aliquots of 100 jil were read at 340nm as described in Section 2.3.4 for 6h, apart for 
the first experiment in which a 5h assay was used. It was found that after 24h the A340 
nm was close to zero; however, the cells did not look morphologically normal as only 
around 200 pi of medium was left. A significant decrease in NADH oxidase activity 
was observed after 6h, and so the experiment was stopped at that point.
8.2.2. Estimation of NADH oxidase activity 
Using an extinction coefficient of 6.22mM'1cm'1 and the rate of loss of NADH 
observed at 340nm for each sample, the concentration of NADH oxidised was first 
calculated. Taking into account the dilution of the sample (lOOpl in 1ml, 1:10), the 
total volume of medium and NADH on the cell surface (1ml) and the time 
(6h=360min), the NADH oxidised activity was expressed in pmoles NADH oxidised 
x 10'4 per min. Finally, an estimation of the quantity of NADH found per number of 
cells was carried out, using the fact that V (pmol min1 mg -1) is equal to 0.3 for the 
human XDH (Sanders et al, 1997).
8.3. Results
8.3.1. NADH oxidase activity on the outer surfaces of EA.hy 926 cells
NADH was directly added in the medium where it is expected to remain extracellular 
(Eisenthal, 1998), and the time course of decrease in A340 was followed over 5h 
(Fig. 8.2 A). A control experiment was carried out by adding NADH directly to cell- 
free medium and following the A340, which did not change. Affinity purified anti­
human XOR antibodies were incubated with the cells. The aim was to block XOR and 
check if NADH oxidation was inhibited. As shown in Fig. 8.2 A (S-Ab), there was no 
inhibition of NADH depletion. This might be due to the feet that the incubation with 
the antibodies was not done in medium and the cells were starting to detach from the 
wells. Effectively, the antibodies have to be incubated with the cells for a few hours, 
and the cells were not fixed as usually done during the procedure (Section 2.7). This 
fact increased the chance of cells detaching from the bottom of the well. Moreover, 

















Fin. 8.2: NADH oxidase activity on the outer surface o f EA.hy 926 cells.
The decrease o f A 340 absorbance was spectrophotometricallyfollowed against time. S 
corresponds to cells alone; S-Ab, addition o f affinity-purified antibodies prior to 
addition o f NADH. High S corresponds to cells set at double density. Allo-S and 
DPI-S are cells which have been treated with respectively allopurinol and DPI for 
20h prior to addition o f NADH. M ed and Med-Ab are controls containing cell-free 
medium and NADH. NADH was added to all samples at t= 0  and aliquots o f  each 




and the other cells. No conclusion can be drawn from the results obtained with cells 
incubated with antibodies. Experiments were then carried out with cells set at higher 
density, in which NADH oxidase activity was expected to be proportional to the 
number of cells present in each well. Therefore, a faster disappearance of NADH was 
expected. However, this experiment was inconclusive. As previously illustrated in 
Fig.3.5, the cell growth pattern was disturbed when EA.hy 926 cells were set at 
higher density. Similar events occurred in this case, in which the cells were starting to 
grow on top of each other and were washed off during the first wash of the medium 
(Section 2.3.4). Inhibitors were incubated with the cells for 20h prior to the addition 
of NADH, allopurinol serving as a negative control. Allopurinol only reacts with the 
molybdenum centre of the enzyme and so will not affect the NADH oxidase activity. 
The results found (Fig.8.2 B, Allo-S) were consistent with the theory as no inhibition 
of the NADH oxidase activity was observed. As shown in Fig. 8.2 B (DPI-S), no 
decrease in A340 absorbance was found in cells treated with DPI. DPI appeared to 
inhibit 90% of the NADH oxidase activity in EA.hy 926 cells (Fig. 8.2 B).
8.3.2. Activity on the outer surfaces of L929 cells
Surface NADH oxidase activity was also determined on L929 cells. As described in 
Chapter 7, L929 cells only express xanthine oxidase activity in the presence of high 
levels of molybdate. It was found that the cells, whether treated or not with 
molybdate, induced a similar rate of NADH depletion, in terms of the rate of decrease 
in absorbance at 340nm As NADH is dependent on the FAD centre rather than the 
Mo, this finding is to be expected, although the similar rates indicate that addition of 
Mo did not lead to increased expression of XOR protein. The controls consisting of 
cell-free medium with or without molybdate showed, as expected, no NADH 
depletion (Fig.8.3). DPI inhibited NADH oxidase activity in all cells. This inhibition 
appeared to be slightly more efficient in cells to which sodium molybdate had been 
added (Fig.8.3 A, DIP-S and Mo-DPI). Cells were also seeded at double the density 
of normal samples. It was observed that the disappearance of NADH was quicker in 
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Fig. 8.3: NADH oxidase activity on the outer surface o f L929 cells.
The decrease o f  A s40 absorbance was spectrophotometrically followed against time. 
Mo symbolises the molybdate added to the medium o f the cells. S corresponds to 
cells alone, High-S and Mo-High-S to cells set at double density. Mo-DPI and DPI-S 
are cells which have been treated with DPI fo r  20h prior to addition o f NADH. Med  
and Mo-Med are controls containing cell-free medium and NADH. NADH was 
added to all samples at t=0 and aliquots o f each samples were 
spectrophotometrically read at 340nm. Values are quoted as mean ±SEM; n=3.
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8.3.3. Interpretation of the NADH oxidase experiments
From Table 8.1, it can be concluded that the level of NADH oxidase activity per cell 
is higher in L929 cells compared to EA.hy cells. These results confirm the subjective 
impressions from immunofluorescence experiments (Chapter 6 and 7). The addition of 
molybdate did not induce any change in NADH oxidation. Concerning the samples 
where cells were at double the density, as previously explained, the EA.hy 926 cells 
seeded at higher densities were starting to detach, so the result obtained is not 
reliable. However, the double density samples for L929 cells gave the expected results 
with an increase of the quantity of NADH enzyme on the surface of the cells of xl.7 
fold and xl.9 fold (Table 8.1).
Samples: A340 rate/hours pmoles NADH 
oxidised 10‘4/min.
pg NADH oxidase 
/number cells.
EA.hy 926 cells. 0. l/5h 5.33 1.7/2xl05 cells.
EA.hy 926 cells. 0.089/6h 3.97 1.32/2xl05 cells.
High EA.hy 926 
cells.
0.063/6h 2.82 0.94/4xl05 cells 
(cells came off).
L929 cells. 0.13/6h 5.8 1.93/1.5xl05 cells.
L929-Mo cells. 0.142/6h 6.38 2.12/1.5xl05 cells.
L929 cells. 0.075/6h 4 1.3/lxlO5 cells.
High L929 cells. 0.1225/6h 6.56 2.19/3xl05 cells.
L929-Mo cells. 0.075/6h 4 1.3/1.5xl05 cells.
High L929-Mo 
cells.
0.13756h 7.37 2.45/3xl05 cells.
Table 8.1: Quantity o f  NAD H  oxidase per 105 cells.
Using the extinction coefficient o f 6.22mM]cm'1 and the rate o f disappearance o f 
NADH observed at 340nm, the loss o f NADH was calculated per minute (Section 
8.2.2). Finally, according to the kinetic parameter for NADH oxidation obtained by 
Sanders et al (1997), V (pmol m in1 mg'1) for the human XDH is equal to 0.3. This 
value was used to calculate the quantity o f NADH enzyme/number o f cells (from 




NADH oxidase activity was found on the surface of human endothelial cells and on 
mouse fibroblasts. This activity can be inactivated by DPI, a NADH inhibitor but not 
by allopurinol.
Although, it was not proven that any of the NADH activity was specific to XOR, 
none of the results refute this hypothesis and are consistent with it. Allopurinol 
interacts with the Mo centre of XOR and should not affect the FAD centre which is 
specific for the NADH oxidase activity. Estimates of the amount of NADH activity 
are, however, very high and other enzymes than XOR may well contribute to the 
NADH oxidase activity observed. As the cells were unpermeabilised and 
morphologically normal, other NADH oxidase activities must result from enzymes 
also present on the outer surface of the cells. Such activities have been reported, for 
example, NADH oxidase activity was found on the external surface of the plasma 
membrane of HeLa cells and other cancer cells (Morre et al, 1998). Various 
endothelial cells also express NADH and/or NADPH linked oxidases on their surfaces 
(Davies, 1995).
DPI inhibits the NADH activity but it is not a specific inhibitor of XOR. To prove that 
XOR is responsible for the NADH activity present on the outer surface of the cells, a 
specific inhibitor of the FAD centre of XOR would be necessary. For the moment, no 
such inhibitor has been found.
Although the presence of NADH oxidase activity on the outer surface of the cells 
neither proves that it is wholly or partly due to XOR nor that XOR is active, these 
experiments were an important first step in investigating a possible NADH oxidase of 
XOR on the surface of cells. They show that NADH oxidase activity is present and 





EA.hy 926 cells have been used as a model system in which to examine the role of 
XOR in human cells. The cells were shown to express levels of XOR enzymic activity 
that were low, albeit somewhat higher than those found in human epithelial cells, 
HB4a (Page et al, 1998). As mentioned in the Introduction, human XOR might be 
tissue-specific, with high activity1 enzyme limited to a number of tissues (liver and 
intestine, for example) and 'low activity1 enzyme, similar to that in breast milk, in most 
other tissues. This raises the question as to the function of the apparently predominant 
low-activity human XOR It is conceivable that the enzyme might be subject to some 
forms of post-translational activation (Harrison, 1997b). Desulpho-sulpho enzyme 
conversion of bovine milk XOR has been effected in vitro by incubation of reduced 
enzyme with sulphide ions (Massey and Edmondson, 1970), and in vivo enzymic 
activation in response to increased protein diet has been attributed to desulpho-sulpho 
conversion in chickens (Itoh et al, 1978) and rats (Furth-Walker and Amy, 1987). 
Evidence of a similar post-translational up-regulation of XOR was found in HB4a 
cells in response to cytokines, particularly interferon-y (Page et al, 1998).
XOR enzymic activity in EA.hy 926 cells followed a characteristic pattern as freshly 
seeded cells grew to confluence. Following a lag phase of four days, enzymic activity 
rose sharply (54% increase), achieving a plateau value as the cells reached confluence. 
Some four days later, another sharp rise (50% increase) occurred a few days before 
the cells began to peel away from the substrate and die. A similar rise in XOR activity 
after cells reached confluence was also observed, but not commented on, in BAECs 
(bovine aorta endothelial cells) in a study of oxygen-mediated cell injury (Panus et al, 
1992).
An obvious question is why the specific XOR activity drops to zero when cells 
expressing high XOR activity are split for subculture. It could be that the specific 
expression in the cells is dependent on the cell cycle or cell contact, as mentioned in
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Chapter 6. If die novo synthesis of XOR ceases at low cell density, then it is possible 
that turnover of existing enzyme would suffice to eliminate activity on reseeding. 
Alternatively, it is conceivable that activity is downregulated at a post-translational 
level in ways discussed above. The use of ELISA will help to clarify this and other 
questions relating to expression of XOR in EA.hy 926 cells during a time course.
The fact that a second rise in activity was observed as the cells are starting to die is 
also of particular interest. Addition of allopurinol, the best characterised inhibitor of 
XOR, did not result in any changes either in cell morphology or in percentage of cell 
viability, so gave no clue as to the relationship between XOR and growth cycle. 
Nevertheless, ROS have been implicated in apoptosis (Khan and Wilson, 1995), which 
can be induced by a wide range of factors, including radiation, growth factor removal, 
glucocorticoids, elevation of Ca2+ etc. In all these cases, mammalian cell death can be 
prevented by the expression of the proto-oncogene bcl-2 (Linette and Korsmeyer,
1994). Bcl-2 is localised in the endoplasmic reticulum, on the outer membrane of 
mitochondria, and on nuclear membranes, also sites of ROS generation (Korsmeyer et 
al, 1995). Possible antioxidant functions of bcl-2 have been examined by different 
groups. It was found that bcl-2 protected cells from H20 2-induced damage, and 
prevented lipid peroxidation or DNA fragmentation (Hockenbery et al, 1993). Suzuki 
and coworkers (1997) developed an experimental model for apoptosis in endothelial 
cells by using snake venom, which was found to generate intracellular ROS leading to 
apoptosis. More recently, a Japanese team showed that ROS generated by xanthine 
and xanthine oxidase triggered cell death associated with nuclear condensation and 
DNA fragmentation in cerebellar granule neurons, which were protected by catalase, 
but not by superoxide dismutase (Satoh et al, 1998). The implied role of H20 2 is 
interesting in view of the results discussed below. In our system, it is not clear if 
EA.hy 926 cells undergo apoptosis in culture. The use of apoptosis kits might give us 
an indication. Further experiments preventing the expression of XOR in the cells by 
addition of catalase or by changing medium should also help to understand the 
relationship between XOR and apoptosis. Moreover, colocalisation of bcl-2 and XOR 
could be investigated using the confocal microscope.
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XOR was found on the outer surface of endothelial cells, concentrated in areas where 
cells were apposed to or extending towards neighbouring cells. These observations 
might suggest a role for XOR in social interactions, particularly involving ROS. ROS 
are known to play a role in the modulation of mammalian cell proliferation (Burdon 
and Rice-Evans, 1989; Burdon 1992; Burdon, 1995), and free radical-derived species 
can have a significant modulatory influence on growth in a variety of cell types 
(hamster and mouse fibroblasts, human primary fibroblasts and mouse epidermal cells) 
when added exogenously to the culture medium (Burdon and Gill, 1993).
Evidence for a secreted signal was found when medium was changed four times a day 
for 48h. Although the cell morphology was not altered, the XOR activity was 
significantly decreased by nearly 90%. This result strongly suggests that XOR 
expression is dependent on agents secreted by the cells in the medium. However, 
attempts to induce XOR expression in endothelial cells by addition of conditioned 
medium were unsuccessful. In attempts to further investigate possible signals, 
extracellular agents (SOD, catalase and H2O2) were added to EA.hy 926 cells and 
their influence on XOR expression was checked. Catalase induced a significant 
decrease of XOR activity, but direct addition of H2O2 to EA.hy 926 cells affected 
neither cell viability nor the specific expression of XOR in the cells. These results are 
similar to the ones found by Phan et al (1989), who showed that XO activity was not 
increased by H2O2 in rat pulmonary artery endothelial cells. It is possible that the 
concentration of H20 2 used was not at the right level to induce any effect on XOR 
activity. Addition of exogenous SOD to the cells also had no effect on the specific 
XOR activity.
Low levels of ROS may be involved not only in intercellular signalling but also in 
intracellular redox signalling events, for example controlling gene expression. From 
the confocal microscope studies, XOR was shown to be distributed not only on the 
outer surface of endothelial cells but also in the cytoplasm, where it is concentrated in 
the perinuclear region. The outer membrane of the nuclear envelope is continuous 
with the membranes of the endoplasmic reticulum (Loewy et al, 1991). ROS are 
increasingly thought to be important as agents of signal transduction and in particular 
in the activation of nuclear transcription factors, such as NF-AB.
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The localisation of XOR on or near the nuclear membrane would be relevant to such a 
role. From these preliminary results, a sketch can be drawn concerning the activation 
of XOR and the possible role of XOR in cell signalling (Fig.9.1).
The presence of extracellular XOR raises the question of how the enzyme is secreted 
from the surface of the cells. XOR was found to have no signal peptide and not to be 
glycosylated (Ichida et al, 1993 and Xu et al, 1994). It is therefore quite likely that 
XOR is not secreted by the classical pathway. In 1993, Kuchler reviewed proteins that 
lack a typical hydrophobic N terminal leader sequence and which are secreted. Among 
these different proteins are cited interleukin-I and factor Xllla. XOR may not be 
involved in the endoplasmic reticulum-Golgi route but instead in the ABC resident 
endosomal transporter which is thought to be involved in the alternative pathway 
(Kuchler, 1993). This could also explain the presence of the enzyme concentrated 
around the perinuclear region of the cells.
Further evidence of the presence of XOR on the surface of the cells was provided by 
the demonstration of NADH oxidase activity. This activity is inhibited by DPI, a 
specific inhibitor of all flavoenzymes, and not all of this NADH oxidase activity can be 
attributed to XOR. An increasing number of NAD(P)H oxidases are being detected 
on mammalian cell surfaces. Such oxidase complexes appear to have a role similar to 
that of phagocytic cell NADPH oxidase, and may generate a constant stream of 0 2’ to 
maintain a local environment that discourages bacterial/fungal infection (Davies
1995). An NADPH oxidase that releases extracellular superoxide was found in the 
rabbit aorta (Pagano et al, 1993; 1995). Similar NADH oxidases were found to be the 
predominant source of superoxide in bovine endothelial and vascular smooth muscle 
cells (Mohazzab et al, 1994; Mohazzab and Wollin, 1994), while the major source of 
vascular superoxide ion and hydrogen peroxide was reported to be a membrane bound 
NADH oxidase (Harrison, 1997a). In many cases, it is not clear to what extent 
reported NADH oxidase activities can be attributed to XOR. This possibility is often 
supposedly eliminated by failure of allopurinol to block that observed activity. In fact, 
XOR-catalysed NADH oxidase activity is not inhibited by allopurinol or by most 


















> Activation of XOR gene?Gene activation
Fig. 9.1: Potential role o f XOR and ROS in cell signalling based on the results
discussed in this thesis (other factors can cause the dissociation o f NF-kB or the 
production o f ROS, but for simplicity these were not shown here).
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Bayraktutan and coworkers (1998) have recently suggested a role for NAD(P)H 
oxidases in cellular signalling pathways in addition to mediating the cellular injury 
associated with excessive free radical generation.
The discovery of XOR on the surface of endothelial cells and other cells could help us 
to understand the role of XOR in inflammation. As mentioned in the General 
Introduction, a proposed endothelial cell trigger mechanism was presented by 
Bulkleys team (Ratych et al, 1987; Bulkley, 1997). This model is based on the fact 
that the endothelial/cell-based XOR system and the neutrophil-based NADPH oxidase 
system each generates reactive oxidants from a different source, and these two 
mechanisms combine to mediate reperfusion injury. The initial production of reactive 
oxidants by endothelial XOR triggers the arrest-trapping, activation and subsequent 
diapedesis of circulating neutrophils. While activation of lymphocytes and rolling have 
been well studied, little is known of the diapedesis process (Springer, 1990; Baumann 
and Gauldie, 1994). XOR situated at the junction of two endothelial cells could 
attract the activated lymphocytes. Obviously, this model depends on the presence of 
cell surface XOR, which was indeed briefly reported in abstracts from the same team 
(Bulkley, 1991; Schiller et al, 1992). Following the publication of our results on the 
distribution of XOR in endothelial and epithelial human cells (Rouquette et al, 1998), 
Vickers and coworkers (1998) published their data providing existence for the 
presence of XOR on the outside surface of primary cultures of bovine (BAECs) and 
porcine (PAECs) aortic endothelial cells. This finding leads one to think that the 
localisation of XOR on the outer surface of cells is not specific to human endothelial 
and epithelial cells.
The occurrence of endothelium-derived XOR might explain systemic complications 
such as acute respiratory distress syndrome (ARDS). ARDS is associated with 
activation of neutrophils and therefore with release of free radicals and ROS in the 
pulmonary circulation (Chabot et al, 1998). Quinlan and coworkers (1997) showed 
that patients with ARDS had higher levels of xanthine and hypoxanthine compared to 
controls. Another team reported that xanthine oxidase activity was associated with 
arterial blood pressure in spontaneously hypertensive rats.
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Xanthine oxidase activity was inhibited by a tungsten diet and by administration of (-) 
BOF 4272. The inhibitory effects of the tungsten diet on the increasing blood pressure 
and arteriolar tone in spontaneously hypertensive rats was reproducible by 
administration of (-) BOF 4272 (Suzuki et al, 1998). It is interesting that NF-kB is 
activated in lungs of patients with ARDS. In this model, blood loss was partly through 
xanthine oxidase-dependent mechanisms (Moine et al, 1997). These facts suggest that 
XOR and ROS are involved in important diseases and syndromes.
Concerning antibodies to XOR in blood, Benboubetra and coworkers (1997) found 
that levels of IgM anti-XOR autoantibodies are remarkably high in normal human 
serum. High levels of anti-XOR antibodies can be seen as advantageous, as they could 
neutralise and/or clear endogenous XOR from the circulation (Benboubetra et al,
1997). The presence of circulating anti-XOR autoantibodies is also relevant in 
considerations of XOR on the surface of vascular endothelial cells. The enzyme has 
been shown to bind reversibly and with high affinity to glycosaminoglycans on the 
surface of endothelial cells (Radi et al, 1997). ROS generated by glycosaminoglycan- 
bound XOR might be expected to diffiise into the intravascular compartment and 
react with circulating blood elements. White and coworkers (1996) showed that levels 
of XOR are increased in the plasma of cholesterol-fed rabbits and that this circulating 
XOR binds to heparin-binding sites on the vessel wall, where it produces excess 
superoxide. Inhibition of XOR with oxypurinol improves endothelium-dependent 
vascular relaxation (White et al, 1996).
A recent finding from our laboratory is relevant to the possible role of endothelial 
XOR. The enzyme was shown to catalyse the reduction of organic and inorganic 
nitrate to nitric oxide (NO) under hypoxic conditions and in the presence of NADH, 
suggesting a vasodilatory role in ischaemia (Millar et al, 1998). These findings could 
also be relevant to the inflammatory response, in which the potential for simultaneous 
release of NO and superoxide suggests a role for XOR-generated peroxynitrite as a 
destruction agent in diseases involving hypoxic episodes.
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The results obtained with L929 mouse fibroblastic cells are worthy of brief comment. 
These cells have been shown to contain inactive XOR protein which can be activated 
by addition of molybdenum salts to the culture medium (Falciani et al, 1994). In the 
present studies, the enzyme was shown to be localised on the outer membrane of the 
cells and in the cytoplasm concentrated around the perinuclear region, as found for 
EA.hy 926 cells. Moreover, NADH oxidase activity was also detected on the surface 
of L929 cells which could in part be attributed to XOR In the previously reported 
work, although XOR-specific mRNA was detected in L929 cells prior to molybdenum 
addition, the inactive protein was not actually determined. We now know that the 
inactive protein is not only present in the cells but is distributed in a manner entirely 
analogous to that in EA.hy 926 cells.
Most of this thesis has been directed to an investigation of the occurrence and 
potential roles of XOR in human endothelial cells. The enzyme is clearly present in 
EA.hy 926 cell line and appears to exist in a form with low specific activity, like that 
in human milk. The relationship between expression of XOR activity and the growth 
of endothelial cells is intriguing, and particularly the sharp rise in activity shortly 
before death of the cells merits further investigation. The most important finding is the 
localisation of XOR on the outer surface of the cells with important implications for 
the role of the enzyme in the inflammatory response. The question as to how the 
enzyme is secreted from the cell remains open. Study of NADH oxidase on the 
surface of the endothelial cells indicated the presence of activity that could not all be 
attributed to XOR, and again needs further investigation.
Overall, EA.hy 926 cells have been shown to be a useful model for study of the role 
of XOR in human endothelial cells and a number of potentially interesting approaches 




Abadeh, S., Kdlacky, J., Benboubetra, M., Harrison, K  (1992) Biochim. Biophys. 
Acta 1117, 25-32. "Purification and partial characterisation of xanthine oxidase from 
human milk."
Adachi, T., Fukushima, T., Usami, Y., Hirano, K. (1993)Biochem. J. 289, 523-527. 
"Binding of human xanthine oxidase to sulphated glycosaminoglycans on the 
endothelial-cell surface."
Ahn, K., Pan, S., Beningo, K , Hupe, D. (1995) Life Science 56, 2331-2341. "A 
permanent human cell line (EA.hy 926) preserves the characteristics of endothelin 
converting enzyme from primary human umbilical vein endothelial cells."
Alberts, B., Bray, D., Johnson, A., Lewis, J., Raff, M., Roberts, K , Walter, P. (1998) 
In: Essential cell Biology. An introduction to the molecular biology of the cell. 
Garland Publishing, Inc-New York and London. 449-463.
Amaya, Y., Yamazaki, K , Sato, M., Noda, K., Nishino, T., Nishino, T. (1990) J.
Biol. Chem. 265, 14170-14175. "Proteolytic conversion of xanthine dehydrogenase 
from the NAD-dependent type of the 0 2-dependent type. Amino-acid-sequence of 
rat-liver xanthine dehydrogenase and identification of the cleavage sites of the enzyme 
protein during irreversible conversion by trypsin. "
Avis, P.G., Bergel, F., Bray, R.C. (1956) J. Chem Soc. 1219-1225. "Cellular 
constituents. The chemistry of xanthine oxidase. Part IQ. Estimations of the cofactors 
and the catalytic activities of enzyme fractions from cow's milk."
Baeuerle, P.A. and Baltimore, D. (1988a) Cell 53, 211-217. "Activation of DNA- 
binding in an apparently cytoplasmic precursor of the NF-kB transcription factor."
Baeuerle, P.A. and Baltimore, D. (1988b) Science 242, 540-546. "IkB: a specific 
inhibitor of the NF-kB transcription factor."
Barritt, G.J. (1992) In: Communication within animal cells. Oxford University Press. 
23-35.
Baumann, H. and Gauldie, J. (1994) Immunol Today 15, 2, 74-80. "The acute phase 
response."
Bayraktutan, U., Draper, N., Lang, D., Shah, A.M. (1998) Cardiovas. Res. 38, 256- 
262. " Expression of a functional neutrophil-type NADPH oxidase in cultured rat 
coronary microvascular endothelial cells."
References
132
Beckman, J.S., Parks, D.A., Pearson, J.D., Marshall, P.A., Freeman, B.A. (1989) 
Free Rad. Biol. Med. 6, 607-615. "A sensitive fluorometric assay for measuring 
xanthine oxidase dehydrogenase and oxidase in tissues."
Beg, A.A., Ruben, S.M., Scheiman, R.I., Haskill, S., Rosen, C.A., Baldwin, A.J.
(1992) Genes & Development 6, 1899-1913. "IkB interacts with the nuclear 
localization sequences of the subunits of N F-kB: a mechanism for cytoplasmic 
retention."
. Benboubetra, M., Gleeson, A., Harris, C.P.D., Khan, J., Arrar, L., Brennand, D., 
Reid, J., Reckless, J.D., Harrison, R  (1997) Eur. J. Clin. Invest. 27, 611-619. 
"Circulating anti-(xanthine oxidoreductase) antibodies in healthy human adults."
Berglund, L., Rasmussen, J.T., Andersen, M.D., Rasmussen, M.S., Pertersen, T.E.
(1996) J. Dairy Sci. 79, 198-204. "Purification of the bovine xanthine oxidoreductase 
from milk fat globule membranes and cloning of complementary deoxyribonucleic 
acid."
Bhat, G.B., Tinsley, S.B., Tolson, J.K., Patel, J.M., Block, E.R (1992) J. Cell. 
Physiol. 151, 228-238. "Hypoxia increases the susceptibility of pulmonary artery 
endothelial cells to hydrogen peroxide injury."
Bradford, M.M. (1976) Anal. Biochem. 72, 248-254. "A rapid and sensitive method 
for the quantification of microgram quantities of protein."
Bradley, J.R, Thiru, S., Pober, J.S. (1995) Am. J. Path. 147, 627-641. "Hydrogen 
peroxide-induced endothelial retraction is accompanied by a loss of the normal spatial 
organization of endothelial cell adhesion molecules."
Brass, C.A. (1995) Hepatology 21, 1757-1758. "Xanthine oxidase and reperfiision 
injury: major player or minor irritant?".
Bray, RC. (1975) In: The Enzymes. "Molybdenum iron-sulfur flavin hydroxylases 
and related enzymes." 3rd Ed, 12, P.D. Boyer Ed. (New York: Academic Press) 299- 
419.
Bray, RC. (1988) Quart. Rev. Biophys. 21, 299-329. "The inorganic biochemistry of 
molybdoenzymes."
Briley, M.J. and Eisenthal, R  (1974) Biochem. J. 143, 149-157. "Association of 
xanthine oxidase with the milk-fat-globule membrane."
Brown, R , Park, S., Kanno, T., Franzoso, T., Siebenlist, U. (1993) Proc. Natl. Acad. 
Sci. USA 90, 2532-2536. "Mutual regulation of the transcriptional activator NF-kB 
and its inhibitor IkB-cc."
Bruder, G., Heid, H.W., Jarasch, E.D., Mather, I.H. (1983) Differentiation 23, 218- 




Bulkley, G.B. (1991) Abstr. Int. Congr. Oxygen Radicals 5th, 28.
Bulkley, G.B. (1994) Lancet 344, 934-936. "Reactive oxygen metabolites and 
reperfusion injury: aberrant triggering of reticuloendothelial function."
Bulkley, G.B. (1997) Biochem. Soc. Trans. B5 25, 804-811. "Physiology of reactive 
oxidant-mediated signal transduction: an overview."
Burdon, R.H. and Rice-Evans, C. (1989) Free Rad. Res. Comms. 6, 345-358. "Free 
radicals and the regulation of mammalian cell proliferation."
Burdon, R.H. (1992) Proceedings o f the Royal Society o f Edinburgh 99B, 169-176. 
"Cell proliferation and oxidative stress: basis for anticancer drugs."
Burdon, R E ,  Gill, V. (1993) Free Rad. Res. Comms. 19, 3, 203-213. "Cellularly 
generated active oxygen species and HeLa cell proliferation."
Burdon, R.H. (1995) Free Rad. Biol. &Med. 18, 775-794. "Superoxide and 
hydrogen peroxide in relation to mammalian cell proliferation."
Bussolino, F., Billignandi, P., Arese, P. (1986) Acta Haematol. (Basel) 75, 129-140. 
"Platelet-activating factor, a powerful lipid autocoid possibly involved in 
microangiopathy."
Carr, P.E., Talbot, J.M., Fisher, RD. (1975) Fed. Am. Soc. Exp. Biol. "A review of 
the significance of bovine milk xanthine oxidase in the etiology of atheroscleroscis."
Chabot, F., Mitchell, J.A., Gutteridge, J.M.C., Evans, T.W. (1998) Eur. Resp. J. 11, 
745-757. "Reactive oxygen species in acute lung injury."
Claise, C., Chalas, J., Edeas, M., Abella, A., Khalfoun, Y., Laurent, D., Lindenbaum, 
A. (1997) Cell. Mol. Life Sci. 53, 156-161. "Comparison of oxidized low-density 
lipoprotein toxicity on EA.hy 926 cells and human vein cells: influence of antioxidant 
systems."
Coon H.G. (1968) J. Cell. Biol. 39, 29a. "Clonal culture of differentiated rat liver 
cells."
Cross, A.R. and Jones, O.T.G. (1986) Biochem. J. 237, 111-116. "The effect of the 
inhibitor dephenylene iodonium on the superoxide-generating system of neutrophils. 
Specific labelling of a component polypeptide of the oxidase."
Cross, P.C., Mercer, K.L. (1993) In: Cell and tissue ultrastructure, a functional 
perspective. W.H. Freeman and Company, New York. 4-8. "Mitotic chromosome."
Darling, D.C. and Morgan, S.J. (1994) In: Animal cells culture and media. J.Wiley 
and sons. 39-53.




De Angelis, E, Moss, S.H., Pouton, C.W. (1996) Advanced Drug Delivery Reviews 
18, 193-218. "Endothelial cell biology and culture methods for drugs transport 
studies."
Debault, L.E., Esmon, N.L., Esmon, C.T., Edgell, C.J.S. (1984) Abstract Fed. Proc. 
43, 783 "Thrombomodulin expressed in human endothelial cell hybrid."
Della Corte, E. and Stirpe, F. (1972) Biochem. J. 126, 739-745. "The regulation of 
rat liver xanthine oxidase."
Devary, Y., Gottlieb, R.A., Lau, L.F., Karin, M. (1991) Mol. Cell. Biol. 11, 2804- 
2811. "Rapid and preferential activation of the c-jun gene during the mammalian UV 
response."
Doussiere, J. and Vignais, P.V. (1992) Eur. J. Biochem. 208, 61-71. "Diphenylene 
iodonium as an inhibitor of the NADPH oxidase complex of bovine neutrophils."
Dupont, G.P., Huecksteadt, T.P., Marshall, B.C., Ryan, U.S., Michael, J.R, Hoidal, 
J.R. (1992) J. Clin. Invest. 89, 197-202. "Regulation of xanthine dehydrogenase and 
xanthine oxidase activity and gene expression in cultured rat pulmonary endothelial 
cells."
Earle, W.R., Schilling, E.L., Stark, T.H., Straus, N.P., Brown, M.F., Shelton, E. 
(1943) Journal o f the National Cancer Institute 4, 165-212. "Production of 
malignancy in vitro. The mouse fibroblast cultures and changes in the living cells."
Edgell, C.J.S., McDonald, C.C., Graham, J.B. (1983) Proc. Natl. Acad. Sci. USA 80, 
3734-3737. "Permanent cell line expressing human factor VDI-related antigen 
established by hybridization."
Eisenthal, R. (1998) Personal communication. Department of Biology and 
Biochemistry. University of Bath.
Emeis, J.J. and Edgell, C.J.S. (1988)P/ooc?71, 1669-1675. "Fribinolytic properties of 
a human endothelial hybrid cell line (EA-hy 926)."
Falciani, F., Terao, M., Goldwurm, S., Ronchi, A., Gatti, A., Minoia, C., Calzim, L., 
Salmona, M., Cazzaniga, G., Garattini, E. (1994) Biochem. J. 292, 69-77. 
"Molybdenum (VI) salts convert the xanthine oxidoreductase apoprotein into the 
active enzyme in mouse L929 fibroblastic cells. "
Fowler, J. and Cohen, L. In: Practical statistics for field biology. Open University 
Press, Philadelphia. 175-176.
Frederiks, W.M., Bosch, K.S., Van Gulik, T. (1993a) Histochemical J. 25, 86-91. "A 
quantitative histochemical procedure for the demonstration of purine nucleoside 
phosphorylase activity in rat and human liver using Tetranitro BT and xanthine 
oxidase as auxiliary enzyme."
References
135
Frederiks, W.M., Marx, F., Kooij, A. (1993b) Int. J. Exp. Path. 74, 21-26. "The 
effect of ischemia on xanthine activity in rat intestine and liver."
Frederiks, W.M. and Bosch, K.S. (1996) Hepatology 24 1179-1218. "The proportion 
of xanthine oxidase activity of total xanthine oxidoreductase activity in situ remains 
constant in rat liver under various (patho) physiological conditions."
Frederiks, W.M. and Bosch, K.S. (1997) Free Rad. Biol. Med. 22, 241-248. 
"Localization of superoxide dismutase activity in rat tissues."
Fridovich, I. (1989) J. Biol. Chem. 264, 7761-7764. "Superoxide dismutase: an 
adaptation to a paramangenic gas."
Furth-Walker, D. and Amy, N.KL (1987)/. Nutr. 117, 1697-1703. "Regulation of 
xanthine-oxidase activity and immunologically detectable protein in rats in response to 
dietary-protein and iron."
Godber, B., Sanders, S., Harrison, K , Eisenthal, R , Bray, RC. (1991) Biochem. Soc. 
Trans. 25, 519S. ">95% of xanthine oxidase in human milk is present as the 
demolybdo form, lacking molybdopterin."
Graham, K , Fleming, J.E., Young, R, Bensih, KG. (1989) Int. J. Biochem. 21, 715- 
722. "Preparation of antibodies against xanthine oxidase from human milk."
Granger, D.N. , Rutili, G ., Me Cord, J.M. (1981) Gastroenterology 81, 22-29. 
"Superoxide radicals in feline intestinal ischemia."
Grisham, M.B. (1994) Lancet 344, 859-861. "Free radicals and anti-oxidants: 
oxidants and free radicals in inflammatory bowel disease."
Grunden, A.M., Ray, KM., Rosentel, J.K, Healy, F.G.H., Shanmugam, K.T. (1996) 
J. Bacteriol. 178, 735-744. "Repression of the Escherichia coli modP&CD 
(Molybdate Transport) Operon by ModE."
Halliwell, B. (1994) Lancet 344, 721-724. "Free radicals, antioxidants, and human 
disease: curiosity, cause, or consequence?"
Hardie, D.G. (1991) In: Biochemical messengers. Hormones, neurotransmitters and 
growth factors. Chapman & Hall-London. 1-18; 93-102.
Harrison, D.G. (1997a) Clin. Cardiol. 20 (Suppl. II), nil-1117. "Endothelialfunction 
and oxidant stress."
Harrison, K  (1997b) Biochem. Soc. Trans. B5 25, 786-790. "Human xanthine 
oxidoreductase: in search of a function."
Hart, L.I., McGartoll, M.A., Chapman, H.K, Bray, RC. (1970) Biochem. J. 116, 
851-864. "The composition of milk xanthine oxidase."
References
136
Hassoun, P.M., Yu, F.S., Shedd, A.L., Zuluetta J.J., Thannickal, V.J., Lanzillo J.J., 
Fanburg, B.L. (1994) Am. J. Physiol. 10, L163-L171. "Regulation of endothelial cell 
xanthine dehydrogenase/xanthine oxidase gene expression by oxygen tension."
Hellsten-Westing, Y. (1993) Histochemistry 100, 215-222. "Immunohistocheniical 
localization of xanthine oxidase in human cardiac and skeletal muscle."
Hellsten, Y., Frandsen, U., 0rthenblad, N., Sjodin, B., Richter, E.A. (1997) J. 
Physiol. 498.1, 239-248. "Xanthine oxidase in human skeletal muscle following 
eccentric exercise: a role in inflammation."
Henderson, L.M. and Chappell, J.B. (1993) Eur. J. Biochem. 217, 973-980. "A 
fluorescent probe for superoxide generation?"
Henkel, T., Machleidt, T., Alkalay, I., Kronke, M., Ben-Neriah, Y., Baeuerle, P.A.
(1993) Nature 365, 182-185. "Rapid proteolysis of IxB-a is necessary for activation 
of transcription factor NF-kB."
Hille, R  and Anderson, RF. (1991) J. Biol. Chem. 266, 5608-5615. "Electron- 
transfer in milk xanthine-oxidase as studied by pulse-radiolysis."
Hille, R  and Massey, V. (1991) J. Biol. Chem. 266, 17401-17408. "Thekinetic- 
behavior of xanthine-oxidase containing chemically modified flavins."
Hille, R  and Nishino, T. (1995) FASEB J. 9, 995-1003. "Flavoprotein structure and 
mechanism .4. Xanthine-oxidase and xanthine dehydrogenase".
Hockenbery, D.M., Oltvai, Z.N., Yin, X-M., Milliman, C.L., Korsmeyer, S.J. (1993) 
Cell 75, 241-251. "Bcl-2 functions in an antioxidant pathway to prevent apoptosis."
Ichida, K , Amaya, Y., Noda, K , Minoshima, S., Hosoya, T., Sakai, O., Shimizu, N, 
Nishino, T. (1993) Gene 133, 279-284. "Cloning of the cDNA-encoding human 
xanthine dehydrogenase (oxidase)- Structural-analysis of the protein and 
chromosomal location of the gene."
Ichikawa, M., Nishino, T, Nishino, T., Ichikawa, A. (1992) J. Histochem. Cytochem. 
40, 1097-1103. "Subcellular localization of xanthine oxidase in rat hepatocytes: high- 
resolution immunoelectron microscopic study with biochemical analysis."
Imlay, J.A. and Fridovich, I. (1991) J. Biol. Chem. 266, 6957-6965. "Assays of 
metabolic superoxide production in Escherichia coli."
Itoh, R , Nishino, T., Usami, C., Tsushima, K  (1978). J. Biochem. (Tokyo) 84, 19- 
26. "An immunochemical study of the changes in chicken liver xanthine 
dehydrogenase activity during dietary adaptation."
Jaffe, E.A., Nachman, RL., Becker, C.G., Minick, C.R (1973)7. Clin. Invest. 52, 
2745-2756. "Culture of human endothelial cells derived from umbilical veins."
References
137
Jarasch, E.D., Grund, C., Bruder, G., Heid, H.W., Keenan, T.W., Franke, W.W. 
(1981) Cell 25, 67-82. "Localization of xanthine oxidase in mammary-gland 
epithelium and capillary endothelium."
Jarasch, E.D., Bruder, G., Heid, H.W. (1986) Acta Physiol Scand. Suppl. 548, 39- 
46. "Significance of xanthine oxidase in capillary endothelial cells."
Joshi, M.S., Johnson, J.L., Rajagopalan, KV. (1996) J. Bacteriol. 178, 4310-4312. 
"Molybdenum cofactor biosynthesis in Escherichia coli mod and mog mutants."
Keith, T.P., Riley, M.A., Kreitman, M., Lewontin, R.C., Curtis, D., Chambers, G. 
(1987) Genetics 116, 67-73. "Sequence of the structural gene for xanthine 
dehydrogenase (rosy locus) in drosophila-melanogaster'i
Khan, A.U. and Wilson, T. (1995) Chemistry & Biology 2, 437-445. "Reactive 
oxygen species as cellular messenger."
Kinnula, V.L., Worton, A.R., Chang, L-Y., Crapo, J.D. (1992) Am. J. Respir. Cell 
Mol. Biol. 6, 175-182. "Regulation of hydrogen peroxide generation in cultured 
endothelial cells."
Kooij, A., Bosch, KS., Frederiks, W.M., Van Noorden, C.J.F. (1992) Virchows 
Archiv. B Cell Pathol. 62, 143-150. "High levels of xanthine oxidoreductase in rat 
endothelial, epithelial and connective tissue cells. A relation between localization and 
function?"
Kooij, A., Schiller, H.J., Schijns, M., Van Noorden, C.J.F., Frederiks W.M. (1994) 
Hepatology 19, 1488-1495. "Conversion of xanthine dehydrogenase into xanthine 
oxidase in rat liver and plasma at the onset of reperfusion after ischemia."
Korsmeyer, S.J., Yin, X.M., Oltvai, Z.N., Veisnovack, D.J., Linette, G.P. (1995) 
Biochim. Biophys. ^cto-Molecular Basis of Disease 1271, 63-66. "Reactive oxygen 
species and the regulation of cell-death by the Bcl-2 gene family."
Krenitsky, T.A., Spector, T., Hall, W.W. (1986) Arch. Biochem. Biophys. 247, 108- 
119. "Xanthine-oxidase from human liver- Purification and characterisation."
Kuchler, K  (1993) Trends Cell Biol. 3, 421-426. "Unusual routes of protein 
secretion: the easy way out."
Laemmli, U.K (1970) Nature 227, 680-685. "Cleavage of structural proteins during 
the assembly of the head of bacteriophage T4."
Larrick, J.W. and Kunkel, S.L. (1988) Pharmaceut. Res. 5, 129-139. "The role of 
tumour necrosis factor and interleukin-1 in the immunoinfiammation response."
Lasky, L.A. (1992) Science 258, 964-969. "Selectins: interpreters of cell-specific 
carbohydrate information during inflammation."
References
138
Linette, G.P. and Korsmeyer, S.J. (1994) Curr. Opin. Cell Biol. 6, 809-815. 
"Differentiation and cell death: lessons from the immune system"
Loewy, A.G., Siekevitz, P., Menninger, J.R, Gallan, J.A.N. (1991) In: Cell Structure 
and Function: an integrated approach." Saunders College Publishing, 64-68.
Lopez-Ongil, S., Hemandez-Perera, O., Navarro-Antolin, J., Perez de Lema, G., 
Rodriguez-Puyol, M., Lamas, S., Rodriguez-Puyol, D. (1998) J. Pharmacol. 124, 
447-454. "Role of reactive oxygen species in the signalling cascade of cyclosporine A- 
mediated up-regulation of eNOS in vascular endothelial cells."
Luzio, J.P., Brake, B., Banting, G., Howell, KE., Braghetta, P., Stanley, K K  (1990) 
Biochem. J. 270, 97-102. "Identification, sequencing and expression of an integral 
membrane-protein of the Traw-Golgi network (TGN38)."
Martz, D., Rayos, G., Schielke, G.P., Betz, A.L. (1989). Stroke 20, 488-494. 
"Allopurinol and dimethylthiourea reduce brain infarction following middle cerebral- 
artery occlusion in rats."
Massey, V., Brumby, P.E., Komai, H., Palmer, G. (1969) J. Biol. Chem. 244, 1682- 
11691. "Studies of milk xanthine oxidase."
Massey, V. and Edmondson, D. (1970)./ Biol. Chem. 245, 6595-6598. " On the 
mechanism of inactivation of xanthine oxidase by cyanide."
Massey, V., Komai, H., Palmer, G. (1970) J. Biol. Chem. 245, 2837-2844. "On the 
mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4- 
d] pyrimidines."
Massey, V. and Harris, C.M. (1997) Biochem. Soc. Trans. 25, 750-755. "Milk 
xanthine oxidoreductase: the first one hundred years."
Mathews, C.K, van Holde, KE. (1990) In "Biochemistry". "Purine degradation and 
clinical disorders of purine metabolism" The Benjamin/Cummings Publishing 
company. 751-753.
Mattila, P., Majuri, M-L, Mattila, P.S., Renkonen, R  (1992) Scand. J. Immunol. 36, 
159-165. "TNF-a induced expression of endothelial adhesion molecules, ICAM-1 and 
VCAM-1, is linked to protein kinase C activation."
Meyer, M., Schreck, R , Bauerle, P.A. (1993)EMBOJ. 12, 2005-2015. "Hydrogen 
peroxide and antioxidants have opposite effects on activation of NF-kB and AP-1 in 
intact cells: AP-1 as secondary antioxidant responsive factor."
Michiels, C., Amould, T., Houbion, A., Remade, J. (1992) J. Cell. Physiol. 153, 53- 
61 "Human umbilical vein endothelial cells submitted to hypoxia-reoxygenation in 
vitro: implication of free radicals, xanthine oxidase and energy deficiency."
References
139
Miesel, R  and Zuber, M. (1993) Inflammation 17, 551-561. "Elevated levels of 
xanthine oxidase in serumpatients with inflammatory and autoimmune rheumatic 
diseases."
Millar, T.M., Stevens, C.R, Benjamin, N., Eisenthal, R , Harrison, R , Blake, D.R 
(1998) FEBS Letters A ll, 225-228. "Xanthine oxidoreductase catalyses the reduction 
of nitrates and nitrite to nitric oxide under hypoxic conditions."
Mohazzab, KM., Kaminski P.M., Wolin, M.S. (1994) Am. J. Physiol. 266, H2568- 
H2572. "NADH oxidoreductase is a major source of superoxide anion in bovine 
coronary artery endothelium"
Mohazzab, KM. and Wollin, M.S. (1994) Am. J. Physiol. 267, L815-L822. "Sites of 
superoxide anion production detected by lucigenin in calf pulmonary artery smooth 
muscle."
Moine, P., Shenkar, R , Kaneko, D, LeTulzo, Y., Abraham, E. (1997) Am. J. 
Physiol.-Lung Cell. Mol. Physiol. 17, L185-L192. "Systemic blood loss affects NF- 
kappa B regulatory mechanisms in the lungs."
Moorhouse, P.C., Grootveld, M., Halliwell, B., Quinlan, J.G., Gutteridge, M.C.J. 
(1987) FEBS 213, 23-28. "Allopurinol and oxypurinol are hydroxyl radical 
scavengers."
Moriwaki, Y., Yamamoto, T., Suda, M., Nasako, Y., Takahashi, S., Agbedana, O.E., 
Hada, T., Higashino, K  (1993)Biochim. Biophys. Acta 1164, 327-330. "Purification 
and immunohistochemical tissue localization of human xanthine oxidase."
Morre, D.J., Wu, L.Y., Morre, D.M. (1998) Biochim. Biophys. Acta-Biomembranes 
1369, 185-192. "Response of a cell-surface NADH oxidase to the antitumor 
sulfonylurea N-(4-methylphenylsulfonyl)-N’-(4-chlorophenylurea) (LY81984) 
modulated by redox."
Neubauer, RA. and James, P.B. (1994) Lancet 344, 1440-1441. "Free radicals and 
antioxidants."
Nishino, T. and Tamura, I. (1991) In: Purine and Pyrimidine metabolism in man. "The 
mechanism of conversion of xanthine dehydrogenase to oxidase and the role of the 
enzyme in reperfusion injury." VII Part A, Ed. RA. Harkness et al. Plenum Press, 
New York. 327-333.
Nishino, T. and Hille, R  (1995)FASEB J. 9, 995-1003. "xanthine oxidase and 
xanthine dehydrogenase."
O'Donnell, V.B., Tew, D.G., Jones, O.T.G., England, P.J. (1993)Biochem. J. 290, 
41-49. "Studies on the inhibitory mechanism of iodonium compounds with special 
reference to neutrophils NADPH oxidase."
Ohara, Y. , Peterson, T.E., Harrison, D.G. (1993) J. Clin. Invest. 91, 2546-2551. 
"Hypercholesteroemia increases endothelial superoxide anion production."
References
140
Ojcius, D.M., Nierdergang, F., Subtil, A., Hellio, R , Dautry-Varsat, A. (1996) Res. 
Immunol 147, 175-188. "Immunology and the confocal microscope."
Okamoto, K  and Nishino, T. (1995) J. Biol Chem. 270, 7816-7821. "Mechanism of 
inhibition of xanthine oxidase with a new tight binding inhibitor."
Olson, J.S., Ballou, D.P., Palmer, G., Massey, V. (1974) J. Biol Chem. 249, 4363- 
4382. "The mechanism of action of xanthine oxidase".
O'Regan, M.H., Smith-Barbour, M., Perkins, L.M., Cao, X., Phillis, J.W. (1994) 
Neuropharmacology 33, 1197-1201. "The effect of amflutizole, a xanthine oxidase 
inhibitor, on ischemia-evoked purine release and free radical formation in the rat 
cerebral cortex."
Pagano, P.J., Ito, Y., Tomheim, K , gallop, P., Cohen, RA. (1993) Circulation 88, 
Abstr. p467. "The superoxide generating-system in the rabbit aorta resembles 
NAD(P)H oxidase."
Pagano, P., Ito, Y., Tomheim, K , Gallop, P., Tauber, A., Cohen, R  (1995) Am. J. 
Physiol.-Heart Circ. Physiol. 268, H2274-H2280. "AnNADPH oxidase superoxide- 
generating system in the rabbit aorta."
Page, S., Powell, D., Benboubetra, M, Stevens, C.R, Blake, D.R, Selase, F., 
Wolstenholme, A.J., Harrison, R  (1998)Biochim. Biophys. Acta-General subjects 
1381, 191-202. "Xanthine oxidoreductase in human mammary epithelial cells; 
activation in response to inflammatory cytokines."
Paler-Martinez, A., Panus, P., Chumley, P.H., Ryan, U., Hardy, M.M., Freeman, B.A. 
(1994) Arch. Biochem. Biophys. 311, 79-85. "Endogenous xanthine oxidase does not 
significantly contribute to vascular endothelial production of reactive oxygen species."
Palluy, O., Morliere, L., Gris, J.C., Bonne, C., Modat, G. (1992) Free Rad. Biol.
Med. 13, 21-30. "Hypoxia/ reoxygenation stimulates endothelium to promote 
neutrophil adhesion."
Palmer, C., Vannuci, RC., Towfighi, J. (1990) Pediatric Res. 27, 332-336. 
"Reduction of perinatal hypoxic-ischemia brain damage with allopurinol."
Palmer, H.J. and Paulson, E. (1997) Nutrition Reviews 55, 353-361. "Reactive 
oxygen species and antioxidants in signal transduction and gene expression."
Panus, P.C., Wright, S.A., Chumley, P.H., Radi, R , Freeman, B.A. (1992) Arch. 
Biochem. Biophys. 294, 695-702. "The contribution of vascular endothelial xanthine 
dehydrogenase/oxidase to oxygen-mediated cell injury."
Parks, D.A., Granger, D.N. (1986) Acta Physiol. Scan. Suppl. 548, 87-89. "Xanthine 
oxidase: biochemistry, distribution and physiology."
References
141
Partrigde, C.A., Blumenstock, F.A., Malik, A.B. (1992) Arch. Biochem. Biophys. 
294, 184-187. "Pulmonary microvascular endothelial cells constitutively release 
xanthine oxidase."
Pechamselin, M.A., Myara, I., Pico, I., Maziere, C., Moatti, N. (1996) Experientia 
52, 234-238. "Oxidative modifications of low density lipoproteins (LDL) by the 
human endothelial-cell line EA.hy 926."
Pfeffer, K.D., Huecksteadt, T.P., Hoidal, J.K (1994) J. Immunol. 153, 1789-1797. 
"Xanthine dehydrogenase and xanthine oxidase activity and gene expression in renal 
epithelial cells."
Phan, S.H., Gannon, D.E., Varani, J., Ryan, U.S., Ward, P.A. (1989) Am. J. Pathol. 
134, 1201-1211. "Xanthine oxidase activity in rat pulmonary artery endothelial cells 
and its alteration by activated neutrophils."
Phillis, J.W., Sen, S., Cao, X.H. (1994) Neuroscience Letters 169, 188-190. 
"Amflutizole, a xanthine-oxidase inhibitor, inhibits free-radical generation in the 
ischemic-reperfused rat cerebral cortex."
Playfair, J.H.L. (1996) In: Immunology at a glance. 6th Edition. Blackwell Science 
Ltd-UK
Pober, J.S. (1988) Am. J. Pathol. 133, 3, 426-433. "Cytokine-mediated activation of 
vascular endothelium. Physiology and pathology."
Ponnambalam, S., Girotti, M, Yaspo, M-L, Owen, C.E., Perry, A.C.F., Suganuma, 
T., Nilsson, T., Fried, M., Banting, G., Waren, G. (1996) J. Cell Science 109, 675- 
685. "Primate homologues of rat TGN38: primary structure, expression and 
functional implications."
Poss, W.B., Huecksteadt, T.P., Panus, P.C., Freeman, B.A., Hoidal, J.K (1996) Am. 
J. Physiol.-Lung Cell. Mol. Physiol. 270, L941-L946. "Regulation of xanthine 
dehydrogenase and xanthine oxidase activity by hypoxia."
Powell, D. (1995) PhD thesis. University of Bath, Avon, UK "Purification, 
characterisation and regulation of human xanthine oxidase".
Price, L., Harrison, K  (1993) Biochem. Soc. Trans. 21, 102S. "Sensitive enzyme- 
linked-immunosorbent-assay for xanthine oxidase."
Quinlan, G.J., Lamb, N.J., Tilley, K , Evans, T.W., Gutteridge, J.M.C. (1997) Am. J. 
Resp. Crit. Care Med. 155,479-484. "Plasma hypoxabthine level in ARDS: 
implications for oxidative stress, morbidity, and mortality."
Radi, K , Rubbo, H., Bush, K , Freeman, B.A. (1997) Arch. Biochem. Biophys. 339, 
125-135. "Xanthine oxidase binding to glycosaminoglycans: kinetics and superoxide 
dismutase interactions of immobilized xanthine oxidase-heparin complexes."
References
142
Rajagopalan, KV. and Johnson, J.L. (1992) J. Biol. Chem. 267, 10199-10202. "The 
pterin molybdenum cofactors."
Ratych, RE., Chuknyiska, R.S., Bulkley, G.B. (1987) Surgery (St Louis) 102, 122. 
"The primary localization of free radical generation after anoxia/reoxygenation in 
isolated endothelial cell."
Riley, M.A. (1989) Mol. Biol. Evol. 6, 33-52. "Nucleotide-sequence oftheXDH 
region in drosophilia pseudoobscura and an analysis of the evolution of synonymous 
codons."
Rodell, T.C., Cheronis, J.C., Ohnemus, C.L., Piermattei, D.J., Repine, J.E. (1987)/. 
Appl. Physiol. 63, 2159-2163. "Xanthine oxidase mediates elastase-induced injury to 
isolated lungs and endothelium"
Roitt, I., Brostoff, J., Male, D. (1989) In: Immunology. Second edition. Gower 
Medical Publishing-UK
Rothe, G. and Valet, G. (1990) In: Advances in Analytical Cellular Pathology. "Flow 
cytometric characterization of oxidative process in neutrophils and monocytes with 
dehydrorhodamine 123, 2', 7' dichlorofluorescein and hydroethidine." Amsterdam, 
Elsevier Science Publishers. 313-314.
Rouquette, M., Stevens, C.S., Blake, D.R, Harrison, R , Whish, J., Whish, W.J.D. 
(1997) Biochem. Soc. Trans. 25, 532S. "Expression of xanthine oxidase activity in 
human endothelial cells as a function of cell density."
Rouquette, M, Page, S., Bryant, R , Benboubetra, M., Stevens, C.R, Blake, D.R, 
Whish, W.D., Harrison, R , Tosh, D. (1998)FEBS letters 426, 397-401. "Xanthine 
oxidoreductase is asymmetrically localised on the outer surface of human endothelial 
and epithelial cells in culture."
Saito, T. and Nishino, T. (1989)/ Biol. Chem. 264, 10015-10022. "Differences in 
redox and kinetic-properties between NAD-dependent and 0 2 dependent types of rat 
liver xanthine dehydrogenase."
Saksela, M. and Raivio, K.O. (1996) Biochem. J. 315, 235-239. "Cloning and 
expression in-vitro of human xanthine dehydrogenase oxidase."
Samra, Z.Q., Oguro, T., Fontaine, R , Ashra£ M. (1991)/. Submicrosc. Cytol.
Pathol. 23, 379-390. "Immunocytochemical localization of xanthine oxidase in rat 
myocardium"
Sanders, S., Eisenthal, R , Harrison, R  (1997) Eur. J. Biochem. 245, 541-548 
"NADH oxidase activity of human xanthine oxidoreductase. Generation of superoxide 
anion."
Samesto, A., Linder, N., Raivio, K.O. (1996) Lab. Invest. 74, 48-56. "Organ 




Sato, S., Tatsumi, K. and Nishino, T. (1991) Adv. Exp. Med. Biol. 309A, 135-138.
"A novel xanthine dehydrogenase inhibitor (BOF-4272)."
Sato, A., Nishino, T., Noda, K., Amaya, Y., Nishino, T. (1995) J. Biol. Chem. 270, 
2818-2826. "The structure of chicken liver xanthine dehydrogenase-cDNA cloning 
and the domain structure."
Satoh, T., Numakawa, T., Abiru, Y., Yamagata, T., Ishikawa, Y., Enokido, Y., 
Hatanaka, H. (1998) J. Neurochem. 70, 316-324. "Production of reactive oxygen 
species and release of L-glutamate during superoxide anion-induced cell death of 
cerebellar granule neurons."
Schiller, H., Vickers, S., Hildreth, J., Mather, I., Kuhajda, F., Bulkley, G. (1991)
Circ. Shock 34, A435. "Immunoaffinity localization of xanthine oxidase on the outside 
surface of the endothelial cell plasma membrane."
Schmidt, K.N., Amstad, P., Cerutti, P. and Baeuerle, P.A. (1995) Chemistry & 
Biology 2, 13-22. "The roles of hydrogen peroxide and superoxide as messengers in 
the activation of transcription factor NF-kB."
Schreck, R. and Baeuerle, P. A. (1991) Trends Cell Biol. 1, 39-42. "A role for oxygen 
radicals as second messengers"
Schreck, R., Rieber, P., Baeuerle, P.A. (1991) EMBO J. 10, 2247-2258. "Reactive 
oxygen intermediates as apparently widely used messengers in the activation of the 
NF-kB transcription factor and HTV-1."
Sen, S.K. and Packer, L. (1996) FASEB J. 10, 709-720. "Antioxidant and redox 
regulation of gene transcription."
Shanmugam, KT., Stewart, V., Gimsalus, R.P., Boxer, D.H., Cole, J.A., Chippaux, 
M., DeMoss, J.A., Giordano, G., Lin, E.C.C., Rajagopalan, K.V. (1992)Mol. 
Microbiol. 6, 3452-3454. "Proposed nomenclature for the genes involved in 
molybdenum metabolism in Escherichia coli and Salmonella typhimurium."
Siegel, S. (1956) In: Nonparametric statistics: for the behavioral sciences. 
McGrawHill-New York,. 117-127.
Sobreira, C., Davidson, M., King, M.P., Miranda, A.F. (1996) J. Histochem. 
Cytochem. 44, 571-579. "Dihydrorhodamine 123 identifies impaired mitochondrial 
respiratory chain function in cultured cells harboring mitochondrial DNA mutations."
Spector, T., Hall, W.W., Krenitsky, T.A. (1986) Biochem. Pharmacol. 35, 3109- 
3114. "Human and bovine xanthine oxidase: inhibition studies with oxypurinol."
Spitzer, W. (1899) Arch. Ges. Physiol. 76, 192-203. "Die Ueberfiihrung von 




Spolarics, Z. (1998)/. Leukoc. Biol. 63, 534-541. "Endotoxemia, pentose cycle, and 
the oxidant/antioxidant balance in the hepatics sinusoid."
Springer, T.A. (1990) Nature 346, 425-434. "Adhesion receptors of the immune 
system."
Springer, T.A. (1995) Annu. Rev. Physiol. 57, 827-872. "Traffic signals on 
endothelium for lymphocyte recirculation and leukocyte emigration."
Stevens, C.R, Benboubetra, M., Harrison, R , Sahinoglu, T., Smith, E.C., Blake,
D.R (1991) Ann. Rheum. Dis. 50, 760-762. "Localisation of xanthine oxidase to 
synovial endothelium"
Stirpe, F. and Della Corte, E. (1969)/ Biol. Chem. 244, 3855-3863. "The regulation 
of rat liver xanthine oxidase."
Stuehr, D.J., Fasehun, O.A., Kwon, N.S., Gross, S.S., Gonzalez, J.A., Levi, R , 
Nathan, C.F. (1991) FASEB J. 5, 98-103. "Inhibition of macrophage and endothelial­
cell nitric-oxide synthase by diphenyleneiodonium and its analogs."
Suggs, J.E., Madden, M.C., Frieman, M., Edgell, C.J.S. (1986) Blood68; 825-829. 
"Prostacyclin expression by a continuous human cell line derived from vascular 
endothelium"
Sun, S.C., Ganchi, P.A., Ballard, D.W., Greene, W.C. (1993) Science 259, 1912- 
1915. "NF-kB controls expression of inhibitor IkB-cc: evidence for an inducible 
autoregulatory pathway."
Sussman, M.S. and Bulkley, G.B. (1990) Methods in Enzymology 186, 711-723. 
"Oxygen-derived free radicals in reperfusion injury."
Suzuki, M., Grishman, M.B., Granger, D.N. (1991)/ Leukoc. Biol. 50, 488-494. 
"Leukocyte-endothelial cell adhesive interactions. Role of xanthine oxidase-derived 
oxidants."
Suzuki, K , Nakamura, M., Hatanaka, Y., Kayanoki, Y., Tatsumi, H., Taniguchi, N.
(1997)/ Biochem. 122, 1260-1264. "Induction ofapoptotic cell death in human 
endothelial cells treated with snake venon: implication of intracellular reactive oxygen 
species and protective effects of glutathione and superoxide dismutases."
Suzuki, H., DeLano, F.A., Parks, D.A., Jamshidi, N., Granger, D.N., Ishii, H., 
Suematsu, M., Zweifach, B.W., SchmidSchonbein, G.W. (1998) Proc. Natl. Acad. 
Sci. USA 95, 4754-4759. "Xanthine oxidase activity associated with arterial blood 
pressure in spontaneously hypertensive rats."
Telfer, J.F., Thomson, A.J., Cameron, I.T., Greer, I.A., Norman, J.E. (1997) Human 
Reproduction 12, 2306-2312. "Expression of superoxide dismutase and xanthine 




Terada, L.S., Willingham, I.R, Rosandich, M.E., Leff^  J.A., Kindt, W., Repine, J.E. 
(1991)/. Cell. Physiol. 148, 191-196. "Generation of superoxide anion by brain 
endothelial cell xanthine oxidase."
Terada, L.S., Guidot, D.M., Leff) J.A., Willingham, I.R, Hanley, M.E., Piermattei,
D., Repine, J.E. (1992) Proc. Natl Acad. Sci. USA 89, 3362-3366. "Hypoxia injures 
endothelial cells by increasing endogenous xanthine oxidase activity."
Terada, L.S. and Arnold, P.D. (1993)/. Interferon Res. 13, 419-422. "Xanthine 
oxidase does not mediate the antiproliferative effects of Interferon-y in Human 
Umbilical Vein Endothelial cells."
Terao, M., Cazzaniga, G., Ghezzi, P., Bianchi, M., Falciani, F., Perani, P., Garattini,
E. (1992) Biochem. J. 283, 863-870. "Molecular cloning of a cDNA for mouse-liver 
xanthine dehydrogenase. Regulation of its transcript by interferons in vivo."
Thornhill, M.H., Li, J., Haskard, D.O. (1993) Scand. J. Immunol. 38, 279-286. 
"Leukocyte endothelial cell adhesion: a study comp arising human umbilical vein 
endothelial cells and the endothelial cell line EA-hy 926."
VandenHoek, T.L., Li, C, Shao, Z., Schumacker, P.T., Becker, L.B. (1997)/ Mol. 
Cell. Cardiol. 29, 2571-2583. "Significant levels of oxidants are generated by isolated 
cardiomyocytes during ischemia prior to reperfusion."
Varani, J. and Ward, P. A. (1994) Shock 2, 311-319. "Mechanisms of endothelial cell 
injury in acute inflammation "
Vickers, S., Schiller, H.J., Hildreth, J.E., Bulkley, G.B. (1998) Surgery 124, 551-560. 
"Immunoaffinity localization of the enzyme xanthine oxidase on the outside surface of 
the endothelial cell plasma membrane."
Visher, U.M., Jomot, L., Wollheim, C.B., Theler, J-M. (1995) Blood 85, 3164-3172. 
"Reactive oxygen intermediates induce regulated secretion of von Willebrand factor 
from cultured human vascular endothelial cells."
Vlot, A.J., Koppelman, S.J., Bouma, B.N., Sixma, J.J. (1998) Thromb. Haemost. 79, 
456-465. "Factor VIE and von Willebrand factor."
Volk, T., Hensel, M., Kox, W.J. (1997)Mol. Cell. Biochem. 171, 11-21. "Transient 
Ca2+ changes in endothelial cells induced by low doses of reactive oxygen species: 
role of hydrogen peroxide."
Vowells, S.J., Sekhsaria, S., Halech, H.L., Shalit, H., Fleisher, T.A. (1995)/ 
Immunol. Methods 179, 89-97. "Flow cytometric analysis of the granulocyte 
respiratory burst: a comparison study of fluorescent probes."
Wahl, R.C. and Rajagopalan, KV. (1982)/ Biol. Chem. 257, 1354-1359. "Evidence 
for the inorganic nature of the cyanolyzable sulfur of molybdenum hydroxylases."
References
146
Wakabayashi, Y., Fujita, H., Morita, I., Kawaguchi, H., Murota, S. (1995) Biochim. 
Biophys. Acta 1265, 103-109. "Conversion of xanthine dehydrogenase to xanthine 
oxidase in bovine carotid artery endothelial cells induced by activated neutrophils: 
involvement of adhesion molecules."
Waud, W.R and Rajagopalan, K.V. (1976) Arch. Biochem. Biophys. 172, 365-379. 
"The mechanism of conversion of rat liver xanthine dehydrogenase from an NAD+- 
dependent from (type D) to an 0 2-dependent form (type O)."
Wems, S.W., Grum, C.M., Ventura, A., Hahn, RA., Ho, P.P.K, Towner, R.D., 
Fantone, J.C., Schork, M.A., Lucchesi, B.R (1991) Circulation 83, 995-1005. 
"Xanthine-oxidase inhibition does not limit canine infarct size."
White, C.R, Darley-Usmar, V., Berrington, W.R, McAdams, M., Gore, J.Z., 
Thompson, J.A., Parks, D.A., Tarpey, M.M., Freeman, B.A. (1996) Proc. Natl. Acad. 
Sci. USA 93, 8745-8749. "Circulating plasma xanthine oxidase contributes to vascular 
dysfunction in hypercholesterolemic rabbits."
Wiezorek, J.S., Brown, D.H., Kupperman, D.E., Brass, C.A. (1994) J. Clin. Invest. 
94, 2224-2230. "Rapid conversion to high xanthine oxidase activity in viable Kupffer 
cells during hypoxia."
Wong, G.H.W. (1995) Biochim. Biophys. Acta 1271, 205-209. "Protective roles of 
cytokines against radicalisation: Induction of mitochondrial MnSOD."
Xu, P., Huecksteadt, T.P., Harrison, R , Hoidal, J.R (1994) Biochem. Biophys. Res. 
Comm. 199, 998-1004. "Molecular cloning, tissue expression of human xanthine 
dehydrogenase."
Yang, W. and Block, E.R (1995) J. Cell. Physiol. 164, 414-423. "Effect of hypoxia 
and reoxygenation on the formation and release of reactive oxygen species by porcine 
pulmonary artery endothelial cells."
Yvonne, Y., Lo, C., Cruz, T.F. (1995) J. Biol. Chem. 270, 11727-11730. 
"Involvement of reactive oxygen species in cytokine and growth factor induction of c- 
fos expression in chondrocytes."
Zeise, L. andZikakis, J.P. (1987)/. Agric. Food Chem. 35, 942-947. 
"Characterization of human colostral xanthine oxidase."
Zhang, Z., Blake, D.R, Stevens, C.R, Kanczler, J.M., Winyard, P.G., Symons, 
M.C.R, Benboubetra, M., Harrison, R  (1998) Free Rad. Res. 28, 151-164. "A 
reappraisal of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: the 
role of NADH as an electron donor."
Zulueta, J.J., Sawhney, R , Feng, S.Y., Cote, C.C., Hassoun, P.M. (1997) Am. J. 
Physiol.-Lung Cell. Mol. Physiol. 16, L897-L902. "Intracellular generation of 
reactive oxygen species in endothelial cells exposed to anoxia-reoxygenation."
References
147
Zweier, J.L. (1988) J. Biol. Chem. 263, 1353-1357. "Measurement of superoxide 
derived free radicals in the reperfused heart-evident for a free mechanism of 
reperfusion injury."
Zweier, J.L., Broderick, R., Kuppusamy, P., Thompson-Gorman, S., Lutty, G.A.
(1994) J. Biol. Chem. 269, 24156-24162. "Determination of the mechanism of free 





Appendix I: XOR in endothelial cells
Cells/tissues
studied.
XOR activity. Method of 
detection.
References.
Bovine EC and 
tissues.
Positive in capillary 
EC from liver, 
heart, lung and 
intestine.
Immunolocalisation. Jarasch et al, 
1981.
Selection of bovine 










Bruder et al, 
1983.
Capillary endothelial 
cells and tissues 
from bovine and 
human.
Positive: capillary 
EC of many tissues 
(liver, heart, lung, 
kidney). But not in 










Increase in XO 
activity after I/R but 
decrease in XDH 




amount of uric acid.





High XO activity in 
EC.
HPLC: uric acid 
peak detected at 
290nm










Phan et al, 
1989.
Normal rat heart. XO activity in EC 
of capillaries, small 




assay of urate 
(295nm).
Samra et al, 
1991.
Bovine brain EC. Bovine brain EC 
had increased level 
of XO & XDH/ 
whole brain 
homogenate.
HPLC: formation of 
uric acid.







No XDH or XO 
activity in PAEC 
exposed to 
normoxia or 
















IFN-y: inducer of 
XDH/XO activity in 
LMVC & PAEC. 
Upregulation at 
transcriptional level.
Fluorimetric assay. Dupont et al, 
1992.
Unfixed cryostat 
sections of various 
rat tissues.
Activity in 
sinusoidal cells of 




Kooii et al, 
1992.




Fluorimetric assay. Michiels et al, 
1992.
HUVECs. H/R: decrease XDH 
and increase XO.
Measuring uric acid 
at 293nm






with a maximum on 
day 9.
Pterin assay on 
fluorimeter.









Hypoxia 60min. no 
effect/normoxia.
HPLC: C18 reverse 
phase column—» 
peaks of uric acid.












Terada et al, 
1992.
Human and rat 
tissues.
High activity: EC & 
Kupffer cells from 
rat and human liver. 
Low activity: liver 








Rat tissues: liver 
and small intestine.
Rat liver: very low 
XO activity, with 
higher activity in 
EC.
High activity in 
epithelial layer of 
small intestine. 
60-120min in vitro 
ischaemia, no effect 






Human tissues. Staining: smooth 
muscle cells of 
larger vessels in 
human cardiac and 
skeletal muscle.
XO in human aorta, 
pulmonary artery, 
umbilical cord.
Weak positive in EC 
of capillary, small 
venules and 
arterioles in human 
cardiac and skeletal 
but negative in EC 













cells from heart, 
kidney, brain, aorta, 
lung, mesentery, 
hepatic tissue.
No protein found in 
tissue cytosol, 











(lOOOU/ml; 24h) no 
change.
Uric acid formation 
by HPLC.












-Rat epididymal fat 
pad EC 
-Rat lung.
No activity in 
porcine PAEC and 
HUVECs even after 
exposure to 
hypoxia. The other 
cells show XO and 
XDH activity.
Fluorimetric assay. Hassoun et al, 
1994.
-Bovine aorta EC 
(BAEC)





-Porcine aorta EC 
-Rat aorta EC 
-Rat pulmonary 
artery EC.
No activity found 














in EC, Kupffer cells 
and hepatocytes. 
Hypoxia:
conversion XDH to 
XO in the three cell 
types.
Sp ectrophotometric 







XO and XDH were 
measurable.
Spectrophotometer. 




















Yang et al, 
1995.
Cultured endothehal 
cells isolated from 
bovine arteries.
EC expressed XDH 
and XO activity. 
Effect of activated 
neutrophils on the 













activity exposed to 
hypoxia and H/R
Fluorimetric assay. Poss et al, 
1996.
Rat tissues. High activity EC 
liver, kidney, 
hepatocytes of liver, 
myocytes of heart, 
smooth and striated 
cehs of muscle, 
acinar cehs of 
pancreas, epithelial 
cehs of ducts and 































EC exposed to I/R: 
ahopurinol and 





Zulueta et al, 
1997.
Legend: EC: endothelial cells; H/R: hypoxia/reoxygenation; I/R: ischaemia 
reperfusion; ROS: reactive oxygen species.
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Abstract Subcellular localisation of xanthine oxidoreductase 
(XOR) was determined by indirect immunofluorescence using 
confocal microscopy in human endothelial and epithelial cell lines 
and in primary cultures of human umbilical vein endothelial cells. 
XOR was diffusely distributed throughout the cytoplasm but with 
higher intensity in the perinuclear region. In non-permeabilised 
cells, XOR was clearly seen to be asymmetrically located on the 
outer surfaces, showing, in many cases, a higher intensity on 
those faces apposed by closely neighbouring cells. Such specific 
distribution suggests a functional role for the enzyme in cell-cell 
interactions, possibly involving signalling via reactive oxygen 
species
© 1998 Federation of European Biochemical Societies.
Key words: Xanthine oxidoreductase; Immunolocalization; 
Endothelial; Epithelial; Hum an
1. Introduction
Xanthine oxidoreductase (XOR) is a molybdenum-contain­
ing flavoenzyme that catalyses the hydroxylation of hypoxan- 
thine to xanthine and o f xanthine to  uric acid in the latter 
stages of purine catabolism [1]. In  mammals, it occurs in two 
interconvertible forms, xanthine dehydrogenase (EC 1.1.1.204) 
and xanthine oxidase (EC 1.1.3.22). Both forms o f the enzyme 
can reduce molecular oxygen, although only the dehydrogen­
ase form can reduce NAD, which it prefers as an electron 
acceptor. Reduction of oxygen leads to  superoxide anion 
and hydrogen peroxide and it is the potential to  generate these 
reactive oxygen species that has led to widespread interest in 
the enzyme as a pathogenic agent in many forms of ischae- 
mia-reperfusion injury [2]. M ore recently, reactive oxygen spe­
cies are being increasingly cited as intermediates in normal 
signal transduction pathways [3,4].
XOR is widely distributed, being particularly rich in mam ­
mary epithelial cells and in capillary endothelium in a range of 
tissues [5,6]. While the enzyme is generally understood to be 
cytosolic, there have been very few published investigations of 
its precise subcellular localisation. Jarasch et al. [5] used both 
light and electron microscopic immunohistochemical proce­
dures to show tha t XOR is located throughout the cytoplasm 
of bovine capillary endothelial cells. This was also found to be
*Corresponding author. Fax: (44) (1225) 826779.
E-mail: bssrh@bath.ac.uk
Abbreviations: XOR, xanthine oxidoreductase; FCS, foetal calf 
serum; HUVEC, human umbilical vein endothelial cell; DIC, 
differential interference contrast
the case in rat liver endothelial cells [7,8]. In  contrast, using 
immunoelectron microscopy, Ichikawa et al. [9] concluded 
that the enzyme was exclusively cytosolic with no significant 
association with intracellular organelles, including endoplas­
mic reticulum, Golgi apparatus, lysosomes or peroxisomes.
The apparent confusion over the subcellular location of 
XOR prompted us to  investigate the situation in hum an cells. 
The hum an enzyme is of especial interest, particularly in view 
of questions regarding its anomalous characteristics and phys­
iological role [10]. We have, accordingly, made use of confocal 
microscopy in immunolocalisation of the enzyme in human 
endothelial and epithelial cells in culture. We show here that 
XOR is present not only in the cytoplasm but also on the 
outer surface of all three cell types studied. Moreover, the 
extracellular enzyme shows a strongly polarised distribution, 
being in many cases concentrated on those surfaces closely 
apposed by neighbouring cells.
2. Materials and methods
2.1. Materials
RPMI 1640 culture medium was obtained from ICN, Costa Mesa, 
CA, USA. Penicillin, streptomycin and foetal calf serum (FCS) were 
from Life Technologies, Paisley, UK. Rabbit anti-TGN 46 antibody 
was a kind gift from Dr. George Banting (Department of Biochemis­
try, University of Bristol, UK). Rabbit anti-(bovine milk XOR) was 
from Chemicon International, Harrow, UK. All other reagents, unless 
otherwise stated, were from Sigma, Poole, UK.
2.2. Cell culture
EA-hy-926, a permanent endothelial cell line [11], was a gift from 
Dr. Andrew George, Imperial College School of Medicine, Hammer­
smith Hospital, London. The cells were routinely grown in an atmos­
phere of 5% C02/95% air in 75-cm2 flasks at 37°C, as previously 
described [12]. Growth medium, RPMI 1640, containing 10% (v/v) 
FCS and penicillin/streptomycin [12], was changed every 3-4 days. 
The cells grew to form a confluent monolayer after approximately 
7 days, exhibiting typical endothelial cell characteristics and were 
shown, by immunofluorescence (results not shown), to be positive 
for factor VIII, as reported by Edgell et al. [11].
HB4a is a human mammary epithelial cell line, conditionally im­
mortalised by transfection with SV40 virus [13] and kindly donated to 
us by Dr T. Kamalati and Professor B. Gusterson of the Institute for 
Cancer Research, Royal Cancer Hospital, Sutton, UK. HB4a cells 
were routinely grown at 37°C in 75-cm2 culture flasks, in an atmos­
phere of 5% C 02/95% air as previously described [14]. Growth me­
dium, RPMI 1640 containing 10% (v/v) FCS and other supplements
[14], was changed every 3-4 days. Cells grew to confluence, forming a 
strict monolayer after 9 days, showing a characteristic ‘crazy paving’ 
appearance and stained strongly positive (results not shown) for the 
epithelial cell marker, cytokeratin [14].
Human umbilical vein endothelial cells (HUVECs) were obtained 
from human umbilical veins (kindly donated by the nursing staff of 
the Princess Anne Wing, Royal United Hospitals, Bath) and cultured 
essentially as described by Jaflfe et al. [15].
0014-5793/98/$ 19.00 © 1998 Federation of European Biochemical Societies. All rights reserved. 
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2.3. Immunolabelling o f cells and confocal microscopy
Cells were seeded (approx. 2X 105 cells/ml) in four-chambered glass 
slides (Nunc Inc., Naperville, IL, USA), incubated for 24 h at 37°C 
and washed twice with pre-warmed PBS before fixing for 20 min at 
room temperature with 4% (w/v) formaldehyde in PBS.
Cells were permeabilised by incubation with 0.1% (w/v) saponin in 
PBS for 45 min, then incubated with rabbit polyclonal anti-(human 
XOR) antibodies in PBS (0.02 mg/ml), containing 0.1% (w/v) saponin, 
3% (v/v) normal goat serum and 1% (w/v) BSA, for 2 h at room 
temperature. The cells were washed three times with 0.1% (w/v) sap­
onin in PBS before incubation, for 2 h at room temperature, with 
secondary antibody [FITC-conjugated goat anti-rabbit IgG (0.025 mg/ 
ml, Jackson Immunoresearch Labs. Inc., West Grove, PA, USA)], 
diluted 1:100 in the same diluant as for the primary antibodies. The 
cells were then washed three times with PBS containing 0.1% (w/v) 
saponin, before removing the chambers from the slides prior to con­
focal microscopy.
Unpermeabilised cells were obtained and treated as above, except 
that saponin was omitted throughout.
The permeabilised or unpermeabilised nature of the cells was con­
firmed by immunolabelling with rabbit anti-TGN 46 antibody, which 
is specific for the trans-Golgi network (results not shown) [16].
Images were collected on a confocal laser-scanning microscope 
(LSM 510, with either X40 1.30 NA or X63 1.40 NA apochromatic 
objective; Carl Zeiss, Welwyn Garden, UK). The 488 lines of an 
argon laser were used for excitation of FITC.
2.4. Assay for XOR enzymic activity
Cell extracts were prepared and assayed for total (oxidase plus 
dehydrogenase) activity as previously described [14], using a sensitive 
fluorimetric procedure [17], EA-hy-926 and HB4a cells contained 1-2 
pmol isoxanthopterin/min/mg. Activity o f HUVECs was below the 
lower limit o f sensitivity of the assay (0.1 pmol isoxanthopterin/min/ 
mg).
2.5. Heparin-Sepharose treatment o f growth medium
A column (3.5 cm X 1.5 cm) of heparin-Sepharose (Sigma) was 
washed with appropriate growth medium (30 ml) lacking FCS. 
Growth medium (100 ml) containing FCS (10%) was then passed 
through the column and collected in a sterile container. The column 
was washed with 25 mM sodium phosphate buffer, pH 7.4, until Aw<> 
reached a baseline level, and then with the same buffer containing 1 M 
NaCl. Protein-containing fraction O^so) was assayed for XOR enzy­
mic activity as described above.
2.6. Generation and affinity purification of rabbit polyclonal 
anti-(human XOR) antibodies
Antibodies were generated and affinity-purified as previously de­
scribed [14]. Their specificity has been previously established by im- 
munoprecipitation of XOR from HB4a cell extracts [14], Incubation 
of HB4a cell extracts with the gel-bound specific antibodies removed 
100% of XOR enzymic activity, while SDS-PAGE of the immunopre- 
cipitate showed only the characteristic band of XOR, apart from 
bands attributable to the antibodies themselves [14],
3. Results
Three human cell types, including endothelial (EA-hy-926) 
and epithelial (HB4a) cell lines and primary endothelial (HU­
VEC) cells in culture, were studied using affinity-purified rab­
bit anti-(human XOR) antibodies (see Section 2). In all cases, 
immunolocalisation of XOR in permeabilised cells showed the 
enzyme to be diffusely distributed throughout the cytoplasm, 
although fluorescence in the perinuclear region was more in­
tense (Fig. 1). Immunolocalisation of XOR in unpermeabi­
lised cells clearly showed the presence of the enzyme on the 
outer cell surface, the distribution being localised to specific 
areas of the cell (Fig. 2). In several cases, XOR appeared to be 
concentrated on those parts of the surface that apposed or 
were extending towards neighbouring cells (Fig. 2C, arrows).




Fig. 1. Distribution of XOR in permeabilised EA-hy-926 cells (A, 
B), HB4a cells (C, D) and HUVECs (E, F). For experimental de­
tails see Section 2. Immunofluorescent (A, C, E) and differential in­
terference contrast (DIC) (B, D, F) images are shown. Magnifica­
tion X630 (A. B), X400 (C-F); bar, 20 pm.
XOR) antibody gave the same results as those described 
above (results not shown).
Because of the possibility that XOR on the surface of our 
cells in culture originated in the growth medium (which con­
tains FCS) the latter was assayed for XOR. Enzymic activity 
could not be detected by the sensitive fluorimetric procedure 
(see Section 2). In view of the high affinity of human XOR for 
heparin [18,19], we sought to concentrate any small amounts 
of XOR in the growth medium by passage down a column of 
heparin-Sepharose (see Section 2). In none of six batches of 
serum was XOR activity detectable by fluorescence assay 
when the heparin column was subsequently eluted with 1 M 
NaCl, conditions known to elute the human enzyme [19]. Two 
further control experiments addressed this issue. In the first of 
these, parallel cultures of EA-hy-926 or HB4a cells were 
grown in 75-cm2 flasks in the corresponding growth medium 
that had, or had not been passed down a heparin-Sepharose 
column (see Section 2). In each case, cells were then seeded 
onto duplicate wells of glass slides as usual and subjected to




Fig. 2. Distribution of XOR in unpermeabilised EA-hy-926 cells (A-C), HB4a cells (D -F) and HUVECs (G-I). For experimental details see 
Section 2. Immunofiuorescent (A, D, G) and DIC (B, E, H) images are overlaid (C, F, I) to emphasise the polarised distribution. Arrows (C) 
show examples where fluorescence is concentrated on surfaces that appose those of neighbouring cells. Magnification X400; bar, 20 pm.
immunolabelling. No difference was apparent in the distribu­
tion or intensity of the fluorescence patterns between unper­
meabilised cells grown in heparin-treated and untreated me­
dium, nor was there any significant difference in total XOR 
activity in the cells, as assayed fluorimetrically. Results for 
EA-hy-926 cells are shown in Fig. 3C-F, in which the polar­
ised distribution of the enzyme is again clearly seen. In the 
second control experiment, heparin-Sepharose beads (300 p.1) 
were washed twice with PBS before incubation overnight, with 
continuous gentle agitation, either with growth medium (con­
taining FCS), PBS or with PBS containing bovine XOR (10 
(ig/ml). Subsequent labelling with anti-XOR antibody showed 
clear immunofluorescence on the surface of the beads in the
latter but not the former case (Fig. 3). Similar incubation of 
heparin beads with normal goat serum, used as a blocking 
agent in immunolabelling, also failed to lead to immunofluo­
rescence on the surface of the beads.
4. Discussion
While reactive oxygen species are increasingly being consid­
ered as agents of signal transduction [3,4], their source is sel­
dom clear, and XOR, with its capacity for generation of 
superoxide anion and hydrogen peroxide, is in many cases 
an attractive candidate [10]. The subcellular localisation of 
the enzyme is clearly relevant to its function and it is with
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Fig. 3. Control experiments showing that cell surface XOR is not 
derived from growth medium. Heparin beads were incubated for 24 
h with growth medium (A) or with PBS containing bovine XOR 
(B) (see Section 3). C, D  and E, F show EA-hy-926 cells grown in 
medium (containing FCS), that has (E, F) or has not (C, D) been 
preabsorbed on a heparin-Sepharose column (see Section 2). Immu­
nofluorescence (A-C, E) and DIC (D, F) images were obtained as 
described in Section 2. Magnification X100; bar, 50 pm (A, B); 
X400; bar, 20 pm (C-F).
this in mind that we examined the former in cultured human 
cells.
XOR is generally assumed to be a cytoplasmic enzyme, 
although its precise localisation is unclear, having been de­
scribed as being both peroxisomal [7,8] and exclusively cyto­
solic [9J. In the permeabilised cells of the present study, XOR 
was seen to be generally distributed throughout the cytoplasm 
but with more intense staining in the perinuclear region. This 
latter localisation has not, to our knowledge, been suggested 
previously and has interesting implications concerning possi­
ble functions of the cytoplasmic enzyme. A perinuclear loca­
tion would, for example, accord with a role for XOR as a
source of reactive oxygen species that activate nuclear tran­
scription factors, such as NF-kB [20].
XOR was clearly detected on the outer surface of unper­
meabilised cells of all three human cell types studied. While 
extracellular localisation of XOR has previously been pro­
posed in bovine aortic endothelial cells [21,22], our presently 
reported findings constitute the first detailed evidence of such 
a localisation in any cell type. In view of the potential impor­
tance of these results, it was necessary to eliminate the possi­
bility that surface enzyme is derived from exogenous sources, 
such as, for example FCS in the growth media. Growth media 
did not contain levels of XOR above the limit of sensitivity of 
the fluorimetric assay. This, in itself, does not necessarily pre­
clude the presence of lower levels of enzyme. However, XOR 
was not detected in the growth media following attempted 
concentration of the enzyme by chromatography on hepa­
rin-Sepharose, nor were any differences in immunolabelling 
detected when any of the three cell types was grown in pre­
absorbed medium. Moreover, growth medium for all three 
cells failed to show fluorescence labelling of heparin-Sephar­
ose beads when incubated with the latter. Similar results were 
obtained with goat serum, routinely used as a blocking agent 
in immunolabelling. Finally, it is highly unlikely that cell sur­
face XOR originated in lysed neighbouring cells, which are at 
low density early in their growth cycle and are essentially 
100% viable.
If we accept that the extracellular XOR is indeed an endog­
enous enzyme, then the mechanisms of its secretion come into 
question. The classical secretory pathway of protein biosyn­
thesis involves transfer from the endoplasmic reticulum 
through the Golgi apparatus to the plasma membrane and 
depends upon the presence of a cleavable signal peptide [23]. 
Human XOR has no signal peptide [24,25] and is not known 
to be glycosylated, a consequence of the classical secretory 
pathway. However, increasing numbers of polypeptides with 
these characteristics, that are nevertheless secreted from both 
prokaryotic and eukaryotic cells, are being discovered [26] and 
it may well be that XOR is another such protein using a non- 
classical secretory pathway. In view of the relatively high af­
finity of XOR for heparin [18,19], it is interesting to note an 
earlier suggestion [27] that muscle L-14 lectin, exported by a 
non-classical pathway, would thus be separated from glyco- 
conjugates, with which it interacted, until after its secretion. 
Similar considerations could apply to XOR, which may be 
expected to bind to cell surface glycosylaminoglycans follow­
ing secretion. It is noteworthy that incubation of EA-hy-926 
cells with heparin, followed by washing, failed to significantly 
diminish the intensity of staining (results not shown), suggest­
ing that other glycosylaminoglycans may be involved.
Our results clearly show that XOR is not only present on 
the outer surface of cultured human endothelial and epithelial 
cells, but is asymmetrically distributed, in many cases appear­
ing to be localised to surfaces apposed to those of closely 
neighbouring cells. This extracellular localisation and partic­
ularly its polarised nature strongly suggest a role for XOR in 
cell-cell interactions, possibly involving signalling via reactive 
oxygen species. We believe this to be an entirely novel concept 
worthy of detailed further investigations. Such investigations 
are, however, beyond the scope of the present study.
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